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Abstract 
Lung cancer was a rare disease in the latter part of the 19th century, but grew into a 
full-scale epidemic in the 20th century, becoming the most common cause of cancer-
related death worldwide. Current cancer chemotherapy, involves the administration 
of cytotoxic drugs that kill all cells exhibiting a high rate of proliferation and 
regeneration, which is a characteristic of cancer cells, but also non-cancerous cells, 
such as hair follicles, bone marrow and gastrointestinal tract cells. Therefore, the 
systemic delivery of chemotherapy leads to adverse effects, such as chemotherapy-
induced alopecia (CIA) and chemotherapy-induced peripheral neuropathy (CIPN), 
which can range from life-altering to life-threatening. Moreover, the economic 
impact of current cancer chemotherapy is unsustainable and, thus, an alternative 
therapy for lung cancer need to be investigated. Towards this goal, resveratrol-
loaded polymeric nanoparticles (NPs) formulated into nanocomposite 
microparticles (NCMPs) using L-leucine and chitosan were developed for the 
pulmonary delivery via dry powder inhalation.  
Resveratrol was loaded into NPs of poly(glycerol adipate-co-ω-pentadecalactone) 
(PGA-co-PDL) with sizes ranging between 220-230 nm, which are ideal for uptake 
into cells. The 5%- and 10% resveratrol-loaded NPs (5% RNP and 10% RNP) had 
a high encapsulation efficiency of 39 ± 0.12 and 70 ± 0.89% and a drug loading of 
78 ± 0.24 µg and 70 ± 0.89 µg (w/w), respectively. The PGA-co-PDL blank NPs 
(BNP) at 1 mg/mL showed good cytocompatibility in Calu 3 cells with a cell viability 
of 87.5±4.7% after 24-hour exposure. Meanwhile, the 5% RNP and 10% RNP 
decreased the IC50 of resveratrol in Calu 3 cells after 24 hours from 213 ± 63 µM to 
47 ± 30 µM and 48 ± 12 µM, respectively. This is a reduction in IC50 of up to 78%. 
The PGA-co-PDL NPs were spray-dried in NCMPs with mass median aerodynamic 
xxvi 
 
diameters (MMADs) between 3.1-4 µm, which is within the ideal range of 1-5 µm for 
particles to be able to deposit in the deep regions of the lung. Furthermore, the 
NCMPs showed a slow release profile, with only 25% of resveratrol being released 
over 24 hours. Lastly, a novel polymer was synthesised which possessed an alkyne 
that can allow for the attachment of various ligands, including a fluorescent probe 
to visualise uptake of the NPs. Overall, the obtained results demonstrate that these 
NPs/NCMPs show promise as pulmonary drug delivery systems for lung cancer.  
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1.1. Introduction 
 Lung cancer  
1.1.1.1 A brief history of lung cancer  
The documented history of lung cancer began in Germany at the Institute of 
Pathology at the University of Dresden, where in 1878 malignant lung tumours 
represented just 1% of all cancers discovered during autopsies (Witschi, 2001; 
Semenova, Nagel and Berns, 2015).  
It took 40 years for that number to increase to almost 10% and another decade 
to reach more than 14% (Witschi, 2001). Dr Isaac Adler, in his 1912 book 
entitled Primary Malignant Growths of the Lungs and Bronchi, could only verify 
374 cases of lung cancer reported in the published literature worldwide (Spiro 
and Silvestri, 2005; Ong and Ost, 2017). In 1910, lung cancer was still such a 
rarity that Dr Alton Ochsner, one of the early leaders in lung cancer surgery, 
recalled, while a student at Washington University, being asked to attend the 
autopsy of a patient with lung cancer since he may never see another case 
again (Ochsner, 1973). It took 17 years for Dr Ochsner to see another case of 
lung cancer while working at Charity Hospital in New Orleans (Ochsner, 1973; 
Spiro and Silvestri, 2005). In less than 6 months, Dr Ochsner witnessed 8 more 
cases of lung cancer at the hospital and noted all were men, they all smoked 
heavily and had begun smoking in World War 1; thus began what he called an 
epidemic (Ochsner, 1973; Spiro and Silvestri, 2005).  
What began as a rarity in the latter part of the 19th century grew into a full-
scale epidemic in the 20th century and it seems that this trend will continue into 
the 21st century.  
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1.1.1.2. Causes of lung cancer  
It is now understood that smoking is one of the leading causes of lung cancer, 
but this was not always the case. For many years smoking was considered 
healthy and even promoted by physicians (Spiro and Silvestri, 2005; Ong and 
Ost, 2017). About 150 years ago lung cancer was a rarity, but during the turn 
of the 20th century the disease became more prevalent and this coincided with 
the increase in tobacco smoking. At first, cigarettes were hand-rolled which 
made them expensive. However, towards the end of the 20th century a tobacco 
rolling machine was patented which increased the production of cigarettes. 
This lowered their price and with World War 1 popularising the smoking of 
cigarettes amongst soldiers to lower the stress experienced in the trenches, 
smoking became a popular habit (Witschi, 2001; Ong and Ost, 2017). In the 
United Kingdom (UK), smoking is linked to 80% of lung cancer cases (Parkin, 
Boyd and Walker, 2011; Gemine et al., 2019). Research shows that with 
tobacco control interventions comes a reduction in lung cancer mortality (Hunt 
et al., 2018; Luo et al., 2019). That said, nearly 10-15% of lung cancer cases 
develop in patients who were never active smokers (Samet et al., 2009; Dias 
et al., 2017). As to what can be the cause of lung cancer in never smokers, 
several epidemiological studies suggest various aetiologies, including second-
hand smoking, other inhalable air pollutants such as asbestos, radon, coal, 
polycyclic aromatic hydrocarbons (PAHs), and nitric oxide, amongst others 
(Witschi, 2001; Anand et al., 2008; Samet et al., 2009; Raaschou-Nielsen et 
al., 2011, 2013; Peddireddy, 2016). Some studies point towards an increase 
in the proportion of lung cancer attributable to never smokers (Toh et al., 
2018).  
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1.1.1.3. Lung cancer statistics  
In 1912, only 374 cases of lung cancer were reported (Spiro and Silvestri, 
2005; Ong and Ost, 2017). However, in 2018 there were over 2 million new 
cases of lung cancer reported worldwide (International Agency for Research 
on Cancer, 2018).  
In the UK alone there were 46 388 new cases of lung cancer in 2015 
corresponding to 35 620 deaths from lung cancer in 2016 (Cancer Research 
UK, 2019). Lung cancer is the 3rd most common cancer in the UK (13% of all 
new cases in 2015) but is by far the most common cause of cancer death (21% 
of all cancer deaths in males and females combined in 2016) (Cancer 
Research UK, 2019). It is estimated that in the UK, 1 in 13 (8%) of males and 
1 in 15 (7%) females will develop lung cancer in their lifetime (Cancer 
Research UK, 2019).  
Roughly 60% of all newly diagnosed malignant tumours and 70% of all cancer 
mortality occurs amongst people aged 65 years or older, adding weight to the 
fact that age is the most significant risk factor for developing cancer (Smith et 
al., 2009; Al-Mansour, Pang and Bathini, 2019). Demographic data from 
around the world shows that the median age of the population is increasing 
with a subsequent increase in cancer incidence (Torre et al., 2016; Bray et al., 
2018; Pilleron et al., 2018; Al-Mansour, Pang and Bathini, 2019). This trend 
leads to the inevitable conclusion that cancer incidence and mortality will 
increase, leading to concerns about the economic impact.  
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1.1.1.4. Economics of lung cancer  
Statistics on the economics of cancer is hard to come by for 2019. However, 
the annual cost of all cancers to the UK economy was £15.8 billion for 2012 
(University of Oxford, 2012). The cost of lung cancer is the highest among all 
cancers at £2.4 billion per annum with the average lung cancer patient costing 
the National Health Service (NHS) £9 071 annually in treatments (Taylor, 
2012; University of Oxford, 2012). The main drivers of the high cost of lung 
cancer is the potential wage loss due to premature deaths from people in 
employment, which accounts for roughly 60% of the total economic costs, and 
the high health care costs (University of Oxford, 2012). That said, there are 
both direct and indirect costs of cancer. 
The direct costs of cancer include the cost of medication and administration of 
the treatment on the NHS. Innovation in cancer therapeutics is making the 
drugs more and more expensive, driving up the cost of cancer treatment. 
There is a growing body of evidence that suggests modern oncology drugs are 
unaffordable and that it is becoming unsustainable for healthcare providers, 
such as the NHS, to make these drugs available (Sullivan et al., 2011; 
Kantarjian and Patel, 2017). Studies have shown that the anticancer drugs 
and the administration of these drugs make up almost 50% of the cost of 
treating cancer (Storme et al., 2016). There has been an overall increase of 
88.6% in new systemic anticancer therapy (SACT) courses for lung cancer 
over a 5 year period from 2013-2018 (Bhimani et al., 2019). The number of 
treatment-related attendances for either intravenous or oral therapies for lung 
cancer saw an increase of 109% (Bhimani et al., 2019). There is also concern 
that this increase in patient numbers and patient treatment visits, along with 
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the complexity and lengthy treatment times, would lead to a scarcity of cancer 
specialists as the demand outstrips the supply (Yang et al., 2014; Cancer 
Research UK, 2017; Bhimani et al., 2019). This concern has already been 
realised as NHS England reported that their ability to meet their own target of 
96% of patients with cancer starting treatment within 31 days of diagnosis, is 
slowly decreasing since they lack the diagnostic capacity to cope with the 
increasing number of patients (Burki, 2019). Evidence suggests that this will 
only worsen with time (Appleby, 2019). The concern is that as these trends 
are projected to increase, it would hinder the ability of the NHS to treat cancer, 
leading to a decrease in the rate of cancer survival (Bupa, 2011; NHS, 2011). 
Although the direct costs of cancer are important for the providers of care, 
indirect costs can also impact the receiver of the care (the patient). When 
diagnosed with cancer, the patient is faced with a myriad of burdens; 
emotional, financial, and physical. The emotional and physical burdens come 
from the effect of the cancer on the patient’s body and mind, as well as their 
families/caregivers. Direct financial costs, such as anticancer medication, are 
handled by the NHS, but the indirect financial costs, for example, 
transportation to and from the health care facility for treatment, child care, and 
lost wages are some of the burdens that the patients and their families have 
to bear (Kim, 2007; CLIC Sargent, 2019). These indirect costs can lead to 
financial distress on top of the angst that comes with the cancer diagnosis 
itself. Evidence shows that financial distress could impact the successful 
completion of the treatment and, in turn, could impact survival rates (Gordon 
et al., 2009; Zafar et al., 2013; Bestvina et al., 2014; Peppercorn, 2014; 
Callahan and Brintzenhofeszoc, 2015; Yousuf Zafar, 2016; Altice et al., 2017). 
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It is quite evident that both the direct as well as the indirect costs of cancer put 
tremendous strain on the resources of all stakeholders, patients and the NHS. 
This strain could lead to a decrease in the positive outcomes of the treatment. 
A report compiled by BUPA gave a few suggestions on how to use resources 
more efficiently, including finding new ways to address the cost of tests and 
treatments for cancer, making it easier for people to navigate their cancer 
treatment pathway, and most importantly, changing how and where cancer 
patients and survivors are treated (Bupa, 2011). It was suggested that the 
option to receive chemotherapy at home should be a standard choice for 
patients (Bupa, 2011). The studies proposing homebased chemotherapy cite 
several benefits, such as a reduction in the amount of time spent in the hospital 
(which lowers the cost to the NHS), reduction in anxiety levels, not having to 
worry about getting to a hospital on time, reduced travel costs to patients and 
decreased exposure to others who may be seriously ill (Nursing Times, 2002; 
O’Neill and Wallis, 2009; Tralongo et al., 2011; Crisp et al., 2014; Evans et al., 
2016).  
This project will aim to propose a way to reduce costs by advocating 
chemotherapy at home by administering resveratrol loaded into 
nanocomposite microparticles (NCMPs) via pulmonary delivery.  
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1.1.2. Side-effects of current cancer chemotherapy treatment  
About of 70% lung cancers are diagnosed during the advanced stages of the 
disease where surgery or radiation alone may no longer be viable options 
(Travis, Brambilla and Riely, 2013).  
Chemotherapy is considered the first line therapy for advanced stages of lung 
cancer. Cancer chemotherapy, involves the administration of cytotoxic drugs 
that kill all cells exhibiting a high rate of proliferation and regeneration 
(Feitelson et al., 2015). Targeting of cells with high proliferation and 
regeneration rates means that the cytotoxic drugs not only affects cancer cells, 
but also rapidly dividing non-cancerous cells such as skin cells, hair matrix 
cells, hematopoietic cells of the bone marrow, and epithelium cells of the 
mouth and gastrointestinal tract. This leads to the common side effects of loss 
of hair (alopecia), impaired bone marrow function, nausea and vomiting 
(Trüeb, 2009; Wagland et al., 2016). This process of normal cells and tissues 
being affected is known as chemotherapy toxicity (Maguire et al., 2018). 
Chemotherapy toxicity may result in symptoms that range from distressing 
(e.g. breathlessness, nausea, vomiting) to dangerous (e.g. neutropenia) and 
have been associated with a decreased quality of life, poor treatment 
adherence, and ultimately increased mortality, which in turn drives up the cost 
of cancer for health care systems (McKenzie et al., 2011; Maguire et al., 2018).  
Chemotherapy-induced alopecia (CIA) is the most neglected side effect of 
chemotherapy and, while not life-threatening, has a lot of stigma attached to it 
and reports suggest that it would lead 8% of people rejecting chemotherapy 
treatment (Hesketh et al., 2004; van den Hurk et al., 2015; Rubio-Gonzalez et 
al., 2018). CIA affects about 65% of those receiving chemotherapy, depending 
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on the type of medication and treatment regimen (Suchonwanit and 
McMichael, 2018). Although in most cases CIA is temporary, there are cases 
where it results in permanent hair loss (Kang et al., 2019). CIA has a severe 
effect on quality of life for patients undergoing chemotherapy (Hesketh et al., 
2004; Freites-Martinez et al., 2019). Another chemotherapy-induced side 
effect that leads to a reduction in quality of life, is peripheral neuropathy. 
Chemotherapy-induced peripheral neuropathy (CIPN) occurs in up to 80% of 
patients receiving oxaliplatin and paclitaxel, which are commonly used in the 
treatment of lung cancer (De Iuliis et al., 2015). If use of the treatment persists 
it often leads to increased severity and permanent damage to the patient 
causing impaired function (Ezendam et al., 2014).  
Although CIA may not be life-threatening, the consequences for the patients 
experiencing it may be as life-altering and devastating as CIPN and other 
chemotherapy side effects and should be considered when evaluating 
treatment options. After all, the primary goal of the therapy is not only the 
prolonging of life, but also the preservation of the quality of life (Mols et al., 
2014).  
It is with that in mind, that the aim of this project is to establish the viability of 
using NCMPs to deliver resveratrol to the lungs via pulmonary delivery to cut 
down on the possible side effects.  
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1.1.3. Resveratrol as an alternative treatment for lung cancer treatment  
1.1.3.1. Phenolic compounds  
Phenolic compounds are diverse in structure, but are characterised as having 
at least one aromatic ring possessing one or more hydroxyl groups (Harborne, 
1999; Yang et al., 2018). Several classes of phenolic compounds exist, 
namely, flavonoids, phenolic acids, phenolic alcohols, stilbenes and lignans 
(Harborne, 1991; Sarker and Nahar, 2019). They are produced as secondary 
metabolites by the plants as a defence to various stressors, including oxidative 
stress (Heleno et al., 2015). Several phenolic compounds have been shown 
to have anti-lung cancer properties, both in vitro and in vivo (Fantini et al., 
2015; Hashemzaei et al., 2017; Duan et al., 2019; Lakshmi et al., 2019; Muller 
et al., 2019; Santos et al., 2019). Resveratrol is one of the phenolic compounds 
that has shown potential (Feng, Zhou and Jiang, 2016; Sun et al., 2017; 
Elshaer et al., 2018; Monteillier et al., 2018; Rauf et al., 2018; Saha et al., 
2018).  
1.1.3.1.1. Resveratrol  
Resveratrol (trans-3,5,4′-trihydroxystilbene) is the most common natural 
stilbene found abundantly in a large number of fruits and vegetables, most 
notably grapes (Figure 1-1) (Francioso et al., 2014). It has anti-inflammatory 
anti-oxidative, proapoptotic and cell cycle arrest properties (Albuquerque et 
al., 2015; Yu et al., 2016).  
A systematic review reported that resveratrol inferred a relative risk reduction 
of 0.64 (p=0.002) for tumour incidence compared to a control group (Feng, 
Zhou and Jiang, 2016).  
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Figure 1-1 Chemical structure of resveratrol  
 
1.1.3.1.1.1. In vitro evidence of efficacy against lung cancer  
There are numerous studies that have looked at the effect of resveratrol as a 
single therapeutic agent in various lung cancer cells, but only the evidence 
accumulated over the last 10 years will be summarised here (Table 1-1). 
Resveratrol (20, 50 & 100 µM) inhibited the phosphatidylinositol-3-kinase 
(PI3K) pathway and decreased mammalian target of rapamycin (mTOR) 
phosphorylation in A549, A427 and NCI-H23 cells (Ebi et al., 2009). SPC-A-1 
cells treated with resveratrol (20, 50 & 100 µM) showed decreased 
proliferation, increased apoptosis and cell cycle arrest caused by activation of 
caspase-3 and reduced survivin levels (Zhao et al., 2010). It was found that 
resveratrol (12.5, 25, & 50 µM) administered to 16HBE-T and H460 cells 
caused upregulation of miR-622 expression (a downstream target of K-ras) 
resulting in a reduction in cell viability and proliferation and initiation of G0 cell 
cycle arrest (Han et al., 2012). Resveratrol (50 µM) induced autophagic 
degradation of P62 activating caspase-8-mediated Beclin-1 cleaving, which 
resulted in apoptosis in A549 cells (Zhang et al., 2015). In A549 and H460 
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cells, resveratrol (10, 20, & 50 µM) was shown to increase senescence-
associated β–galactosidase (SA-β-gal), NAPDH oxidase-5 (Nox5), p53 and 
p21 expression, while decreasing elongation factor 1-alpha (EF1A) expression 
and causing reactive oxygen species (ROS)-mediated deoxyribonucleic acid 
(DNA) damage leading to inhibition of cell growth. Resveratrol (10 µM) 
inhibited cell viability and induced G2/M cell cycle arrest and apoptosis by 
increasing p53, p21, and tumour necrosis factor-related apoptosis-inducing 
ligand (TRAIL) receptor 1 and 2 expression, while downregulating B-cell 
lymphoma 2 (Bcl-2), cyclin D, nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) and IκB kinase 1 (Iκκ1) expression in A549 cells pre-
treated with Benzo(a)pyrene (20 µM), a carcinogenic polycyclic aromatic 
hydrocarbon (Ulasli et al., 2013). Resveratrol (2, 4, 8, 16, 32, & 64 µM) caused 
a dose-dependent inhibition of A549 cells via caspase 3 activation (Yin et al., 
2013). Another study showed the effect of resveratrol (5.5-175.2 µM) on 
activation of caspase 3 and subsequent cell inhibition and viability (Lucas and 
Kolodziej, 2015). Resveratrol (25 µM) was also shown to downregulate 
AK001796, long noncoding RNAs (lncRNAs), that acts as an oncogene in lung 
cancer carcinogenesis (Yang et al., 2015). This downregulation results in 
reduced cell viability and increased cell cycle arrest, which results in a 
reduction in cell proliferation (Yang et al., 2015). Yang et al. administered 
resveratrol (25-150 µM) to A549 cells which caused decreased cell 
proliferation and G0/G1 cell cycle arrest in a p53-independent manner. 
Resveratrol (20 µM) showed the ability to inhibit CL1-5, A549, H322 and 
H1435 tumour cell migration by upregulating miR-520h-mediated protein 
phosphatase 2 (PP2A/C) expression leading to inactivation of NF-κB and 
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further inhibition of the expression of forkhead box protein C2 (FOXC2), an 
important factor in epithelial–mesenchymal transition (EMT), which correlate 
with tumour metastasis (Yu et al., 2013). In another study, resveratrol (10-40 
µM) was shown to inhibit the invasion and migration of A549 cells by 
preventing transforming growth factor beta 1 (TGF-β1) induced EMT (Wang et 
al., 2013).  
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Table 1-1 List of resveratrol in vitro studies against lung cancer cells 
Cancer Cell Line Dose/Duration Findings Mechanism Reference 
A549, A427 and 
NCI-H23 
20, 50, 100 µM for 2, 4 or 8 h ↓ PI3K pathway  
↓ tumour formation 
↓ mTOR phosphorylation  Ebi et al., 2009 
 
SPC-A-1  20, 50, 100 µM for up to 96 h ↓ cell proliferation  
↑ apoptosis 
↑ cell cycle arrest 
↑ caspase-3 
↓ survivin levels 
Zhao et al., 2010 
16HBE-T and 
H460  
12.5, 25, 50 µM for 48 h ↓ cell proliferation  
↓ cell viability  
↑ cell cycle arrest 
↑ G0 cell cycle arrest  
↑ miR-622 expression  
K-ras is downstream target of miR-622 
Han et al., 2012 
A549  50 µM for up to 96 h ↑ apoptosis 
↑ autophagy 
Degradation of P62 
Activation of caspase-8 
Zhang et al., 2015 
A549 and H460 10, 20, 50 µM 24 h to 10-12 days ↓ cell growth  
 
↑ SA-B-gal  
↑ p53 and p21 expression 
↓ EF1A expression  
↑ DNA damage 
↑ ROS  
↑ Nox5 expression 
Luo et al., 2013 
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Cancer Cell Line Dose/Duration Findings Mechanism Reference 
A549 20 µM Benzo(a)pyrene for 48 h 
pre-treatment + 10 µM 
resveratrol for 24 h 
↑ G2/M cell cycle arrest 
↑ apoptosis 
↓ cell viability 
 
↑ p21 and p53 
↑ TRAIL receptor 1 and 2 
↓ Bcl-2 and cyclin D  
↓ NF-kB and IKK1 
Ulasli et al., 2013 
A549 2, 4, 8, 16, 32, 64 µM for 48 h ↑ cell inhibition 
 
↑ caspase-3 
 
Yin et al., 2013 
A549 5.5-175.2 µM for 24h ↓ cell viability 
 
↑ caspase-3 
 
Lucas and Kolodziej, 
2015 
A549  25 µM for 48 h ↓ cell proliferation 
↓ cell viability 
↑ cell cycle arrest 
 
Downregulation of AK001796  Yang et al., 2015 
A549 25, 50, 100, 150 µM for 24, 48, 
72 h 
↓ cell proliferation 
G0/G1 cell cycle arrest 
↑ p53 nuclear expression 
↓ cyclin D1, CDK4, CDK6 expression 
↑ CDK inhibitors (p21 & p27) 
Yuan et al., 2015 
CL1-5, A549, H322 
and H1435 
20 µM for 48 h ↑ tumour suppression 
↓ cell migration 
 
↑ miR-520h-mediated PP2A/C 
expression 
↓ FOXC2 expression  
Yu et al., 2013 
A549 10-40 µM for 48 h ↓ cell migration 
↓ cell invasion  
 
Preventing TGF-β1-induced EMT Wang et al., 2013 
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1.1.3.1.1.2. In vivo evidence of efficacy against lung cancer  
In contrast to in vitro studies, in vivo studies for resveratrol as a single 
therapeutic agent against lung cancer are a little harder to come by (Table 1-
2). Resveratrol (1 or 3 g/kg/day) consumed in the diet for 28 days inhibited 
tumour growth in BALB/c mice injected subcutaneously with SPC-A-1 cells 
into their flanks (Zhao et al., 2010). Sun et al. showed that resveratrol (20 
mg/kg) for 25 days led to an inhibition of metastasis and sirtuin 1 (SIRT1), the 
class III deacetylase, activation leading to a suppression of EMT in Nude mice 
inoculated with A549 cells (Sun et al., 2013). Similarly, nude mice inoculated 
with A549 cells and then treated with resveratrol (15, 30 or 60 mg/kg) injections 
for 15 days showed a dose-dependent inhibition of lung cancer cell growth 
(Yin et al., 2013). C57BL/6 mice were subcutaneously injected with Lewis lung 
cancer (LLC) tumour cells. After 10 days, the mice were treated with 
resveratrol (100 mg/kg) for 4 weeks and then sacrificed. It was found that 
resveratrol reduced expression of F4/80 positive cells, a type of antigen found 
on mouse macrophage cells and M2 polarisation in tumours leading to 
inhibition of lung cancer cell growth (Sun et al., 2017). Tumour associated 
macrophages (TAMs) have an important role in cancer progression and 
evasion of the immune system and inhibition of M2 polarisation of TAMs is an 
effective therapy for cancer (Ostuni et al., 2015).  
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Table 1-2 List of resveratrol in vivo studies against lung cancer animal models 
Animal Model Dose/Duration Findings Mechanism Reference 
18 female BALB/c 
mice injected with 
SPC-A-1 cells  
Diet supplemented with 1 or 3 
g/kg/day resveratrol for 28 days  
↓ tumour growth  
 
No mechanism identified  Zhao et al., 2010 
4-6 weeks old nude 
mice inoculated 
with A549 cells 
20 mg/kg resveratrol every other 
day for 25 days  
↓ metastasis  Activation of SIRT1 Sun et al., 2013 
old nude mice 
inoculated with 
A549 cells 
15, 30 or 60 mg/kg resveratrol 
injections for 15 days 
↓ lung cancer growth  No mechanism identified  
 
Yin et al., 2013 
C57BL/6 mice 
injected with LLC 
tumour cells 
100 mg/kg resveratrol 10 days 
after injection for 4 weeks 
↓ lung cancer growth  
 
↓ F4/80+ macrophages expression  
↓ M2 polarisation 
Sun et al., 2017 
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1.1.3.1.2. Bioavailability 
Both the in vitro and in vivo studies on the effects of resveratrol against lung 
cancer shows that there is great promise for its therapeutic application to treat 
cancer, but one major hindrance to this use is the low bioavailability resveratrol 
exhibits. Bioavailability refers to the fraction of the drug, i.e. resveratrol, that 
reaches the bloodstream unaltered (Peng et al., 2018). 
According to the Biopharmaceutical Classification System (BCS),  resveratrol, 
due to its poor water solubility and high membrane permeability, is classified 
as a class II compound (Santos et al., 2019). Resveratrol has relatively high 
oral absorption (at least 70% absorbed), but has a low oral bioavailability 
(Walle et al., 2004; Chimento et al., 2019). It is postulated that the low oral 
bioavailability could be due to the rapid sulphate conjugation of resveratrol by 
the liver/intestine (Walle et al., 2004; Chimento et al., 2019). Resveratrol is 
rapidly metabolised into several forms including, resveratrol 3-O-glucuronide, 
resveratrol 4-O-glucuronide, and resveratrol trisulphate, that retain some 
biological effects (Gambini et al., 2015; Wang and Sang, 2018).  
Several studies in humans concluded that after oral administration of 
approximately 25 mg resveratrol, the blood plasma concentration of the free 
form of resveratrol was between 1 and 5 ng/mL (Soleas, Yan and Goldberg, 
2001a, 2001b; Almeida et al., 2009; Loira-Pastoriza, Todoroff and Vanbever, 
2014). Higher doses of resveratrol (up to 5 g) yielded blood plasma levels of 
539 ng/mL for free resveratrol (Boocock et al., 2007). Repeated doses, 13 in 
total, of resveratrol (150 mg each) in 2 days did not yield better results, with a 
maximum plasma level of 64 ng/mL (Almeida et al., 2009; Wang and Sang, 
2018).  
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Resveratrol has shown to be effective in vivo, despite having a low oral 
bioavailability. This could be due to target organs such as the liver converting 
the resveratrol metabolites back into its original form, enterohepatic 
recirculation of the metabolites, followed by deconjugation and reabsorption, 
or it could all just be due to the metabolites and their own activity (Gambini et 
al., 2015).  
In vitro studies of the effects of resveratrol on lung cancer are quite promising, 
but concerns arise when trying to replicate the effects in vivo. In mammalian 
models, resveratrol, despite being lipophilic, shows poor oral bioavailability 
due to its extensive metabolism and rapid elimination (Wang and Sang, 2018). 
The in vitro studies indicate what resveratrol can do once accumulated at the 
site of action and in sufficient concentration. However, in reality when orally 
ingesting resveratrol from your diet, it has to navigate many obstacles to get 
to the bloodstream and ultimately the site of action. Phenolic compounds, such 
as resveratrol, degrade in the high acidity environment of the stomach which 
can cause uncontrolled release which, in turn, can cause decreased 
absorption from the intestines (Esfanjani, Assadpour and Jafari, 2018) 
Therefore, it is not possible to obtain, via the oral route, the concentration of 
resveratrol necessary to have the effects described in the in vitro studies.  
Resveratrol seems to be well tolerated with minimal side effects, even, at very 
high concentrations (Patel et al., 2011). There is tremendous potential for 
resveratrol, as evident by the preclinical testing, but it is yet to fully be realised 
in human trials (Tomé-Carneiro et al., 2013; Borriello et al., 2014; Singh, 
Ndiaye and Ahmad, 2015). The crux of the matter is the low oral bioavailability 
of resveratrol and, therefore, the focus should be on improving the 
20 
 
pharmacokinetic profile of resveratrol (Chimento et al., 2019). Towards this 
endeavour nanoparticulate drug delivery systems could efficiently transport 
the resveratrol to the site of action.  
1.1.4. Nanoparticulate delivery systems  
Nanoparticles (NPs) and liposomes are useful strategies to overcome the poor 
absorption, rapid metabolism, and elimination inherent in most natural 
products; helping to increase their bioavailability and target specific sites, such 
as the lung tumour cells. Several different nanoparticle (NP) systems exist that 
have been used to improve the bioavailability and efficacy of nutraceuticals, 
such as resveratrol (Arora and Jaglan, 2016). These NP systems include, 
liposomes, micelles, and polymeric NPs. 
1.1.4.1. Polymeric nanoparticulate drug delivery system  
Polymeric NPs refer to colloidal systems with a spherical or irregular shape 
that either encapsulates or entraps a biologically active substance (Vittorio et 
al., 2017). The advantages of polymeric NPs include; controllable physico-
chemical properties, high stability, homogenous size distribution, high drug 
encapsulation, and controllable drug release (Hu, Aryal and Zhang, 2010; 
Farooq et al., 2019). The therapeutic agents (i.e. resveratrol) can be delivered 
through adsorption, encapsulation, or conjugation either internally or on the 
surface of the polymeric NPs (Ahmadi, Mohammadinejad and Ashrafizadeh, 
2019). Numerous biodegradable polymers, both synthetic and natural, can be 
utilised to create polymeric NPs, including poly(D,L-lactic-co-glycolic acid) 
(PLGA), poly(D,L-lactic acid) (PLA), poly(ε-caprolactone) (PCL), chitosan and 
gelatin (Kumari, Yadav and Yadav, 2010).  
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The United States of America (USA) Food and Drug Administration (FDA) 
have approved PLA and PLGA for human applications. PLA and PLGA are 
broken down in an organism into their biodegradable biocompatible 
monomeric building blocks, lactic and glycolic acid, which can enter cell 
metabolic pathways (Kumari, Yadav and Yadav, 2010; Chereddy, Payen and 
Préat, 2018). When PLA and PLGA are administered intravenously, they are 
normally quickly cleared by the immune system of the host (Siddiqui et al., 
2009; Sharma et al., 2016). To combat this, and increase the circulation time, 
NPs are often coated with poly(ethylene glycol) (PEG), a polymer that can aid 
in evading clearance by the immune system (Sanchez, Yi and Yu, 2016). 
Chitosan is a natural polycationic linear polysaccharide, that has been shown 
to be mucoadhesive, non-immunogenic and non-toxic (Cheung et al., 2015). 
Gelatin is a protein-based biopolymer that is highly biocompatible and 
biodegradable with low toxicity and low antigenicity (Karthikeyan, Hoti and 
Prasad, 2015).  
Polymeric NPs have been extensively studied for their drug delivery capacity 
(Table 1-3). PLGA is, due to FDA approval, the most popular polymer used 
for NP delivery. It is safe and highly stable in colloidal suspensions and 
particles have been shown to have controlled release properties (Jensen et 
al., 2012; Sharma et al., 2016). PLGA NPs with or without chitosan coating 
have cytocompatibility with A549 cells at concentrations as high as 5 mg/mL 
(Tahara et al., 2009). 
Resveratrol-loaded PLGA (Res-PLGA) NPs were prepared via 
nanoprecipitation and compared with free-resveratrol against a prostate 
cancer cell line (LNCaP) (Nassir et al., 2018). Encapsulation of resveratrol in 
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the Res-PLGA NPs decreased the IC50 and IC90 by nearly half as compared to 
the free-resveratrol, 15.6 µM and 41.1 µM and 9.7 µM and 77.2 µM, 
respectively (Nassir et al., 2018). It was shown that Res-PLGA induced 
apoptosis in LNCaP cells through cell cycle arrest, DNA damage, 
externalisation of phosphatidylserine, generation of reactive ROS, and loss of 
mitochondrial membrane potential (MMP) (Nassir et al., 2018). The Res-PLGA 
showed cytocompatibility with murine macrophages even at 200  µM (Nassir 
et al., 2018). A solvent diffusion technique, using PLGA, N-oleoyl-d-
galactosamine and Tween 80, was employed to synthesise resveratrol-loaded 
galactosylated NPs (Res-GNPs) and compared with both resveratrol NPs 
made with PEG (Res-NPs) and free-resveratrol (Siu et al., 2018). The Res-
GNPs presented with a high encapsulation efficiency (EE%) (97.22% ± 2.31%) 
and a slow release profile (Siu et al., 2018). To assess oral bioavailability, 
Sprague-Dawley rats were given either, resveratrol suspensions (dispersed in 
0.3% carboxymethylcellulose sodium solution) (intragastric), Res-NPs 
(intragastric), Res-GNPs (intragastric) or resveratrol solution (intravenous) 
(Siu et al., 2018). Intragastric and intravenous preparations were administered 
40 mg/kg and 8 mg/kg, respectively. Compared with resveratrol suspensions 
(intragastric), the administration of Res-NPs (intragastric) and Res-GNPs 
(intragastric) resulted in a 165.7% and 335.7% increase in the relative 
bioavailability (AUC), respectively (Siu et al., 2018). Res-GNPs administration 
to mouse macrophage RAW 264.7 cells caused a significant decrease in 
proinflammatory cytokines (Interleukin 6 (IL)-6, nitrous oxide (NO), and tumour 
necrosis factor (TNF)-α) as compared with Res-NPs and free-resveratrol (Siu 
et al., 2018). A single-emulsion solvent evaporation technique was utilised to 
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synthesise resveratrol-loaded PLGA-α-tocopheryl PEG 1000 succinate 
(TPGS) blend NPs (Res-PLGA-BNPs) (Vijayakumar et al., 2016). The Res-
PLGA-BNPs had an EE% of 31.79–61.81%, depending on the ratio of 
PLGA:TPGS, with a sustained release profile (Vijayakumar et al., 2016). The 
MTT assay was used to evaluate the in vitro cytotoxicity of resveratrol, RSV-
PLGA-BNPs and blank PLGA-BNPs on C6 glioma cells. The RSV-PLGA-
BNPs showed the highest cytotoxicity and subsequent tests using coumarin 6 
attached to the PLGA-BNPs showed good cellular uptake in the C6 glioma 
cells (Vijayakumar et al., 2016). Charles Foster rats were used in the 
pharmacokinetic and tissue distribution studies. The rats were intravenously 
injected with either resveratrol solubilised using β-cyclodextrin (0.3 M) or RSV-
PLGA-BNPs (equivalent to 2 mg/kg of resveratrol). The RSV-PLGA-BNPs had 
an increased systemic circulation of time (up to 36 h) and a 18-fold higher plasma 
half-life compared to free-resveratrol (Vijayakumar et al., 2016). More recently, 
trans-resveratrol (t-Res) nanocrystals were prepared via probe sonication using 
TPGS as a stabiliser and lecithin and pluronic F127 as co-stabilisers (Singh et al., 
2017). Sprague Dawley rats were orally administered, either, the t-Res 
nanocrystals or a resveratrol suspension, both equivalent to 20 mg/kg. Results 
showed that t-Res nanocrystals increased the Cmax (2.2-fold), area under curve 
(AUC), (3.5-fold) and mean residence time (MRT) (1.2-fold) as compared to 
free-resveratrol (Singh et al., 2017). All this evidence points to an overall 
increase in bioavailability produced by the t-Res nanocrystals. The reasons 
given for the increase included, enhanced nanocrystal dissolution in the 
gastrointestinal fluid, increased bio-adhesion and/or direct uptake of 
nanocrystals across the intestinal barrier (Singh et al., 2017). The 
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nanoprecipitation method was used to produce resveratrol-loaded PLGA 
(Res-PLGA) NPs (Singh and Pai, 2014). The Res-PLGA NPs had an EE% of 
between 42-72% with a long, sustained release profile over 12 days (Singh 
and Pai, 2014). In vivo pharmacokinetic studies and biodistribution assays 
were performed via oral administration of the Res-PLGA NPs to male Wistar 
rats. The Res-PLGA increased bioavailability (10.6-fold increase in AUC 
values, 28-fold increase in tmax and 1.2-fold increase in Cmax values compared 
with free-resveratrol) (Singh and Pai, 2014). Resveratrol-loaded PEG-PLGA 
NPs (Res-PEG-PLGA) were prepared using double emulsion solvent evaporation 
(Li et al., 2016). The Res-PEG-PLGA NPs had an EE% of 68.2% and showed 
sustained release for more than 13 days (Li et al., 2016). The in vitro cytotoxicity 
studies performed on HepG2 liver cancer cells showed a time- and dosage-
dependent inhibition of cell growth caused by the Res-PEG-PLGA NPs (Li et al., 
2016). 
Resveratrol-loaded PEG–PLA NPs showed dose-dependent inhibitory effects 
on CT26 colon cancer cell viability and proliferation (Jung et al., 2015). BALB/c 
nude mice injected with CT26 colon cancer cells to form a tumour were used 
as an animal model for the in vivo studies. When the tumour mass grew to a 
visible size, the mice were injected with either empty PEG-PLA NPs or RSV-
PEG-PLA NPs twice per week for 21 days (Jung et al., 2015). Subsequent 
analysis showed a significant decrease in tumour growth with an increase in 
survival of the mice that received the RSV-PEG-PLA NPs as compared with 
the empty PEG-PLA NPs (Jung et al., 2015).  
Resveratrol-loaded PCL nanocapsules (Res-PCL) were prepared using 
interfacial deposition followed by solvent displacement (Carletto et al., 2016). 
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The Res-PCL had a very high EE% (97%) and reduced cell viability of B16F10 
murine melanoma cells (Carletto et al., 2016). C57BL/6J mice were 
subcutaneously injected with B16F10 cells (5 × 104) into their posterior flank. 
About 10 days after the injection, the mice developed a visible and palpable 
tumour. Then, the mice were either given no treatment, blank PCL 
nanocapsules, Res-PCL nanocapsules (5 mg/kg/day), or free-resveratrol (5 
mg/kg/day). The mice treated with Res-PCL nanocapsules showed a 
statistically significant decrease in tumour volume as compared with the other 
groups (Carletto et al., 2016).  
An ionic cross-linking method was used to prepare resveratrol-loaded 
chitosan-sodium tripolyphosphate (TPP) NPs (J. Wu et al., 2017). Particle size 
analysis showed that the chitosan-TPP NPs were between 172–217 nm (J. 
Wu et al., 2017). The highest EE% obtained was 11.1%, which is quite low, 
and the NPs had a biphasic release with an initial burst for 2 hours followed 
by a slow and sustained release. The resveratrol-loaded chitosan-TPP NPs 
elicited a 10-30% increase in antioxidant activity as compared with the free-
resveratrol (J. Wu et al., 2017). Fluorescence microscopy and the MTT assay 
were used to show cellular uptake and cytotoxicity, respectively, in both human 
hepatocellular carcinoma cells SMMC7721 and human normal hepatocyte 
cells LO2 (J. Wu et al., 2017). The resveratrol-loaded chitosan-TPP NPs had 
a higher uptake and increased cytotoxicity as compared with free-resveratrol 
against the cancerous cell line, but had a lower cytotoxic effect than free-
resveratrol on the normal cell line (J. Wu et al., 2017). Emulsion cross-linking 
was used to prepare resveratrol-loaded carboxymethyl chitosan NPs (Res-
CMCSNPs) (Zu et al., 2016). The Res-CMCSNPs had an EE% of 44.5% and 
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the in vitro drug release in simulated GI tract gave a delayed release profile as 
compared to free-resveratrol (Zu et al., 2016). Six healthy male Sprague-
Dawley rats were separated into two groups and orally administered, either, 
free-resveratrol or Res-CMCSNPs (both 50 mg/kg dosage equivalent 
resveratrol). The resveratrol absorption and bioavailability in rats was 
enhanced, 3.5 times higher, when encapsulated as compared to non-
encapsulated resveratrol (Zu et al., 2016). Bu et al., prepared resveratrol-
loaded avidin (Avi) and biotin (Bio) modified chitosan (CS) (Res-AviBioCS). 
The Res-AviBioCS NPs had a good EE% (66.4%) with a sustained release 
profile (Bu et al., 2013). Kunming mice (4 groups of 28) were injected (0.25 
mg/kg) with, either, free-resveratrol, resveratrol-loaded CS NPs, Bio-CS NPs, 
and Res-AviBioCS NPs. Compared with free-resveratrol , the Res-AviBioCS 
NPs showed an AUC that was 2.6-fold higher, tmax that was 25-fold higher, and 
an MRT which was 4.5-fold greater (Bu et al., 2013).  
Resveratrol-loaded gelatin (Res-Gel) NPs were synthesised through a 
coacervation-phase separation technique (Karthikeyan et al., 2013). The Res-
Gel NPs had a very high EE% (93.6%) and a sustained release profile over 2 
days (Karthikeyan et al., 2013). NCI-H460 non-small cell lung cancer cells 
were used to assess the in vitro uptake and cytotoxicity of Res-Gel NPs. 
Compared to free-resveratrol, the Res-Gel NPs had a very rapid and 
enhanced cellular uptake, higher generation of ROS, DNA damage, apoptotic 
incidence and reduced the IC50 by half from 10 µg/mL for free-resveratrol to 5 
µg/mL for Res-Gel NPs (Karthikeyan et al., 2013). Swiss albino mice (2 groups 
of 6) were intravenously administered (10 mg/kg) free-resveratrol or Res-Gel 
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NPs. The resveratrol serum concentration of the mice treated with Res-Gel 
NPs were twice as high as the mice treated with free-resveratrol.  
Epidermal growth factor (EGF) conjugated lipid-polymer hybrid NPs (LPNs) 
were synthesised to co-deliver docetaxel (DTX) and resveratrol for lung cancer 
therapy (Song et al., 2018). The EGF-LPNs had an encapsulation efficiency 
(EE%) of 90% with a sustained release profile (Song et al., 2018). Flow 
cytometry showed significantly higher uptake of blank and DTX/resveratrol 
loaded EGF-LPNs as compared with normal LPNs and the free drugs in 
HCC827 human adenocarcinoma cells (Song et al., 2018). The in vitro studies 
showed a significant decrease in tumour cell (HCC827 and NCIH2135) viability 
as compared to DTX or resveratrol LPNs (Song et al., 2018). The in vivo 
studies showed that mice injected with DTX/resveratrol EGF-LPNs presented 
with inhibition of tumour growth with a reduction in the size of the tumour (Song 
et al., 2018). The method developed by Chou and Talalay to assess the effects 
of multiple drugs to determine their summation, synergism and antagonism, 
was used to evaluate the interaction of resveratrol and DTX (Chou and 
Talalay, 1984). The equation showed that resveratrol and DTX had a 
synergistic effect (Song et al., 2018). 
The wide range of studies reported in the literature demonstrate that polymeric 
NPs can enhance the bioavailability of resveratrol and many other studies also 
show that encapsulated resveratrol not only retain the anticancer effects 
mentioned in sections 1.1.3.1.1.1 and 1.1.3.1.1.2, but the polymeric NPs also 
help enhance these effects (Karthikeyan, Hoti and Prasad, 2015; Summerlin 
et al., 2015; Singh, Lillard and Singh, 2018; Suktham et al., 2018). However, 
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to maximise efficacy, delivery of the drug directly to the required site of action 
is crucial. In the case of lung cancer, local delivery to the lungs is beneficial. 
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Table 1-3 Resveratrol loaded into polymeric NPs  
Polymeric Nanoparticle Cell Line/ 
Animal Model 
Finding(s) Reference 
PLGA LNCaP Halved IC50 and IC90 as compared to free-resveratrol.  
Induced apoptosis via: 
cell cycle arrest 
DNA damage 
Externalisation of phosphatidylserine 
ROS generation  
Loss of MMP.  
Well tolerated by murine macrophages even at 200 µM.  
Nassir et al., 2018 
Galactosylated PLGA  RAW 264.7 cells 
Sprague-Dawley rats 
Increased bioavailability of resveratrol. 
Suppression of proinflammatory cytokines.  
Siu et al., 2018 
PLGA-BNPs C6 glioma cells  
Charles Foster rats 
Increased cytotoxicity and cellular uptake. 
Enhanced systemic circulation and half-life vs free-
resveratrol (increased bioavailability).  
Vijayakumar et al., 
2016 
TPGS Sprague-Dawley rats Increased bioavailability 
Compared to free-resveratrol: 
increased Cmax (2.2-fold),   
Singh et al., 2017 
30 
 
Polymeric Nanoparticle Cell Line/ 
Animal Model 
Finding(s) Reference 
AUC (3.5-fold)  
MRT (1.2-fold) 
PLGA  Male Wistar rats Good EE% and prolonged release profile. 
Compared to free-resveratrol: 
10.6-fold increase in AUC values 
28-fold increase in tmax  
1.2-fold increase in Cmax values  
Singh and Pai, 2014 
PEG-PLGA HepG2 Good EE% and prolonged release profile. 
Dose and time dependant growth inhibitory effects.  
Li et al., 2016 
PEG-PLA CT26 colon cancer cells 
BALB/c nude mice injected with 
CT26 cells 
Dose dependant inhibitory effect.  
Increased survival time of mice and decreased tumour 
growth.  
Jung et al., 2015 
PCL B16F10 
C57BL/6J mice injected with B16F10 
High EE% and reduction of cell viability.  
Statistically significant decrease in tumour volume vs 
free-resveratrol 
Carletto et al., 2016 
Chitosan-TPP SMMC7721 and LO2 Increased cellular uptake. 
Increased cytotoxicity against cancer cells vs resveratrol. 
Wu et al., 2017 
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Polymeric Nanoparticle Cell Line/ 
Animal Model 
Finding(s) Reference 
Less cytotoxic to normal cells vs free-resveratrol.  
CMCS Sprague-Dawley Good EE% and prolonged release profile. 
Increased bioavailability compared with free-resveratrol: 
AUC 3.5-fold increase 
Cmax 1.2-fold increase 
tmax 2.1-fold increase 
Zu et al., 2016 
AviBioCS Kunming mice Good EE% and prolonged release profile. 
Increased bioavailability vs free-resveratrol: 
AUC 2.6-fold higher 
tmax 25-fold higher 
MRT 4.5-fold greater 
Bu et al., 2013 
Gelatin NCI-H460 
Swiss albino mice  
Very high EE% and a sustained release profile over 2 
days 
Increased bioavailability 
2-fold increase in serum levels  
Karthikeyan et al., 2013 
EGF conjugated LPNs HCC827 and NCIH2135 High EE% and sustained in vitro release. 
Decreased tumour cell viability in cell lines. 
Song et al., 2018 
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Polymeric Nanoparticle Cell Line/ 
Animal Model 
Finding(s) Reference 
BALB/c nude mice (6–8 weeks old) 
injected with HCC827 cells  
Inhibition of tumour growth and decreased size in vivo.  
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1.1.4.2. Preparation of nanoparticles  
Methods for the preparation of polymeric NPs are usually broken down into 
two main groups, viz. 1. diffusion of preformed polymer; and 2. polymerisation 
of monomers (Soppimath et al., 2001; Amoabediny et al., 2018). 
There are several methods for manufacturing polymeric NPs from preformed 
polymers, namely; dialysis, emulsification/solvent diffusion, emulsion solvent 
evaporation, high-pressure homogenisation, nanoprecipitation, salting out, 
spray drying, and supercritical fluid technology (Amoabediny et al., 2018). The 
intended use of the polymeric NPs and the chemistry of the drug determines 
the method to be used. For the purposes of this project, the emulsion solvent 
evaporation method will be employed.  
1.1.4.2.1. Emulsion solvent evaporation  
Emulsion solvent evaporation was the first technique developed to 
manufacture polymeric NPs (Masood, 2016).  
In this method, an emulsion is created by dissolving the polymer in an organic 
volatile solvent, such as dichloromethane and chloroform (Amoabediny et al., 
2018) (Figure 1-2). The organic phase consists of the polymer (synthetic, 
semi-synthetic or natural) dissolved in the organic solvent and the aqueous 
phase consists of the water along with stabiliser/surfactant (Masood, 2016). 
Single (oil-in-water, o/w) and double emulsification (water-in-oil/in-water, 
w1/o/w2) methods are employed for the creation of the emulsion (Masood, 
2016). Secondly, the exposure of the emulsion to a high energy source, such 
as a homogeniser or ultrasonicator, converts it into a nanoparticle suspension 
(Amoabediny et al., 2018). Lastly, the volatile solvent is removed by 
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evaporation through increasing the temperature under pressure or by 
continuous stirring (Reis et al., 2006; Iqbal et al., 2015). The polymeric NPs 
are then usually collected via lyophilisation or centrifugation (Nagavarma et 
al., 2012). 
Several factors influence and control NP characteristics, including 
homogeniser type, polymer concentration, and stirring speed (Amoabediny et 
al., 2018).  
 
Figure 1-2 Schematic diagram of emulsion solvent evaporation 
technique (modified from (Kunda et al., 2013) ) 
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1.1.5. Pulmonary delivery  
1.1.5.1. Anatomy of the lungs 
The lungs consist of the right lung, separated into three lobes (upper, middle, 
lower) by the oblique and horizontal fissures, and the left lung, separated into 
two lobes (upper and lower) by a single oblique fissure (Kradin, 2017). The 
visceral and parietal pleura, which are lubricated with pleural fluid, separates 
the lungs from the thoracic cage (Barrow and Pandit, 2014). Upon inhalation, 
air travels via the oral (mouth) and nasal (nose) cavity, from the larynx to the 
trachea. In the trachea, the air splits at the carina into the left and right 
mainstem bronchi, then it branches into lobar bronchi (one for each of the 
lobes (two on the left and three on the right), followed by segmental bronchi 
which divides further for approximately 15 to 20 times down to the level of the 
terminal bronchioles (Weinberger, Cockrill and Mandel, 2019). These 
conductive airways are the smallest units that do not play a part in gas 
exchange (Weinberger, Cockrill and Mandel, 2019). The entire airway as far 
as the respiratory bronchioles are lined with ciliated columnar epithelium 
containing mucus-secreting goblet cells, which acts as a physical defence 
barrier via the mucociliary escalator (Barrow and Pandit, 2014). The mucus 
covering the airways is moved towards the mouth via the coordinated 
movement of the cilia. This process is known as the mucociliary escalator. It 
serves as a line of defence and removes any foreign material that lands on the 
bronchial surfaces (Kradin, 2017). 
After the terminal bronchioles, further divisions give rise to the respiratory 
bronchioles, alveolar ducts, and alveoli which form the part of the lung 
responsible for gas exchange.(Weinberger, Cockrill and Mandel, 2019). These 
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alveolar ducts and sacs are lined with squamous epithelium (Barrow and 
Pandit, 2014). The average human lung is said to comprise of 300 million 
alveoli with the surface area approximately the size of a tennis court 
(Weinberger, Cockrill and Mandel, 2019).  
Any particles, including that of a drug delivery system, encounter several 
obstacles before getting to the lung cells.  
1.1.5.2. Drug delivery to the lungs  
Pulmonary drug delivery allows for the non-invasive administration of a 
drug/bioactive compound via inhalation (Zhang et al., 2018). There are many 
advantages to delivering drugs via the lungs for both local and systemic 
treatment, including high bioavailability since the first pass metabolism is 
bypassed, rapid onset of action due to direct targeting at the site of action (lung 
cancer cells), self-administration (similar to how asthmatics use their inhalation 
devices) and non-invasiveness (which increases patient compliance) (Sung, 
Pulliam and Edwards, 2007; Mahmud and Discher, 2011; Thorley and Tetley, 
2013; Lee et al., 2015).  
One of the biggest challenges for cancer chemotherapy is the non-specific 
targeting/ distribution of the anticancer agent and the severe side effects this 
produces (Alexiou et al., 2000; Ray, 2019). NP-mediated pulmonary delivery 
will aid in overcoming this obstacle through targeted delivery; by reducing the 
dosage required to treat the cancer and reducing the amount of drug the 
healthy cells are exposed to. 
However, there are several obstacles to overcome in order for pulmonary 
delivery to be effective. The pulmonary drug delivery system will have to evade 
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the natural defences of the lung, including phagocytosis by alveolar 
macrophages and the mucociliary escalator (Chishti et al., 2019). 
Furthermore, the delivery system has to be carefully designed to ensure the 
highest delivery of the formulation to the middle or deep regions of the lungs 
where NPs have effectiveness (Kaminskas et al., 2014). The reduced 
clearance of macromolecules from tumours leads to more inhalable particles 
depositing in tumour tissue than in healthy cells, thus increasing the circulation 
time of the drug-loaded NPs in the interstitial tissue of the tumours (Maeda, 
2001; Godugu et al., 2013; d’Angelo et al., 2015) 
The nano-sized (< 1 µm) nanoparticulate system inherently has the ability to 
overcome mucociliary clearance and macrophages phagocytosis (Kanehira et 
al., 2016). That said, that same size advantage makes spray-dried NPs 
incapable of depositing directly into the lungs since they get exhaled without 
settling in the alveoli (Pilcer and Amighi, 2010; Rezazadeh et al., 2018). 
Aerodynamic particle size has an important role in determining the deposition 
and retention of the inhaled particles. The ideal range for particles to be able 
to deposit in the deep regions of the lung is between 1 and 5 µm aerodynamic 
diameter (El-Sherbiny and Smyth, 2012; Elsayed and AbouGhaly, 2016; 
Rezazadeh et al., 2018). 
If the inhaled particles are <1 µm, they may be exhaled rather than deposited 
in the lung, due the effect of Brownian movement (Florence, 2012). However, 
if the inhaled particles are > 5 µm, they would collide with the lining of the 
mucosal membranes, particularly at bifurcations, due to inertial impaction 
caused by gravity (Islam et al., 2017).  
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1.1.5.3. Pulmonary delivery of nanocomposite microparticles  
NPs can be placed into nanocomposite microparticles (NCMPs) using a carrier 
system such as lactose or mannitol microparticles (MPs). This carrier system 
should improve the size of the particles and allow for a suitable fine particle 
fraction (FPF) for delivery to the deep regions of the lungs. FPF refers to the 
fraction of the dose ≤ to the effective cut-off aerodynamic diameter of 5.5 µm 
at a specific flow rate (i.e. 60 L/min) (Rezazadeh et al., 2018).  
1.1.5.3.1. Preparation of nanocomposite microparticles  
1.1.5.3.1.1. Spray drying  
Spray drying is an established technique for the production of particles which 
involves the transformation of a fluid material into dried particles, by means of 
a gaseous hot drying medium (Cal and Sollohub, 2010; Deshmukh, Wagh and 
Naik, 2016). The spray drying process can be divided into three major phases, 
namely, atomisation, droplet-to-particle conversion (solvent evaporation), and 
particle collection (Sosnik and Seremeta, 2015).  
Firstly, a solution (emulsion or suspension) is pumped to an atomiser which 
breaks up the liquid feed into a spray of fine droplets (Santos et al., 2017). 
Secondly, the fine droplets are expelled into a drying gas chamber which 
causes solvent evaporation, leading to the formation of dry particles (Santos 
et al., 2017). Lastly, the dried particles are separated from the drying medium, 
using an appropriate device such as a cyclone, and can then be collected in a 
tank (Santos et al., 2017).  
Several parameters influence the characteristics of the final dry particles, 
including atomisation pressure, feed flow rate, feed viscosity, feed surface 
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tension, inlet temperature, drying gas flow rate, outlet temperature, residence 
time inside drying chamber, and glass transition temperature (Santos et al., 
2017).  
Spray drying is advantageous for pulmonary delivery since it can produce 
inhalable powder that is in the respirable size range for pulmonary delivery 
(Santos et al., 2017). Spray drying allows for the control of the particle size, 
shape, density and moisture content by altering the parameters mentioned 
before (Muralidharan et al., 2015). This combined with the possibility of 
continuous manufacturing, ease of scalability, good uniformity of molecular 
dispersion and cost-effectiveness in large scale production with high 
recoveries, make spray drying an attractive method to use (Patel, Patel and 
Chakraborty, 2014). Recently, spray drying has been used to produce NCMPs 
loaded with levofloxacin and bovine serum albumin (Merchant et al., 2014; 
Kunda, Alfagih, Dennison, Tawfeek, et al., 2015).  
1.1.5.3.2. Delivery of nanocomposite microparticles 
Delivery of inhalable particles can be achieved by different inhalation devices, 
namely, the nebuliser, the pressurized metered dose inhaler (pMDI), 
Respimat® Soft Mist™ inhaler, and the dry powder inhaler (DPI). The 
nebuliser was the first inhalation therapy device developed and uses an air jet 
or ultrasound to generate aerosol droplets from a drug solution or suspension 
which are then inhaled by the patient over a couple of minutes (Steckel and 
Eskandar, 2003; Hertel, Winter and Friess, 2015). The main disadvantages of 
the nebuliser is that it is non-portable, requires lengthy administration, needs 
constant cleaning and maintenance, and they suffer from poor reproducibility 
in delivering an accurate dose and are only commonly used in hospitals 
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(Malcolmson and Embleton, 1998; Peng et al., 2016). The pMDI is a portable 
and convenient multidose device which generates a metered dose of an 
aerosol through an atomisation nozzle using a propellant under pressure 
(Dolovich and Dhand, 2011; Ivey, Vehring and Finlay, 2015). However, pMDI 
require successful coordination between the actuation of the device and 
inhalation by the patient (Dolovich et al., 2019). Some other concerns include 
issues with the environmental impacts of the propellant, solubility and 
compatibility between the drug and propellant, as well as physicochemical 
stability concerns (Muralidharan et al., 2015). On top of that, DPIs often give 
a better stability profile for the loaded bioactive compound than aerosols or 
nebulisers (Ungaro et al., 2012). It is with this in mind that the DPI has emerged 
as a better candidate.  
1.1.5.3.2.1. Dry powder inhaler (DPI) 
The DPI is a device that contains an active pharmaceutical ingredient (API) 
that is in a suitable aerodynamic size (usually 1–5 µm) for inhalation, which 
upon inhalation, causes sufficient deagglomeration of particles resulting in the 
delivery of a therapeutic dose to the lungs (Peng et al., 2016). There are 
several advantages of the DPI, including propellant-free, non-invasive, 
portable, user-friendly, low-cost, and the powder is more stable than liquid 
dosage forms (Lee et al., 2015).  
The DPI was developed in response to the poor actuation–inhalation 
coordination inherent with other inhalers of the time (Hoppentocht et al., 2014). 
The biggest hurdle with micron-sized particles as used in the DPI is that they 
have high cohesive forces (making them stick together) and adhesive forces 
(making them stick to any surface they encounter) (Young et al., 2008; Peng 
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et al., 2016). This results in poor flowability and performance with the 
formulation being prone to get stuck within the inhaler (Young et al., 2008). 
Many of the APIs also require a lower dose for pulmonary delivery than 
systemic delivery, which necessitate their reduction in order to give accurate 
metering of doses. These limitations has led to the development of carriers or 
excipients which have several functions including, enhancing the flowability of 
drug particles to ease filling of the DPI, enhancing dispersion of drug particles 
during emission, and decreasing concentration of the drug to facilitate 
accurate delivery of dose (Peng et al., 2016).  
A formulation for DPI either consists of a respirable API or an API blended with 
non-respirable excipients such as lactose, which, until now, is the sole FDA-
approved non-respirable carrier in the US (Lee et al., 2015). Outside the USA, 
several other non-respirable excipients have been used including glucose, 
maltitol, mannitol, raffinose, sorbitol, sucrose, and xylitol (Lee et al., 2015).  
One of the first DPIs, Spinhaler®, started being commercially available in 1971 
(Sanders, 2011; Hoppentocht et al., 2014). Since then, many others have 
followed.  
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1.1.5.3.3. Delivery described in literature  
Polymeric NPs have been used for the pulmonary delivery of small molecules, 
genes and proteins/peptides (Yamamoto et al., 2005; Azarmi, Roa and 
Löbenberg, 2008; Mansour, Rhee and Wu, 2009; Menon et al., 2014; Gaul et 
al., 2018; Nieto-Orellana et al., 2018; Rodrigues et al., 2018).  
However, studies using polymeric NP-mediated microparticles for pulmonary 
delivery of phenolic compounds are a little less ubiquitous in the literature 
(Table 1-4).  
NPs in MPs, that is NCMPs, were synthesised for deep lung delivery. PLGA 
NPs loaded with TAS-103, an anti-cancer drug, was synthesised with an 
average size of 200 nm (Tomoda et al., 2009). The TAS-103-loaded PLGA 
NPs were then spray-dried with trehalose as an excipient (Tomoda et al., 
2009). The TSA-103-loaded nanocomposite microparticles (T-NCMPs) had an 
enhanced in vitro cytotoxicity effect against A549 cells when compared to free 
TAS-103 (Tomoda et al., 2009). It is thought that the NCMPs are completely 
disintegrated into NPs in the presence of cell media and, therefore, this might 
lead to better internalisation of NPs through endocytosis or passive diffusion 
(Tomoda et al., 2009). Male Sprague-Dawley rats were divided into two groups 
and administered the TAS-103-loaded NCMPs using an animal DPI or free 
TAS-103 in saline (equivalent to the drug concentration administered via DPI) 
using intravenous administration as a control. Administration via DPI resulted 
in significantly higher drug concentration in the lungs (300-fold) than in the 
plasma (Tomoda et al., 2009). Moreover, the drug concentration in the lungs 
via inhalation was 13 times higher than with intravenous administration 
(Tomoda et al., 2009).  
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2-Methoxyestradiol (2-ME) PLGA NPs were prepared using a single emulsion 
(o/w) method and coated with chitosan (Guo et al., 2014). The 2-ME PLGA-
chitosan NPs were incorporated into NCMPs using lactose, leucine, and 
Poloxamer 188, as excipients. The 2-ME PLGA-chitosan NPs had an average 
size of 221 nm before spray drying and 225 nm after reconstitution from the 
NCMPs (Guo et al., 2014). Two cell lines, SPC-A1 and A549, were exposed 
to free 2-ME in solution or encapsulated in the various particles (PLGA NPs, 
PLGA-chitosan NPs and the 2-ME-loaded PLGA-chitosan NCMPs (2-ME-
PLGA-chitosan MPs)). The 2-ME-PLGA-chitosan MPs resulted in an 9-fold 
and 4-fold decrease of IC50 in SPC-A1 and A549, respectively (Guo et al., 
2014). The 2-ME was replaced with 6-cumarin to prepare 6-cumarin-PLGA-
chitosan MPs and it was intratracheally administered to rats. Results showed 
uptake of 6-cumarin-PLGA-chitosan MPs in alveolar and bronchial wall, 
showing that the 2-ME PLGA-chitosan NPs could reach deep lung tissue 
through nanocomposite microparticle delivery(Guo et al., 2014). The strong 
fluorescence on the bronchial wall indicates chitosan NPs easily sticks to the 
mucus layer of the cilia surface (Guo et al., 2014).  
More recently, sildenafil citrate (SC)-loaded PLGA NPs (SC-PLGA NPs) with 
an average size of 210 nm were formulated (Ghasemian et al., 2016). The SC-
PLGA NPs were then incorporated into microparticles using spray drying with 
lactose (1:1 w/w) as an excipient. Free SC was also spray dried using lactose 
(1:50 w/w). The average size and fine particle fraction of the spray-dried 
sildenafil nanocomposite (SSN) and spray-dried free SC (SFS) was 7 µm and 
4.5 µm, and 60.2% and 68.2%, respectively (Ghasemian et al., 2016). Male 
Sprague-Dawley rats were randomly divided into four experimental groups 
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and either received 1 mL intravenous injection (100 µg/mL SC solution), 1 mL 
oral administration (100 µg/mL SC solution), SSN or SFS (both equal to 100 
µg SC). The SSN and SFS was delivered to the rats via insufflation. Results 
showed that SSN is detected in the lung twice as long as the next best 
formulation (SFS), 12 hours vs 6 hours, and unlike SFS, it has a sustained 
release profile in the lung (Ghasemian et al., 2016).  
Liu et al. prepared paclitaxel- oleic acid-conjugated chitosan NPs (P-OA-CTS) 
and quercetin-oleic acid-conjugated chitosan NPs (Q-OA-CTS) and then co-
loaded both NPs into microparticles by spray drying the NPs with 
hydroxypropyl-β-cyclodextrin, lactose, and mannitol as excipients (Liu et al., 
2017). The microparticles (PQ-CTS-MPs) obtained was shown to be in the 
ideal range of between 1 and 5 µm with a slow release profile (Liu et al., 2017). 
Wistar rats were separated into four groups. The four groups received 
equivalent doses of either, PQ-CTS-MPs (intratracheally), paclitaxel, 
quercetin, or paclitaxel and quercetin (all intravenously). The study 
ascertained that intravenous delivery of the microspheres caused more 
accumulation of the encapsulated drug in the liver and kidney than in the lung, 
while pulmonary administration lead to a significant majority of the drug 
depositing in the lungs with minimal amounts accumulating in the other organs 
(Liu et al., 2017). Furthermore, 6 hours after pulmonary administration, 
paclitaxel and quercetin concentration in the lung remained high (206.27 µg/g) 
with comparatively low distribution in the liver (8.82 µg/g), spleen (6.94 µg/g), 
kidney (5.01 µg/g) and heart (2.61 µg/g) at the same time. Whereas, 6 hours 
after intravenous delivery the concentration of paclitaxel and quercetin in all 
organs were ≤ 5 µg/g. It was reported that quercetin helped increase the 
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circulatory time of paclitaxel (Liu et al., 2017). Combined, this shows that 
pulmonary delivery of microparticles not only improved the retention time of 
the drugs, but also allowed for the accumulation of the drug in the lung with 
only minimal amount of drug accumulating in other organs. This should lead 
to lower side-effects. 
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Table 1-4 Delivery of nanocomposite microparticles 
Dry Powder Formulation  Cell Line/ 
Animal Model 
Finding(s) Reference 
NPs Drug Excipient 
PLGA TAS-103 Trehalose A549  
Sprague-Dawley 
rats  
T-NCMPs more cytotoxic, in vitro, than free-TAS-103.  
13-fold increase in drug concentration in lungs from DPI 
administration of T-NCMPs vs free-TAS-103. 
300-fold increase in drug concentration in lungs vs 
plasma when administering T-NCMPs using DPI.  
Tomoda et al., 2009 
PLGA-
chitosan 
2-
methoxyestradiol 
(2-ME) 
lactose, 
leucine, and 
Poloxamer 188 
SPC-A1 and 
A549 
Rats 
2-ME-loaded NCMPs vs free-drug 
9-fold and 4-fold decrease of IC50 in SPC-A1 and A549, 
respectively.  
Strong uptake of NCMPs in the lungs.  
Guo et al., 2014 
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Dry Powder Formulation  Cell Line/ 
Animal Model 
Finding(s) Reference 
NPs Drug Excipient 
PLGA sildenafil citrate Lactose Sprague-Dawley 
rats 
NCMPs has enhanced pharmacokinetics vs spray-dried 
free drug following pulmonary delivery.  
Ghasemian et al., 
2016 
Chitosan 
and oleic 
acid 
 
Paclitaxel 
Quercetin  
Hydroxypropyl-
β-cyclodextrin, 
lactose, and 
mannitol 
Wistar rats Pulmonary delivery: 
 Improved the retention time of the drugs.  
Allowed for the accumulation of the drug in the lung with 
only minimal amount of drug accumulating in other 
organs. 
Liu et al., 2017 
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1.2. Thesis hypothesis  
Resveratrol-loaded aerosolisable NCMPs can be used for the treatment of 
lung cancer.  
1.3. Thesis aim and objectives  
To develop, design, formulate and characterise resveratrol-loaded 
aerosolisable NCMPs as a potential treatment for lung cancer by dry powder 
delivery directly to the lungs.  
In order to achieve the aim of the thesis a systematic study was designed 
considering the following objectives:  
1) Development of a resveratrol-loaded nanoparticle delivery system   
a. To optimise formulation of resveratrol into various polymeric NPs and 
assess their characteristics. 
b. To design protocols to evaluate the effect of free-resveratrol and 
nanoparticle-loaded resveratrol on lung cancer cells.  
2) Incorporation of optimum resveratrol-loaded NPs into NCMPs via spray  
drying with L-leucine and chitosan as microcarrier.  
a. Optimisation of NCMPs formulations in term of morphology and yield%.  
b. A study of the in vitro aerosolisation behaviour, in vitro release and cell 
toxicity.  
3) To design and synthesise a modified polymer to allow for attachment of 
fluorescent ligands to enable detection of the particles within cells 
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a. Designing chemical experiments in order to evaluate the feasibility for using 
click chemistry.  
b. Modification of glycerol to attach alkyne group.  
c. Polymerisation of modified polymer. 
d. Development of a fluorescent azide to attach to alkyne group.  
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2 CHAPTER 2: The Formulation and Evaluation of Resveratrol 
Nanoparticles  
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2.1. Introduction 
Resveratrol has shown very good anticancer activity both in vitro and in vivo, 
but, like many phenolic compounds, it suffers from poor oral bioavailability 
(Walle et al., 2004; Yuan et al., 2015; Zhang et al., 2015; Sun et al., 2017). 
Therefore, this chapter focusses on our aim to enhance bioavailability by 
encapsulating resveratrol into polymeric nanoparticles (NPs) which protects it 
from metabolic degradation.  
Polymeric NPs possess many advantages including controllable physico-
chemical properties, high stability, homogenous size distribution, high drug 
encapsulation, and controllable drug release (Hu, Aryal and Zhang, 2010; 
Farooq et al., 2019). Several biodegradable polymers, both synthetic and 
natural, can be utilised to create polymeric NPs, including poly (lactic-co-
glycolic acid) (PLGA), polylactic acid (PLA), polycaprolactone (PCL), 
poly(glycerol adipate-co-ω-pentadecalactone) (PGA-co-PDL), chitosan and 
gelatin (Kumari, Yadav and Yadav, 2010; Kunda, Alfagih, Dennison, Tawfeek, 
et al., 2015). The resveratrol can be incorporated into the NPs through either 
adsorption, encapsulation, or by conjugation, either to the polymer or 
externally to the nanoparticle (NP) surface (Ahmadi, Mohammadinejad and 
Ashrafizadeh, 2019). 
There are various methods for manufacturing polymeric NPs from preformed 
polymers, namely, dialysis, emulsification/solvent diffusion, emulsion solvent 
evaporation, high-pressure homogenisation, nanoprecipitation, salting out, 
spray drying, and supercritical fluid technology (Amoabediny et al., 2018). The 
solvent evaporation method was used in this study. 
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In this method, an emulsion is created by dissolving the polymer in a volatile 
organic solvent, such as dichloromethane and chloroform, which is known as 
the organic phase (Masood, 2016; Amoabediny et al., 2018). The aqueous 
phase consists of the water along with stabiliser/surfactant (Masood, 2016). 
Single (oil-in-water, o/w) and double emulsification (water-in-oil/in-water, 
w1/o/w2) methods are employed for the creation of the emulsion (Masood, 
2016). Secondly, the exposure of the emulsion to a high energy source, such 
as a homogeniser or ultrasonicator, converts it into a NP suspension 
(Amoabediny et al., 2018). Lastly, the volatile solvent is removed by 
evaporation through increasing the temperature under pressure or by 
continuous stirring (Reis et al., 2006). 
Several factors influence and control NP characteristics, including 
homogenizer type, polymer concentration, ratio of organic and aqueous 
phases and stirring speed (Kunda, Alfagih, Dennison, Tawfeek, et al., 2015; 
Amoabediny et al., 2018). Polymeric NPs of between 100-200 nm were 
desirable since studies suggests these particles are ideal for uptake and 
evasion of the alveolar macrophages and they show rapid penetration of the 
respiratory mucus (Dandekar et al., 2010; Schuster et al., 2013; Youngren-
Ortiz et al., 2017; Dabbagh et al., 2018). 
Cell culture is an intrinsic and versatile methodological platform in cellular and 
molecular biology, facilitating the study of the normal biochemistry and 
physiology of cells and how drugs and toxic compounds affect cells, 
carcinogenesis and mutagenesis (Shwetha et al., 2019). The bronchial Calu 3 
epithelial cell line, originating from a human lung adenocarcinoma, can be 
used for cytotoxicity studies as a relevant in vitro pulmonary model for 
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polymeric NP delivery (Dekali et al., 2014; Kreft et al., 2015).The Calu 3 cell 
line expresses many characteristics of the bronchial epithelium including the 
formation of tight polarised monolayers with tight junctions and appreciable 
transepithelial resistance values, expression of microvilli, along with mucin 
granules, and the lung surfactant-specific protein prosurfactant protein-C 
(Fiegel et al., 2003; Grainger et al., 2006; Kreft et al., 2015). Lastly, Calu-3 
cells show rapid and reliable growth over a wide passage range (Foster et al., 
2000; Kreft et al., 2015).  
Cell proliferation assessment is a good indicator of cell health maintenance or 
cell death induction in response to drugs or chemical agents and is thus used 
to determine cell viability (Adan, Kiraz and Baran, 2016). Cell viability is the 
amount of healthy, living cells in a given population (Adan, Kiraz and Baran, 
2016). There are various methods for measuring cytotoxicity that are based 
on  biochemical or morphological aberrations induced in healthy cells, 
including with respect to ATP production, cell adherence, cell membrane 
permeability, co-enzyme production, DNA synthesis, dye uptake, enzyme 
release, metabolic activities and nucleotide uptake activity (Weyermann, 
Lochmann and Zimmer, 2005; Aslantürk, 2018). This study made use of two 
assays, one of which is a metabolic cell proliferation assay (Alamar Blue 
Assay, assessed cell viability) and the other a cell membrane integrity and cell 
metabolism assay (Lactate Dehydrogenase Assay - assessed cell death). 
The Alamar Blue (resazurin sodium salt) assay involves the reduction of 
resazurin (blue and nonfluorescent) by healthy cells to resorufin, which is pink 
and highly fluorescent (Brien et al., 2000). The reduction is due to the 
enzymatic actions of mitochondrial, cytosolic, and microsomal enzymes 
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(Vega-Avila and Pugsley, 2011; Rampersad, 2012; Munshi, Twining and Dahl, 
2014). Alamar Blue is extremely stable, exhibits no toxicity to the cells, and 
allows for continuous monitoring of cultures over time (Al-Nasiry et al., 2007). 
The lactate dehydrogenase (LDH) assay was first developed to measure 
cytotoxicity in immune cells (Adan, Kiraz and Baran, 2016). It works on the 
principle that the cytosolic enzyme, LDH, is present in many cells and that 
upon plasma membrane damage, in cases of necrotic or late apoptotic cells, 
it gets released into the cell culture medium. Extracellular LDH then catalyses 
the conversion of lactate to pyruvate via the reduction of NAD+ to NADH 
(Decker and Lohmann-Matthes, 1988; Fotakis and Timbrell, 2006; Han et al., 
2011). Diaphorase, NADH dehydrogenase, utilises NADH to reduce a 
tetrazolium salt (INT) to a red formazan product which can be measured to 
determine the amount of LDH released into the cell culture medium (Nachlas 
et al., 1960; Decker and Lohmann-Matthes, 1988).  
2.2. Aim and Objectives  
The aim of this study was to synthesise and analyse optimised polymeric NPs 
containing resveratrol and to evaluate the efficacy of the formulation compared 
to free-resveratrol.  
The main objectives were: 
To optimise the formulation of resveratrol-encapsulated PLGA, mPEG-PLGA, 
PGA-co-PDL, and PGA-co-PDL-PEG2000 NPs.  
To evaluate the nanoparticles in terms of; particle size, polydispersibilty index 
(PDI), zeta potential, resveratrol encapsulation efficiency, and NP stability;  
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To study the in vitro cytotoxicity of the optimised formulation on Calu 3 cells. 
2.3. Materials and Methods 
2.3.1. Materials  
Polymer synthesis: Divinyl adipate (DVA) was purchased from TCI, USA. ω-
pentadecalactone (PDL) was obtained from Sigma-Aldrich Fine Chemicals 
(SAFC, UK). Glycerol, Novozyme® 435 (discontinued and replaced by lipase 
acrylic resin), polyvinyl alcohol (PVA) 89000-98000 molecular weight (MWt), 
PLGA, mPEG-PLGA, PEG-2000, and the various polystyrene standards (2430 
Da, 3680 Da, 13 700 Da, 18 700 Da, and 29 300 Da) were purchased from 
Sigma-Aldrich, UK. Tetrahydrofuran (THF), dichloromethane (DCM), and 
methanol (HPLC grade) were purchased from Fisher Scientific, UK. 
Cell culture: Minimum Essential Medium Eagle (MEM), L-glutamine, 
Penicillin-Streptomycin, foetal bovine serum (FBS), resazurin sodium salt, and 
sodium pyruvate solution were obtained from Sigma-Aldrich, UK. TrypLE™1X 
was purchased from Thermofisher, US. Phosphate buffered saline (PBS) was 
purchased from Fisher Scientific, UK. Human lung adenocarcinoma cell line, 
Calu-3, was purchased from American Type Culture Collection (ATCC). The 
Alamar Blue and LDH assay kit were purchased from Fisher Scientific, UK. 
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2.3.2. Methods 
2.3.2.1. Polymer synthesis 
2.3.2.1.1. PGA-co-PDL synthesis 
PGA-co-PDL was synthesised via enzyme catalysed ring opening 
polymerisation and polycondensation as described in various papers 
(Namekawa, Uyama and Kobayashi, 2000; Thompson et al., 2006) (Figure 2-
1). The various monomers were added in an equimolar ratio (1:1:1) - PDL 
(0.125 mol), DVA (0.125 mol), and glycerol (0.125 mol) - to a dry 250 mL three-
necked round-bottomed flask. THF (20 mL) was then added to prevent the 
reaction from becoming too viscous. The filled flask was then placed in a water 
bath (50 °C) to the level of the solution. The central neck of the round-bottomed 
flask was equipped with a mechanical stirring rod fitted with a Teflon paddle 
(105 mm) and kept in place with an adaptor. One of the other necks was fitted 
with an open top condenser to act as an outlet for the acetaldehyde produced 
by the reaction. The third neck which was used to add the monomers was 
closed with a stopper. The solution in the round-bottomed flask was stirred for 
20 minutes to allow the monomers to dissolve and the temperatures to 
equilibrate. The enzyme, Novozyme® 435 (1 g), was weighed into a glass 
dispenser and then added to the free open neck of the round-bottomed flask. 
THF (5 mL) was used to wash any of the remaining enzyme into the flask. The 
open neck was then closed again using the stopper and the reaction was 
permitted to proceed for 6.5 hours. 
After 6.5 hours, the resultant viscous polymer was dissolved using DCM (200 
mL) while still being stirred. The enzyme complex was removed via Buchner 
filtration using 1 layer of filter paper (Whatman GF/A). Warm DCM (300 mL) 
57 
 
was used to expedite the filtration. The filtrate was then transferred to a round-
bottomed flask and the DCM was then removed via rotary evaporation at 80 °C 
(Laborota 4000, Heidolph Instruments attached to a Divac pump) until 
approximately 20 mL DCM remained. 
This solution was then charged with methanol (100 mL) and the round-
bottomed flask was agitated to precipitate the co-polymer. The co-polymer was 
then filtered using Buchner filtration with 1 layer of filter paper (Whatman 
GF/A). Methanol was used to expedite the filtration. The solid co-polymer 
trapped on the filter paper was left to air dry overnight. 
 
Figure 2-1 Enzymatic synthesis of PGA-co-PDL via ring opening 
polymerisation and polycondensation 
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2.3.2.1.2. PGA-co-PDL-PEG2000  
Synthesis of Poly(ethylene glycol methyl ether)-PGA-co-PDL (PGA-co-PDL-
PEG2000) followed the same procedure as in 2.3.2.1.1, except that 
Poly(ethylene glycol) methyl ether (mPEG2000) monomer was added at a molar 
ratio of 0.01 (PDL:DVA:Glycerol:mPEG2000, 1:1:1:0.01) (Figure 2-2). 
 
Figure 2-2 Enzymatic synthesis of PGA-co-PDL-PEG2000 via ring 
opening polymerisation and polycondensation 
 
2.3.2.1.3. Poly(D,L-lactide-co-glycolide) (PLGA) 
Resomer® RG 502 H, Poly(D,L-lactide-co-glycolide) (Figure 2-3) was 
purchased from Aldrich chemistry.  
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Figure 2-3 PLGA structure 
 
2.3.2.1.4. PEG methyl ether-block-poly(lactide-co-glycolide) (mPEG-PLGA) 
Poly(ethylene glycol) methyl ether-block-poly(lactide-co-glycolide) (Figure 2-
4) was purchased from Aldrich chemistry. 
 
 
Figure 2-4 mPEG-PLGA structure 
 
2.3.2.2. Polymer analysis 
2.3.2.2.1. Molecular weight analysis - Gel Permeation Chromatography (GPC) 
GPC was used to obtain the molecular weight (MWt) of the polymers. The 
GPC instrument (Malvern Viscotek TDA Model 300) connected to a GPC max 
integrated solvent and sample module (degasser, pump, and auto sampler) 
was used with OmniSEC 5.1 software to determine molecular weight and 
molecular weight distribution. The GPC system was equipped with two 
ViscoGEL GMHHR-N columns, stored in the detector oven at 40 °C. The 
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eluent used was THF, at a flow rate of 1 mL/min. Prior to analysis, the GPC 
system was purged for 5 minutes, every 30 minutes, until stability of the RI 
detector baseline was achieved. 
The GPC was calibrated using polystyrene standards (2430 Da, 3680 Da, 13 
700 Da, 18 700 Da, and 29 300 Da). Preparation of the polystyrene standard 
samples (5 mg/mL) involved dissolving each polystyrene standard (10 mg) in 
THF (2 mL) and mixing it using a benchtop vortex mixer (Velp Scientifica 
Vortex) at 3000 rpm for 20 seconds. The standard solutions were filtered into 
clean GPC vials using a glass syringe coupled with a filter system fitted with 1 
layer of PTFE syringe filter (0.2 µm, Whatman). The filter was wetted with THF 
(1 mL) before use. A new filter was used for each polystyrene standard. 
Polytetrafluoroethylene (PTFE) septa (Sigma) were used in vial lids to prevent 
evaporation and clogging up of the injection needle. A GPC vial containing 
THF (used as a blank) was also prepared and all vials were placed in the 
instrument. The GPC system was set up to take 3 injections (100 µL) from 
each vial beginning with the THF blank and then the polystyrene standards 
from the lowest to the highest MWt. A calibration curve of log MWt versus 
retention volume was obtained by analysing the retention volume at the peak 
maxima of each polystyrene standard. 
Preparation of polymer samples (5 mg/mL) involved dissolving the co-polymer 
(10 mg) in THF (2 mL) and mixing it using a benchtop vortex mixer (Velp 
Scientifica Vortex) at 3000 rpm for 20 seconds. The co-polymer sample was 
filtered using the method described earlier. The retention volume of the peak 
maxima was used to determine the MWt by using the calibration curve 
obtained previously. 
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2.3.2.2.2. Chemical structure analysis – Fourier Transform Infra-Red (FT-IR) 
Spectroscopy and Nuclear Magnetic Resonance (NMR) Spectroscopy 
2.3.2.2.2.1. Fourier Transform Infra-Red (FT-IR) Spectroscopy 
The chemical structures of the co-polymers were obtained using Agilent 
Technologies MicroLab FT-IR software running on an Agilent Technologies 
Cary 630 FT-IR Spectrometer (Agilent, USA). The spectra were collected from 
650-4000 cm-1 at a resolution of 4 cm-1. 
2.3.2.2.2.2. Nuclear Magnetic Resonance (NMR) 
Proton nuclear magnetic resonance (1H NMR) spectra for the polymers were 
obtained using a Bruker Avance III 300 MHz spectrometer operated with 
Topspin v3.2. The NMR spectra were expressed in parts per million (δ) with 
trimethylsiline as an internal standard.  
A sample of each polymer (10 mg) was measured and dissolved into 
deuterated chloroform (CDCL3) (0.7 mL). This solution was then filtered and 
transferred into an NMR tube (Wilmad 5 mm NMR tube, Goss Scientific 
Instruments Ltd.) and capped. The obtained spectra were analysed using 
MestReNova software. 
2.3.2.2.3. Thermal analysis – Differential Scanning Calorimetry (DSC) 
The thermal stability of each polymer was determined using a Perkin Elmer 
DSC 8000 with Pyris software. An indium reference standard was used to 
calibrate the system. A small sample of the polymer (4-15 mg) was 
hermetically sealed in standard aluminium pans (Perkin Elmer, USA) and 
placed in the sample chamber. The samples were heated from 25 °C to 70 °C 
at a rate of 20 °C/min and then cooled from 70 °C to 25 °C at a rate of 
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20 °C/min. The samples were then reheated from 25 °C to 70 °C at a rate of 
20 °C/min. 
2.3.2.3. Polymeric nanoparticle synthesis 
Blank polymeric NPs were synthesised via a modified water-in-oil-in water 
(w1/o/w2) double emulsion evaporation method. The co-polymer (50 mg) was 
weighed into a clean vial and dissolved using DCM (2 mL). This co-polymer 
solution (organic phase) was subsequently mixed using an ultrasonic water 
bath (Ultrawave) for 2 minutes. The organic phase was then probe sonicated 
for 2 minutes at 65% amplitude (QSonica sonicator, USA) while adding 
dropwise 10% w/v PVA (0.5 mL) (1st aqueous solution) to form an emulsion. 
This process was performed in ice. This primary emulsion was then probe 
sonicated for 2 minutes at 65% amplitude (QSonica sonicator, USA) while 
adding dropwise 1% w/v PVA (20 mL) (2nd aqueous solution) to form a second 
emulsion. This process was also performed in ice. This final emulsion was 
immediately added to a beaker on a Jeio Tech MS-53M magnetic stirrer 
(Jeiotech, South Korea) stirring at a speed of 500 rpm. The mixture was left 
stirring at room temperature for 3 hours to facilitate the evaporation of DCM. 
After 3 hours, the nanoparticle suspensions were collected via 
ultracentrifugation (Beckman Coulter Optima XPN-80) using a 70.1 Ti rotor at 
35 000 rpm for 40 minutes at 4 °C. The resulting NPs were washed and then 
fresh deionised water (dH2O) (5mL) was added before another 
ultracentrifugation step at the same parameters was performed.  
A series of 5% (2.5 mg) w/w- and 10 % (5 mg) w/w resveratrol-encapsulated 
polymeric NPs (5% RNP and 10% RNP) were synthesised using the 
procedure described for the blank nanoparticles (BNP). The resveratrol was 
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added to the polymer (50 mg) before the addition of DCM (2 mL) to produce 
the organic phase. The procedure was then followed exactly as with the BNP. 
2.3.2.4. Polymeric nanoparticle analysis 
2.3.2.4.1. Particle size and zeta potential 
Dynamic light scattering with a particle size analyser (Zetasizer Nano ZS, 
Malvern Instruments Ltd, UK) was employed to measure the particle size, zeta 
potential, and polydispersity index (PDI). An aliquot (100 µL) of the 
nanoparticle suspension (before ultracentrifugation) was diluted in dH2O (5 
mL), then it was transferred into a cuvette and measured at 25 °C (n=3). 
Measurements were also taken from the NPs obtained after 
ultracentrifugation. The NPs (10 mg) were suspended in dH2O (5 mL) and 
dispersed using an ultrasonic water bath (Ultrawave, UK) for 1 minute. An 
aliquot (500 µL) of the resulting suspension was diluted in dH2O (5 mL), then 
it was transferred into a cuvette and measured at 25 °C (n=3).  
2.3.2.4.2. Drug loading and encapsulation efficiency (EE%) 
Centrifugation of the polymeric NPs (BNP, 5% RNP, 10% RNP) resulted in the 
formation of a pellet of NPs. The NPs were dispersed in dH2O (5 mL). This 
solution was then transferred to 5mL screw top vials (Agilent Technologies, 
USA) and frozen using liquid nitrogen. These solid samples were then loaded 
into a beaker and attached to a Telstar Lyoquest Freeze-drier coupled with a 
Telstar bomba Torricelli vacuum pump (Azbil Telstar, UK). The samples were 
allowed to dry overnight. The dry samples were collected and weighed.  
High performance liquid chromatography (HPLC) (1200 series; Agilent 
Technologies, USA) using a YMC-Triart C18 150 x 4.6 mm I.D. S-5 µm, 12 nm 
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column (YMC Co. LTD., Japan) was used to determine the amount of 
resveratrol encapsulated in the polymeric NPs. A sample (10 mg) of the 
previously freeze dried polymeric NPs (BNP, 5% RNP, and 10% RNP) were 
dispersed in the mobile phase methanol:water (51:49; v/v) (2.5 mL). These 
solutions (4mg/mL) were filtered into clean 2mL crimp vials (Agilent 
Technologies, USA) using a plastic syringe fitted with a Captiva Econofilter 
PTFE 13 mm 0.45 µm filter (Agilent Technologies, USA). The samples (10 µL) 
were injected into the system with a flow rate of 0.54 mL/min. The variable 
wavelength detector (VWD; Agilent Technologies, USA) was set at 306 nm. 
The BNP was used as a control.  
Previously, resveratrol standards (0.3 µg–625 µg) were run on the HLPC using 
the same parameters as above. The results of the area under the curve were 
plotted against the various concentrations to obtain a calibration curve. This 
calibration curve was used to determine the amount of resveratrol 
encapsulated in the polymeric NPs. 
Theoretical drug loading (TDL) was calculated using the following equation: 
𝑇𝐷𝐿 =
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑟𝑒𝑠𝑣𝑒𝑟𝑎𝑡𝑟𝑜𝑙 (mg) 𝑎𝑑𝑑𝑒𝑑 
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑝𝑜𝑙𝑦𝑚𝑒𝑟 (𝑚𝑔)
                          Equation 2-1 
5% 𝑅𝑁𝑃 (𝑇𝐷𝐿) =
2.5 𝑚𝑔 
50 𝑚𝑔
= 0.05 𝑚𝑔 = 50 µg/mg (w/w) 
10% 𝑅𝑁𝑃 (𝑇𝐷𝐿) =
5 𝑚𝑔 
50 𝑚𝑔
= 0.1 𝑚𝑔 = 100 µg/mg (w/w) 
EE% was calculated using the following equation: 
𝐸𝐸% =
𝐷𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 𝑐𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑𝑓𝑟𝑜𝑚 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑐𝑢𝑟𝑣𝑒 (µg) 
𝑇𝐷𝐿 (µg)
 𝑥 100 Equation 2-2  
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2.3.2.4.3. Release study  
PGA-co-PDL NPs (BNP, 5% RNP, and 10% RNP; 10mg) were obtained after 
centrifugation (Beckman Coulter Optima XPN-80) using a 70.1 Ti rotor at 35 
000 rpm for 40 minutes at 4 °C. Percentage resveratrol released (RR) was 
calculated as follows: 
𝑅𝑅 % =
 𝑟𝑒𝑠𝑣𝑒𝑟𝑎𝑡𝑟𝑜𝑙 𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 𝑎𝑡 𝑡𝑖𝑚𝑒 𝑝𝑜𝑖𝑛𝑡 (µ𝑔)
𝑟𝑒𝑠𝑣𝑒𝑟𝑎𝑡𝑟𝑜𝑙 𝑙𝑜𝑎𝑑𝑒𝑑 (µ𝑔)
 𝑥 100 %        Equation 2-3 
 
Two methods were attempted: 
2.3.2.4.3.1. Sacrificial method 
A weighted amount (10 mg) of the NPs (BNP, 5% RNP, and 10 %RNP) were 
placed in separate sealed Falcon tubes containing PBS (10 mL; pH 7.4). An 
aliquot (2 mL) was transferred to a fresh Eppendorf tube (1 mg/mL). The 
Eppendorf tubes (3x5) were placed on a Grant-Bio PTR-35 multi-function 
rotator (Grant Instruments, UK) stirring at 30 rpm in a Stuart S160 incubator 
(Stuart Equipment, UK) at 37 °C. At pre-determined intervals, one Eppendorf 
tube per formulation was removed from stirring and centrifuged using an 
Eppendorf 5415 D centrifuge (Eppendorf, Germany) at 12000 rpm for 10 
minutes. The supernatant was analysed via HPLC for resveratrol content using 
the method described in 2.3.2.4.2. 
2.3.2.4.3.2. Replacement method  
This method was performed in the same way as in 2.3.2.4.3.1. However, there 
was only 1 Eppendorf tube per formulation. At pre-determined intervals, the 
Eppendorf tubes, one for each formulation, were removed from stirring and 
centrifuged using an Eppendorf 5415 D centrifuge (Eppendorf, Germany) at 
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12000 rpm for 10 minutes. Afterwards, an aliquot (1 mL) of the supernatant 
was removed and replaced with a fresh aliquot of PBS (1 mL). The supernatant 
was analysed via HPLC for resveratrol content using the method described in 
2.3.2.4.2. 
2.3.2.5. Cell culture 
Human lung adenocarcinoma cells (Calu-3) were grown in Minimum Essential 
Medium Eagle (MEM) media supplemented with 10% foetal bovine serum 
(FBS), 1% L-glutamine, 1% penicillin-streptomycin, 1% MEM Non-essential 
amino acids and 1% sodium pyruvate in a 75 cm2 tissue culture flask in a 
humidified incubator at 37 °C with 5% CO2. 
2.3.2.6. Cell viability studies 
2.3.2.6.1. Alamar Blue (resazurin sodium salt) 
Resazurin sodium salt (7-Hydroxy-3H-phenoxazin-3-one-10-oxide sodium 
salt), also known as Alamar Blue, was used to assess the in vitro cytotoxicity 
of the PGA-co-PDL BNP and resveratrol-encapsulated NPs. Resazurin, which 
is blue and nonfluorescent, is reduced by healthy cells, to resorufin, which is 
pink and highly fluorescent (O’Brien et al., 2000). 
The cells were cultured as described in 2.3.2.5.  
For the assay, cells in the T75 flask were counted using a C-Chip Neubauer 
improved haemocytometer (LabTech, UK) and diluted with fresh cell culture 
media to give a density of 104 cells/mL in a final volume of 10 mL. An aliquot 
(100 µL) of this suspension of cells was seeded into each well (103 cells/well) 
of a Corning 96-well, opaque, clear flat-bottom plate (Sigma-Aldrich, UK). The 
plate was then placed in the incubator at 37 °C for 48 hours with 5% CO2. After 
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48 hours, the spent media was removed and replaced with fresh cell culture 
medium (100 µL/well). Then, an aliquot (100 µL) each of BNP, 5% RNP, and 
10% RNP, freshly prepared in complete cell culture medium to an appropriate 
range of working concentrations (0-1 mg/mL) (n=3), was added to the wells, 
with 10% dimethyl sulfoxide (DMSO) used as a positive control. After 24 hours 
of incubation at 37 °C with 5% CO2, all the spent media was removed and the 
wells were rinsed with PBS (100 µL). Then, resazurin sodium salt (50 mg) was 
added to PBS (10 mL) to form a 10x solution of resazurin sodium salt. 
Afterwards, an aliquot (1 mL) of the 10x resazurin sodium salt solution was 
added to PBS (9 mL) to make up a 1x solution. An aliquot (10 µL) of this 1x 
solution was then added to each well, which already contained fresh cell 
culture media (100 µL), giving a final concentration of 50 µg/mL that the cells 
were exposed to, and the plate was again incubated at 37 °C with 5% CO2. 
After 3 hours, the fluorescence intensity of the solution, which directly 
correlates with the number of viable cells, was measured (excitation: 540 nm; 
emission: 590 nm) using a CLARIOstar plate reader (BMG Labtech, 
Germany). The percentage of viable cells in each well was determined by 
taking the fluorescence intensity of the negative (untreated) control as 100% 
viability and normalising the fluorescence intensity of each treatment to it. 
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2.3.2.6.2. Lactate Dehydrogenase (LDH) assay 
The cells were cultured and plated as described in 2.3.2.6.1, except the cells 
were treated with different concentrations: BNP, 10% RNP, Free-resveratrol 
(18.8-300 µM) and 5% RNP (9.375-150 µM) (n=3). After 48 hours or 72 hours 
of incubation at 37 °C with 5% CO2, the protocol supplied with the kit was 
followed (catalogue #: 88954, ThermoFisher). Briefly, lysis buffer (10 µL), 
supplied with the kit, and ultrapure water (10 µL), as a control for the lysis 
buffer, were added to separate wells (triplicates). The plate was then incubated 
at 37 °C with 5% CO2 for 45 minutes. After 45 minutes, an aliquot (25 µL) of 
each well containing cells was taken and transferred to a fresh Falcon 96-well 
flat bottom plate (Corning, USA) (Figure 2-5). Reaction mixture (25 µL) was 
added to each sample well and mixed by gentle tapping. The plate was 
incubated at room temperature for 30 minutes protected from light. After 30 
minutes, stop solution (25 µL) was added to each sample well and mix by 
gentle tapping. The absorbance at 490nm and 680nm was measured using a 
CLARIOstar plate reader (BMG Labtech, Germany). For the analysis, the 
absorbance value at 680 nm (background signal from instrument) was 
subtracted from the absorbance value at 490 nm.
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Figure 2-5 Plate layout for LDH assay
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2.3.2.7. Statistical analyses and IC50 calculations  
All statistical analyses were performed using Graphpad Prism 7. One-way 
analysis of variance (ANOVA) followed with Tukey's multiple comparisons test 
was employed to compare the mean values (from the formulations) with each 
other. Statistically significant differences were assumed when p<0.05. The 
level of confidence was set as 95%. All values are expressed as their mean ± 
standard error of mean (SE) (cell studies) or mean ± standard deviation (SD) 
(all other studies). IC50 was calculated in GraphPad Prism using the non-linear 
regression equation log (inhibitor) vs. response (three parameters) or log 
(inhibitor) vs. response -variable slope (four parameters).  
2.3.3. Results 
2.3.3.1. Monomer analysis  
2.3.3.1.1. FT-IR and NMR 
2.3.3.1.1.1. ω-Pentadecalactone (PDL) 
 
Figure 2-6 Structure of ω-pentadecalactone 
 
FT-IR v max: 3469, 2924, 2853, 2686, 1731, 1461, 1378, 1348, 1284, 1248, 
1242, 1235, 1157, 1108, 1070, 1060, 1054, 1013, 964, 880 cm-1. 1H NMR (300 
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MHz, CDCl3) δ 4.15 – 4.10 (m, 2H, H-l), 2.35 – 2.29 (m, 2H, h-a), 1.70 – 1.57 
(m, 4H, H-b,k), 1.44 – 1.26 (m, 20H, H-c-j).  
 
2.3.3.1.1.2. Divinyl adipate (DVA)  
 
Figure 2-7 Structure of divinyl adipate 
 
FT-IR v max: 3466, 3095, 3047, 2993, 2963, 2953, 2914, 2883, 1736, 1641, 
1407 cm-1. 1H NMR (300 MHz, CDCl3) δ 7.31 – 7.23 (m, 2H, H-a, a’), 4.88 (dd, 
J = 14.0, 1.6 Hz, 2H, H-b), 4.57 (dd, J = 6.3, 1.6 Hz, 2H, H-b’), 2.47 – 2.37 (m, 
4H, H-c,c’), 1.77 – 1.67 (m, 4H, d,d’). 
 
2.3.3.1.1.3. Glycerol  
 
Figure 2-8 Structure of glycerol 
 
FT-IR v max: 3255, 2929, 2877, 1026 cm-1. 1H NMR (300 MHz, Deuterium 
Oxide) δ 3.84 – 3.76 (m, 1H, H-c), 3.70 – 3.53 (m, 4H, H-b,b’). 
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2.3.3.1.1.4. Poly(ethylene glycol) methyl ether (mPEG2000) 
 
Figure 2-9 Structure of mPEG2000 
 
FT-IR v max: 2900, 1120 cm-1. 1H NMR (300 MHz, CDCl3) δ 3.64 (s, 182H, 
H-a,a’). 
2.3.3.2. Polymer analysis  
2.3.3.2.1. Molecular weight – GPC  
Mwts of polymers were ascertained from a standard curve (Figure 2-10) made 
from the polystyrene standards. 
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Figure 2-10 Polymer standard curve using GPC (R2=0.992) n=3 
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2.3.3.2.1.1. PGA-co-PDL 
The PGA-co-PDL polymer with a monomer ratio of 1:1:1 was a white powder. 
GPC analysis of the polymer revealed a MWt of 16.5 KDa with respect to (wrt) 
polystyrene standards.  
2.3.3.2.1.2. PGA-co-PDL-PEG2000 
The PGA-co-PDL-PEG2000 with a monomer ratio of 1:1:1:0.01 was a fine white 
powder. GPC analysis of the polymer revealed a MWt of 21.4 KDa wrt 
polystyrene standards.  
2.3.3.2.1.3. PLGA  
The PLGA polymer was a fine white powder that was reported to have a MWt 
of between 7 and 17KDa. GPC analysis of the polymer revealed a MWt of 14.9 
KDa wrt polystyrene standards.  
2.3.3.2.1.4. mPEG-PLGA 
The mPEG-PLGA polymer was a hard, white block. The monomers were 
reported to have an average MWt of 2KDa (PEG) and 11.5 KDa (PLGA). GPC 
analysis of the polymer revealed a MWt of 30.4 KDa wrt polystyrene 
standards.  
 
2.3.3.2.2. Chemical structure – FT-IR and NMR 
2.3.3.2.2.1. PGA-co-PDL  
Both FT-IR and NMR (Figure 2-12) were utilised for structural confirmation. 
FT-IR spectroscopy was used to analyse the end groups of the polymer, in 
order to confirm the completion of the reaction and formation of the product. 
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The FT-IR spectrum of PGA-co-PDL showed a trough at 3455 cm-1 which 
specifies an O-H bond and a sharp peak signifying a carbonyl stretch at 1727 
cm-1 (Figure 2-11). Additionally, the lack of characteristic bands linked to the 
terminal vinyl groups of DVA at 1650 cm-1 (Figure 2-7) confirms the complete 
consumption of monomers during polymerisation. 
The monomer ratio was estimated by using the 1H-NMR integration method 
(Kolhe et al., 2004).  
PGA-co-PDL – theoretical molar ratio (1:1:1) 
a. Number of -CH2 protons at δ 2.43 – 2.21 = 4 protons = 1 molecule of 
DVA 
b. Number of -CH2 protons at δ 4.20 – 3.99 = 4 protons = 1 molecule of 
glycerol 
c. Number of -CH2 protons at δ 4.20 – 3.99, 2.43 – 2.21, 1.69 – 1.57 and 
1.27 = 28 protons = 1 molecule of PDL 
PGA-co-PDL – calculated molar ratio (1:1:1) 
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Figure 2-11 FT-IR spectrum of PGA-co-PDL 
 
 
Figure 2-12 1H-NMR spectrum (A) and structure of PGA-co-PDL 
(B) with protons labelled  
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2.3.3.2.2.2. PGA-co-PDL-PEG2000 
Both FT-IR and NMR (Figure 2-14) was again used for the structural 
confirmation of the PGA-co-PDL-PEG2000 copolymer. The FT-IR spectrum was 
used to analyse the end groups of the polymer, in order to confirm the 
completion of the reaction and formation of the product. The FT-IR spectrum 
of PGA-co-PDL-PEG2000, like the one for PGA-co-PDL, showed a trough at 
3455 cm-1 which specifies an O-H bond and a sharp peak signifying a carbonyl 
stretch at 1727 cm-1 (Figure 2-13). Additionally, the lack of characteristic 
bands linked to the terminal vinyl groups of DVA at 1650 cm-1 (Figure 2-7) 
confirms the complete consumption of monomers during polymerisation. 
Additionally, the singlet peak on the NMR (Figure 2-14) showed that there was 
integration of the PEG monomer.  
The monomer ratio was estimated by using the 1H-NMR integration method 
(Kolhe et al., 2004).  
PGA-co-PDL-PEG2000 – theoretical molar ratio (1:1:1:0.01) 
a. Number of -CH2 protons at δ 2.42 – 2.24 = 4 protons = 1 molecule of 
DVA 
b. Number of -CH2 protons at δ 4.19 – 4.00 = 4 protons = 1 molecule of 
glycerol 
c. Number of -CH2 protons at δ 4.19 – 4.00, 2.42 – 2.24, 1.72 – 1.54, 1.26 
= 26 protons = 0.93 molecule of PDL 
d. Number of -CH2 protons at δ 3.64 = 1 proton = 0.005 molecule of 
PEG2000 
PGA-co-PDL-PEG2000 – calculated molar ratio (1:1:0.93:0.005) 
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Figure 2-13 FT-IR spectrum of PGA-co-PDL-PEG2000 
 
Figure 2-14 1H-NMR spectrum (A) and structure of PGA-co-PDL-
PEG2000 (B) with protons labelled  
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2.3.3.2.2.3. PLGA 
Both FT-IR (Figure 2-15) and NMR (Figure 2-16) gave similar results to 
previous reports (Carvalho and Erbetta, 2012). This analysis was done to 
confirm the structure of the purchased polymer. The equations provided in 
(Carvalho and Erbetta, 2012) were used to determine the monomer make-up 
of the PLGA copolymer (Equations 2-4, 2-5): 
% 𝐷, 𝐿 − 𝑙𝑎𝑐𝑡𝑖𝑑𝑒 𝑚𝑜𝑛𝑜𝑚𝑒𝑟 =
(𝐶𝐻3 1.56 𝑝𝑝𝑚 𝑖𝑛𝑡𝑒𝑔𝑟𝑎𝑙 𝑎𝑟𝑒𝑎÷3)
((𝐶𝐻3 1.56 𝑝𝑝𝑚 𝑖𝑛𝑡𝑒𝑔𝑟𝑎𝑙 𝑎𝑟𝑒𝑎÷3))+(𝐶𝐻2 4.73 𝑝𝑝𝑚 𝑖𝑛𝑡𝑒𝑔𝑟𝑎𝑙 𝑎𝑟𝑒𝑎÷2)
𝑥 100% Equation 2-4 
 
 
 
% 𝑔𝑙𝑦𝑐𝑜𝑙𝑖𝑑𝑒 𝑚𝑜𝑛𝑜𝑚𝑒𝑟 =
(𝐶𝐻2 4.73 𝑝𝑝𝑚 𝑖𝑛𝑡𝑒𝑔𝑟𝑎𝑙 𝑎𝑟𝑒𝑎÷2)
((𝐶𝐻3 1.56 𝑝𝑝𝑚 𝑖𝑛𝑡𝑒𝑔𝑟𝑎𝑙 𝑎𝑟𝑒𝑎÷3))+(𝐶𝐻2 4.73 𝑝𝑝𝑚 𝑖𝑛𝑡𝑒𝑔𝑟𝑎𝑙 𝑎𝑟𝑒𝑎÷2)
𝑥 100%  Equation 2-5 
 
The results from Equations 2-4, 2-5 showed that the PLGA copolymer 
consisted of a 50:50 blend (D,L-lactide: glycolide).  
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Figure 2-15 FT-IR spectrum of PLGA 
 
1H NMR (300 MHz, CDCl3) δ 5.38 – 5.06 (m, 1H), 4.73 (d, J = 3.9 Hz, 2H), 
1.56 (d, J = 7.5 Hz, 3H). 
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Figure 2-16 1H-NMR spectrum of PLGA 
 
2.3.3.2.2.4. mPEG-PLGA 
Both FT-IR (Figure 2-17) and NMR (Figure 2-18) gave similar results to 
previous reports (Pereira et al., 2016). This analysis was done to confirm the 
structure of the purchased polymer. The 1H-NMR for PEG-PLGA has the same 
peaks as PLGA, with the addition of a new peak at 3.64 ppm corresponding to 
the methylene groups present in PEG. The peaks for the monomers of PLGA, 
D,L-lactide and glycolide correspond to the peaks at 1.58 ppm and peaks at 
4.82 ppm & 5.22 ppm, respectively (Koopaei et al., 2012). The relationship 
between the peak areas and the number of protons was used to calculate the 
molar amount of each monomer of the copolymer.  
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D,L-lactide = δ 1.58-1.64 = 3/7.5 = 40% 
Glycolide = δ 4.58-4.95, 5.22 = 3/7.5 = 40% 
PLGA = 6/7.5 = 80% 
PEG = δ 3.64 = 1.5/7.5 = 20% 
The FT-IR structure for PEG-PLGA is similar to the PLGA FT-IR spectrum, 
which is due to the low amount of PEG present in the copolymer (20% w/w), 
which is similar to values reported by the manufacturer (17%).  
1 0 0 02 0 0 04 0 0 0
0
5 0
1 0 0
W a v e n u m b e r  ( c m
- 1
)
T
r
a
n
s
m
i
t
t
a
n
c
e
 
(
%
)
3 0 0 0 1 6 5 0
 
Figure 2-17 FT-IR spectrum of PEG-PLGA 
 
1H NMR (300 MHz, CDCl3) δ 5.22 (tdd, 1H), 4.95 – 4.58 (m, 2H), 3.64 (s, 
1.5H), 1.64 –1.58 (m, 3H). 
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Figure 2-18 1H-NMR spectrum of mPEG-PLGA 
 
2.3.3.2.3. Thermal analysis – DSC 
2.3.3.2.3.1. PGA-co-PDL 
The Tm (melting point) of PGA-co-PDL (Figure 2-19) as determined by DSC 
was 58.5 °C, which is similar to 55.3 °C previously reported (Tawfeek et al., 
2011).  
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Figure 2-19 DSC of PGA-co-PDL 
 
2.3.3.2.3.2. PGA-co-PDL-PEG2000 
The Tm (melting point) of PGA-co-PDL-PEG2000 (Figure 2-20) as determined 
by DSC was 44.9 °C.  
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Figure 2-20 DSC of PGA-co-PDL-PEG2000 
 
2.3.3.2.3.3. PLGA 
The absence of a melting transition phase (Figure 2-21) infers that the 
analysed copolymers are amorphous, which is in agreement with the literature. 
PLGA containing less than 85% glycolide are amorphous (Carvalho and 
Erbetta, 2012).  
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Figure 2-21 DSC of PLGA 
 
2.3.3.2.3.4. mPEG-PLGA 
Transition temperature at 241-246 °C according to the manufacturer. 
 
2.3.3.3. Nanoparticle analysis  
2.3.3.3.1. Particle size, polydispersity index (PDI), and zeta potential 
Results from the zetasizer showing the particle size, polydispersity index, and 
zeta potential of all four different types of NPs. NPs of PGA-co-PDL-PEG2000, 
PLGA, and mPEG-PLGA are all under 205 nm, while PGA-co-PDL NPs were 
between 220 and 252 nm (Table 2-1). All NPs were highly negatively charged 
with good polydispersity, indicating high stability and good size distribution, 
respectively. 
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Table 2-1 Particle size, PDI, and zeta potential of NPs before and after centrifugation 
Before centrifugation  After centrifugation  
Polymer Formulation Size (d.nm) PDI Zeta potential 
(mV) 
Size (d.nm) PDI Zeta potential 
(mV) 
PGA-co-PDL 
BNP 200 ± 5 0.120 ± 0.040 -9.06 ± 0.22 252 ± 9 0.293 ± 0.043 -30.00 ± 1.11 
5% RNP 205 ± 1 0.142 ± 0.002 -7.25 ± 0.31 229 ± 5 0.257 ± 0.032 -28.70 ± 0.05 
10% RNP 210 ± 5 0.091 ± 0.024 -4.25 ± 0.21 221 ± 5 0.219 ± 0.008 -30.27 ± 0.31 
PGA-co-PDL-
PEG2000 
BNP 188 ± 4 0.130 ± 0.031 -20.50 ± 0.98 190 ± 6 0.126 ± 0.011 -32.17 ± 0.47 
5% RNP 192 ± 2 0.091 ± 0.043 -19.17 ± 1.31 199 ± 5 0.126 ± 0.032 -31.80 ± 0.66 
10% RNP 208 ± 2 0.106 ± 0.047 -21.17 ± 1.33 200 ± 6 0.112 ± 0.040 -32.33 ± 1.61 
PLGA 
BNP 205 ± 1 0.125 ± 0.021 -12.97 ± 0.21 195 ± 5 0.257 ± 0.033 -35.37 ± 1.44 
5% RNP 201 ± 7 0.128 ± 0.018 -12.03 ± 0.06 202 ± 10 0.294 ± 0.002 -28.27 ± 1.27 
10% RNP 204 ± 2 0.170 ± 0.043 -10.78 ± 0.82 202 ± 5 0.290 ± 0.018 -30.40 ± 195 
mPEG-PLGA 
BNP 211 ± 7 0.353 ± 0.008 -18.57 ± 0.23 204 ± 5 0.285 ± 0.013 -36.37 ± 0.58 
5% RNP 198 ± 1 0.248 ± 0.020 -17.80 ± 1.65 197 ± 6 0.249 ± 0.024 -37.40 ± 0.17 
10% RNP 191 ± 6 0.276 ± 0.028 -22.00 ± 0.78 184 ± 4 0.230 ± 0.013 -36.97 ± 1.40 
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2.3.3.3.2. Drug loading and encapsulation efficiency (EE%) 
2.3.3.3.2.1. Drug loading and encapsulation efficiency  
Drug loading (DL) of the various polymeric NPs was calculated using a 
standard curve (Figure 2-22). The lowest concentration at which resveratrol 
can be detected (LOD) or quantified (LOQ) with acceptable precision and 
accuracy was calculated from the standard deviation (SD) of the response and 
the slope obtained from the linear regression of a specific calibration curve 
(0.5 µg/mL – 7.5 µg/mL) in the low-end region of the proposed range (ICH, 
2005). The LOD and LOQ was calculated as 0.2 and 0.6 µg/mL, respectively. 
PGA-co-PDL NPs showed a drug loading capacity of 1.75 to 4 times that of its 
nearest competitor (PGA-co-PDL-PEG2000) for 10% RNP and 5% RNP, 
respectively (Table 2-2). PGA-co-PDL-PEG2000 showed an increase in EE% 
between 5% RNP and 10% RNP, while the other 3 formulations showed an 
decrease in EE% between 5% RNP and 10% RNP.  
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Figure 2-22 Resveratrol standard curve (R2=0.9981) with SD as 
error bars (n=3) 
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Table 2-2 Drug loading and encapsulation efficiency of 5% 
resveratrol-loaded NPs (RNP) and 10% RNP of various polymeric 
NPs 
Polymer Formulation 
Drug loading 
(µg/mg)* 
encapsulation 
efficiency (%) 
PGA-co-PDL  
5% RNP 39 ± 0.12 78 ± 0.24 
10% RNP 70 ± 0.89 70 ± 0.89 
PGA-co-PDL-PEG2000 
5% RNP 10 ± 0.39 20 ± 0.78 
10% RNP 40 ± 2.32 40 ± 2.32 
PLGA 
5% RNP 10 ± 0.13 20 ± 0.27 
10% RNP 14 ± 0.39 14 ± 0.39 
PEG-PLGA 
5% RNP 10 ± 0.24 20 ± 0.48 
10% RNP 13 ± 0.33 13 ± 0.33 
* µg/mg – concentration of resveratrol in micrograms in 1 milligram of 
polymeric nanoparticles 
 
2.3.3.3.3. PGA-co-PDL NPs stability  
2.3.3.3.3.1. Size and zeta potential at 4°C 
The short-term stability of the PGA-co-PDL NPs (BNP, 5% RNP, and 10% 
RNP) was investigated for up to 28 days when stored at 4°C. With the BNP 
there was no statistically significant difference in the particle size compared to 
the initial preparation over the course of the stability study at 4°C (p> 0.05), 
apart from days 9 (p< 0.0001), 23 (p< 0.005), and 28 (p< 0.0001) (Figure 2-
23). For zeta potential there was a lot more variation with days 3, 6, 8, 9, 13, 
15, 19, 20. 27, and 28 showing statistically significant differences (p< 0.005) 
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compared to the day 1 sample with the rest of the days showing no statistically 
significant differences (p> 0.05) (Figure 2-24). For 5% RNP there was no 
statistically significant difference in the particle size compared to the initial 
preparation over the course of the stability study at 4°C (p> 0.05), apart from 
day 22 (p< 0.05) (Figure 2-23). For zeta potential, the same sample showed 
statistically significant differences (p< 0.0001) compared to the day 1 sample 
(Figure 2-24). The 10% RNP showed no statistically significant difference in 
the particle size compared to the initial preparation over the course of the 
stability study at 4°C (p> 0.05) (Figure 2-23). The zeta potential showed 
statistically significant differences (p< 0.0001) for all days compared to the day 
1 sample (Figure 2-24).  
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Figure 2-23 Effect of storage time on size of PGA-co-PDL NPs in 
water stored at 4°C ± SD (n=3) 
91 
 
7 1 4 2 1 2 8
- 3 0
- 2 0
- 1 0
0
S t o r a g e  p e r i o d  ( d a y s )
Z
e
t
a
 
p
o
t
e
n
t
i
a
l
 
(
m
V
)
B N P
5 %  R N P
1 0 %  R N P
 
Figure 2-24 Effect of storage time on zeta potential of PGA-co-PDL 
NPs in water stored at 4°C ± SD (n=3) 
 
2.3.3.3.3.2. Size when NPs are stored at 37 °C 
The short-term stability of blank PGA-co-PDL NPs (BNP, 5% RNP, and 10% 
RNP) was investigated for up to 28 days when stored at 37°C in water (Figure 
2-25). There was no statistically significant difference in the particle size of 
BNP compared to the initial preparation over the course of the stability study 
at 37°C in water (p> 0.05), apart from days 2 (p<0.0001), 17 (p<0.005), 18 
(p<0.05), 21 (p<0.0001), 23-25 (p<0.0001). The 5% RNP stored in water 
showed greater statistical significance (p< 0.05) compared to the initial sample 
with only days 17, 18, 24, and 24 showing no statistical significance (p> 0.05). 
10% RNP in water was similar with all days showing statistical significance (p< 
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0.05) compared to the initial sample with only days 17, 18, and 28 showing no 
statistical significance (p> 0.05). 
The short-term stability of blank PGA-co-PDL NPs (BNP, 5% RNP, and 10% 
RNP) were investigated for up to 18 days when stored at 37°C in cell culture 
media (Figure 2-26). For the first 4 days of the BNP in media at 37 °C, there 
was no statistically significant difference (p>0.05), but for the rest of the days 
5-18 there were statistically significant differences (p< 0.0001) compared to 
the day 1 sample. There was no statistically significant difference (p> 0.05) 
between days 1-4 and 9-11, but there were statistically significant differences 
(p< 0.05) for the other days compared to the initial sample for 5% RNP in 
media. 10% RNP in media showed no statistically significant difference (p> 
0.05) between days 1-4, 8, 9, and 11, but the other days showed statistically 
significant differences (p< 0.0001) compared to the initial sample. 
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Figure 2-25 Effect of storage time on size of PGA-co-PDL NPs 
stored at 37°C in water ± SD (n=3) 
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Figure 2-26 Effect of storage time on size of PGA-co-PDL NPs 
stored at 37°C in media ± SD (n=3) 
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2.3.3.3.4. Release study of PGA-co-PDL 
A burst release of resveratrol from 5% RNP and 10% RNP was observed with 
17 ± 0.04 µg and 25 ± 0.02 µg released at time point zero, respectively. The 
amount of resveratrol released from 5% RNP and 10% RNP was 36 ± 0.03 µg 
and 69 ± 0.04 µg after 30 and 60 minutes, respectively. There were no 
resveratrol peaks detected after this time. 
2.3.3.3.5. Cell viability studies of PGA-co-PDL 
2.3.3.3.5.1. Alamar Blue (resazurin sodium salt) 
2.3.3.3.5.1.1. Determining the IC50 of free-resveratrol 
Figure 2-27 consists of a representative Log concentration-viability response 
curve of 1 experiment since with an accompanying table that gives the results 
of all 3 experiments. The relative 50% inhibitory concentration (IC50) for free-
resveratrol on Calu 3 cells after 24 hours was shown to be 0.049 ± 0.014 
mg/mL (Figure 2-27). This is equivalent to 213 ± 63 µM. It should be stated 
that one of the results was quite different to the other two, leading to a huge 
SE. If the calculations were based on two replicates that were very similar in 
value, the IC50 would have been 150 ± 3 µM. 
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Figure 2-27 Representative Log concentration-viability response 
curve showing effects of free-resveratrol using Alamar blue assay 
± SE  
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2.3.3.3.5.1.2. Determining IC50 of resveratrol loaded into PGA-co-PDL NPs 
2.3.3.3.5.1.2.1. 5% Resveratrol-loaded NPs 
Figure 2-28 consists of a representative Log concentration-viability response 
curve of 1 experiment since with an accompanying table that gives the results 
of all 3 experiments. The IC50 for 5% resveratrol-encapsulated NPs (5% RNPs) 
on Calu 3 cells after 24 hours was shown to be 0.276 ± 0.175 mg/mL (Figure 
2-28). Using the drug loading results (Table 2-2), it was determined that the 
amount of resveratrol present would be 0.011 ± 0.007 mg. This means that the 
IC50 for resveratrol encapsulated into 5% RNPs was 47 ± 30 µM. It should be 
stated that one of the results was quite different to the other two, leading to a 
huge SE. If the calculations were based on two replicates that were very 
similar in value, the IC50 would have been 17 ± 3 µM. 
 
97 
 
- 4 - 3 - 2 - 1 0
5 0
6 0
7 0
8 0
9 0
1 0 0
1 1 0
l o g ( C o n c e n t r a t i o n )
C
e
l
l
 
v
i
a
b
i
l
i
t
y
 
(
%
 
o
f
 
c
o
n
t
r
o
l
)
I C
5 0
=  0 . 0 1 1    0 . 0 0 7  m g / m L
I C
5 0
=  4 7   3 0  M
Experiment R-square mg/mL µM
1 0.909 0.024 107
2 0.964 0.005 20
3 0.907 0.003 14
IC50
 
Figure 2-28 Representative Log concentration-viability response 
curve showing effects of 5% resveratrol-loaded NPs using Alamar 
blue assay ± SE  
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2.3.3.3.5.1.2.2. 10% Resveratrol-loaded NPs 
Figure 2-29 consists of a representative Log concentration-viability response 
curve of 1 experiment since with an accompanying table that gives the results 
of all 3 experiments. The IC50 for 10% resveratrol-encapsulated NPs (10% 
RNPs) on Calu 3 cells after 24 hours was shown to be 0.279 ± 0.123 mg/mL 
(Figure 2-29). Using the drug loading results (Table 2-2), it was determined 
that the amount of resveratrol present would be 0.020 ± 0.009 mg. This means 
that the IC50 for resveratrol encapsulated into 10% RNPs is 86 ± 38 µM. It 
should be stated that one of the results was quite different to the other two, 
leading to a huge SE. If the calculations were based on two replicates that 
were very similar in value, the IC50 would have been 48 ± 12 µM. 
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Figure 2-29 Representative Log concentration-viability response 
curve showing effects of 10% resveratrol-loaded NPs using Alamar 
blue assay ± SE  
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2.3.3.3.5.1.2.3. Percentage changes in IC50 
The 5% RNPs and 10% RNPs formulations decreased the IC50 as compared 
to free-resveratrol by 78±7% and 60±7%, respectively (Table 2-3). 
 Table 2-3 Percentage changes in IC50 for resveratrol-
encapsulated NPs compared to free resveratrol 
IC50 (µM) Percent 
change in 
IC50 (%) Experiments 
Formulation 1 2 3 Average Average SE 
Free-resveratrol 338 153 147 213 0 0 
5% RNP 107 20 14 47 78 7 
10% RNP 160 60 37 86 60 7 
 
2.3.3.3.5.1.3. Effect of resveratrol-loaded NPs vs blank NPs on Calu 3 cells 
The BNP (0.03125-1 mg/mL) showed good cytocompatibility in Calu 3 cells 
(Figure 2-30). The viability of the cells treated with BNP at a concentration of 
1 mg/mL was 87.5±4.7% after 24-hour exposure. There was no statistically 
significant difference between the viability of cells treated with BNP up to 
1mg/ml and the control cells treated with the vehicle alone (p> 0.99, ANOVA, 
Tukey’s comparison).  
However, the 5% RNP and 10% RNP decreased the viability of Calu 3 cells in 
a concentration-dependent manner (Figure 2-30). There was a statistically 
significant difference between 5% RNP and BNP at a concentration of 1 
mg/mL (p<0.005). There were also statistically significant differences between 
10% RNPs and BNPs at concentrations 0.25 (p<0.05), 0.5 (p<0.005) and 1 
mg/mL (p<0.001).  
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Figure 2-30 Calu 3 cell viability as determined by Alamar blue 
assay after 24-hour exposure to blank nanoparticles (BNP), 5% 
resveratrol-loaded PGA-co-PDL nanoparticles (5% RNP), and 10% 
resveratrol-loaded PGA-co-PDL nanoparticles (10% RNP). Data 
represent mean ± standard error of mean for n=3 independent 
experiments. 
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2.3.3.3.5.2. LDH assay 
2.3.3.3.5.2.1. 48-hour treatment   
The LDH assay showed that both the BNP (300 µM) and 10% RNP (300 µM) 
caused a statistically significant increase in LDH release compared with the 
control (p< 0.05) after 48-hour exposure (Figure 2-31). However, there was 
no statistically significant difference between the BNP (300 µM) and 10% RNP 
(300 µM) (p> 0.9999).  
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Figure 2-31 The effects of blank PGA-co-PDL nanoparticles 
(BNP), 5% resveratrol-loaded PGA-co-PDL nanoparticles (5% 
RNP), 10% resveratrol-loaded PGA-co-PDL nanoparticles (10% 
RNP), and free-resveratrol on LDH release in Calu 3 cells after 48 
hours. Data represent mean ± standard error of mean for n=3 
independent experiments. 
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2.3.3.3.5.2.2. 72-hour treatment  
The LDH assay showed that the BNP (300 µM) caused a statistically 
significant increase in LDH release compared with the control (p< 0.05) after 
72-hour exposure (Figure 2-32). 5% RNP (150 µM) caused a statistically 
significant increase in LDH release compared with the control (p< 0.0005) after 
72-hour exposure. 10% RNP, 300 µM and 150 µM, caused a statistically 
significant increase in LDH release compared with the control (p< 0.0001 and 
p< 0.005, respectively) after 48-hour exposure. Moreover, there was a 
statistically significant difference (p> 0.005) between the BNP (300 µM) and 
10% RNP (300 µM), which could indicate that the LDH release could be due 
to encapsulated resveratrol since the polymer content of both formulations are 
equal. 
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Figure 2-32 The effects of blank PGA-co-PDL nanoparticles 
(BNP), 5% resveratrol-loaded PGA-co-PDL nanoparticles (5% 
RNP), 10% resveratrol-loaded PGA-co-PDL nanoparticles (10% 
RNP), and free-resveratrol on LDH release in Calu 3 cells after 72 
hours. Data represent mean ± standard error of mean of n=3 
independent experiments 
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2.3.4. Discussion 
2.3.4.1. Polymer synthesis and analysis 
PGA-co-PDL and PGA-co-PDL-PEG2000 were synthesised via ring opening 
polymerisation and polycondensation as described in literature (Namekawa, 
Uyama and Kobayashi, 2000; Thompson et al., 2006). The polymers were 
synthesised via polymerisation of PDL (Figure 2-6), DVA (Figure 2-7), and 
glycerol (Figure 2-8) for PGA-co-PDL (Figure 2-1), with mPEG2000 (Figure 2-
9) added to obtain PGA-co-PDL-PEG2000 (Figure 2-2). The polymerisation is 
enzyme-dependent with the highest yield of polymer obtained when using a 
lipase enzyme obtained from Candida antarctica (Namekawa, Uyama and 
Kobayashi, 2000; Kim, D.Y., Wu, X. and Dordick, 2003; Sivalingam and 
Madras, 2004). The hydrolytic enzyme, commercially available as Novozyme 
435®, has regio-selectivity for primary hydroxyl groups and has been shown 
to be over 90% selective in this reaction (Kline, Beckman and Russell, 1998; 
Thompson et al., 2006; Kobayashi, 2009). Increasing the ratio of glycerol:PDL, 
due to the increase in free hydroxyl groups, would increase the hydrophilicity 
of the PGA-co-PDL and PGA-co-PDL-PEG2000 polymers (Thompson et al., 
2006). PGA-co-PDL is soluble in both non-polar solvents, such as DCM, 
chloroform, THF, and diethyl ether, as well as polar solvents, such as 
phosphate buffer at pH 7.4.This could be due to the hydroxyl group present on 
the polymer from the glycerol monomer (Thompson et al., 2006). However, it 
should be noted that PGA-co-PDL is more hydrophobic than hydrophilic 
(Tawfeek, 2013; Tawfeek et al., 2013). Increasing the contact time of the lipase 
enzyme with the polymer leads to an increase in the molecular weight of the 
polymer (Kunda, Alfagih, Dennison, Tawfeek, et al., 2015) up to 24 hours, after 
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which the dominating hydrolytic reaction leads to a decrease in polymer 
molecular weight (Kline, Beckman and Russell, 1998; Thompson et al., 2006). 
Thus, complete removal of the enzyme from the reacted copolymers is an 
important step in controlling the size of the polymer and subsequent 
degradation (Thompson et al., 2006). Kunda et al. illustrated this, where PGA-
co-PDL synthesis of 24 and 6 hours resulted in polymers of 24 KDa and 14.7 
KDa, respectively, which is similar to the 16.5 KDa PGA-co-PDL polymer 
produced in this study in 6.5 hours (Kunda, Alfagih, Dennison, Tawfeek, et al., 
2015). The 1H-NMR analysis showed that the PGA-co-PDL polymer consisted 
of a 1:1:1 ratio of the three monomers and previous studies have shown that 
the PGA-co-PDL polymer is a random mixture of these monomers (Thompson 
et al., 2006; Gaskell et al., 2008). This is due to the nature of the polymerisation 
reaction. Namekawa et al, showed that the reaction begins with the coupling 
of DVA to glycerol and then the ring-opening of PDL is initiated by the OH of 
either glycerol or the DVA-glycerol (Namekawa, Uyama and Kobayashi, 
2000). Since the DVA can react with either glycerol or, the recently opened, 
PDL, multiple possibilities for the attachment of the monomers exist. Similarly, 
for the PGA-co-PDL-PEG2000 polymer, after the ring-opening, the OH of the 
mPEG can be the starting point of the polymer chain (Azhari et al., 2018). 
However, the mPEG only possesses a single free hydroxyl group (Figure 2-
9). Therefore, it can only be attached to the end of the polymer backbone 
(Tawfeek, 2013; Ghasemi et al., 2018). Thus, the feed ratio of mPEG can 
dictate the length of the polymer i.e. too much mPEG can lead to the formation 
of small chains, while too little mPEG can lead to longer chains or some chains 
absent any mPEG  
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Interestingly, studies by Perkins showed that PGA-co-PDL-PEG2000 synthesis 
over 5 hours, using the same molar feed ratio as in this study, produced a 
polymer of 13.5 KDa, while the polymer produced in this current study in 6.5 
hours was almost double the size at 21.4 KDa (Perkins, 2015). Moreover, 
previous studies showed a reduction in the molecular weight of the PGA-co-
PDL polymer with mPEG polymerisation to form PGA-co-PDL-PEG (Tawfeek, 
2013; Perkins, 2015). However, increasing mPEG molecular weight leads to 
an increase in molecular weight of polymer at the expense of PDL 
concentration (Iftikhar, 2011; Perkins, 2015). The reason for this seems to be 
that the reaction medium becomes biphasic with polar molecules, PEG and 
glycerol, being one phase and non-polar, lactone, the other phase (Poojari and 
Clarson, 2010; Iftikhar, 2011). The attachment of PEG, a hydrophilic, non-ionic 
polymer, to a molecule is known as PEGylation and is used to enhance the 
pharmaceutical properties of various molecules or drugs (Turecek et al., 
2016). PEGylation has been used to shield NPs from opsonisation and 
phagocytosis, thereby, increasing the circulation time of the NPs (Partikel et 
al., 2019; Wani, Raza and Khan, 2019). PEG reduces the muco-adhesion of 
a particle, allowing the quick diffusion of the particles through the low viscosity 
interstitial fluids between mucin fibres (Huckaby and Lai, 2018). 
Polymerisation with mPEG2000 increases the hydrophilicity of the polymer 
(Hong, Hu and Yuan, 2006; Saini and Sinha, 2019). Opsonisation occurs on 
negative and hydrophobic surfaces such as those found on PLGA polymer 
based NPs (Carvalho and Erbetta, 2012). The PLGA, purchased from Sigma, 
was confirmed as a 50:50 blend of D,L-lactide:glycolide (Figure 2-3). D,L-
lactide increases the hydrophobicity of PLGA, leading to less water absorption 
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and less degradation, while glycolide increases the hydrophilicity which 
increases water absorption and degradation (Keles et al., 2015; Sharma et al., 
2016). However, the 50:50 blend PLGA shows the fastest degradation rate of 
all PLGA blends (Makadia and Siegel, 2011; Kapoor et al., 2015). PEGylation 
of PLGA, such as the mPEG-PLGA purchased from Sigma (Figure 2-4) has 
been shown to increase hydrophilicity and reduce opsonisation The difference 
in polymer hydrophilicity/hydrophobicity, along with the solubility and 
molecular weight can all influence the encapsulation and release of the 
encapsulated drug (Pagels and Prud’Homme, 2015). 
2.3.4.2. Polymeric nanoparticle synthesis and analysis  
All polymeric NPs were prepared using a (w1/o/w2) double emulsion/solvent 
evaporation method previously optimised for the preparation of PGA-co-PDL 
blank NPs of 200 nm (after centrifugation) (Kunda, Alfagih, Dennison, 
Tawfeek, et al., 2015). Studies suggests that particles < 200 nm are ideal since 
they show increased uptake compared to larger particles with the ability to 
evade detection and removal by alveolar macrophages and also shows rapid 
penetration of the respiratory mucus (Dandekar et al., 2010; Schuster et al., 
2013; Youngren-Ortiz et al., 2017; Dabbagh et al., 2018).  
2.3.4.2.1. Size and charge 
This is the first-time resveratrol has been encapsulated into PGA-co-PDL and 
PGA-co-PDL-PEG2000 NPs. The NPs prepared from PGA-co-PDL- PEG2000, 
mPEG-PLGA, and PLGA were all under 205 nm (Table 2-1). Although, the 
method was optimised for PGA-co-PDL blank NPs (BNP), it was statistically 
larger (p< 0.0001) than the BNP of the three other polymers. Moreover, at 
252±9 nm, the PGA co-PDL BNP was statistically larger than the PGA-co-PDL 
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5% RNP (p< 0.005) and 10% RNP (p< 0.0001). However, these sizes are still 
acceptable for internalisation via caveolae-mediated endocytosis (Rejman et 
al., 2004; Panariti, Miserocchi and Rivolta, 2012; Prabha et al., 2016; Behzadi 
et al., 2017; Foroozandeh and Aziz, 2018).The NPs of the four polymers were 
all negative between -28 and -37 mV with no discernible pattern between BNP, 
5% RNP, and 10% RNP (Table 2-1). The negative zeta potential of the 
polymers can be attributed to the coating with PVA (Ranjan et al., 2011; 
Shagholani, Ghoreishi and Mousazadeh, 2015). The resveratrol did not have 
an impact on the zeta potential of the NPs which has been confirmed in 
literature (Neves et al., 2016). The high zeta potential (-30 mV) can confer 
physical stability due the electrostatic repulsions between particles which will 
help to avoid flocculation and aggregation of the NPs (Neves et al., 2016).  
2.3.4.2.2.  Drug loading and encapsulation efficiency (EE%) 
The polymers showed the following order with regards to drug loading and 
encapsulation efficiency (EE%): PGA-co-PDL > PGA-co-PDL- PEG2000 > 
PLGA > PLGA-PEG. Where drug loading is defined by the ratio between the 
mass of the API (in this case resveratrol) and the drug carrier (in this case 
polymer) (Shen et al., 2017b) Meanwhile, the encapsulation efficiency is the 
ratio between the mass of the API inside the particle (drug loading) and the 
mass of the API in the feed, which is determined by several factors including 
the solubility of the polymer in the organic solvent, concentration of the 
polymer, ratio of drug to polymer, and rate of removal of organic solvent 
(Tayade and Kale, 2004; Jyothi et al., 2010; Shen et al., 2017a). 
As expected, the drug loading significantly increased between the 5% RNP 
and 10% RNP of all four polymers, with the PGA-co-PDL NPs having the 
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highest drug loading at 39 ± 0.12 µg and 70 ± 0.89 µg (p< 0.0001), 
respectively. However, although the drug loading (mass of resveratrol inside 
NPs) increased between the 5% RNP and 10% RNP, the EE% decreased 
between the 5% RNP and 10% RNP of PLGA, mPEG-PLGA, PGA-co-PDL. 
Similarly, Wan et al. observed that increasing the mass of resveratrol in the 
formulation of PLGA-NPs, initially increased the drug loading and EE% (Wan 
et al., 2018) However, further increases in the mass of resveratrol, although 
increasing the drug loading, showed a decrease in EE% , which was attributed 
to the excessive amount of resveratrol causing destabilisation of the formed 
resveratrol-loaded PLGA-NPs when PLGA reached saturation (Wan et al., 
2018). The PGA-co-PDL-PEG2000 5% RNP and 10% RNP showed both an 
increase in drug loading and EE%, which could indicate that the optimal 
amount of resveratrol had not been reached for this polymer.  
Resveratrol is not very soluble in water (0.05 mg/mL) and normally a single 
o/w emulsion method would be used for such hydrophobic drugs (Robinson, 
Mock and Liang, 2015; Sharma et al., 2016). However, previous studies have 
shown the suitability of w1/o/w2 double emulsions for encapsulation of 
resveratrol, due to the increased protection offered (Hemar et al., 2010; Matos 
et al., 2014; Wang et al., 2017). One study found that the encapsulation 
efficiency and drug loading of resveratrol-loaded PLGA NPs formulated using 
double emulsion w1/o/w2, where w1 was resveratrol and PLGA dissolved in 
DCM, was 48.7 ± 6.9 % and 8.2 ± 0.5% (w/w), respectively (Shen et al., 2018). 
This is more than twice than that obtained in this study (Table 2-2). 
Resveratrol-loaded PEG-PLGA NPs prepared using a double emulsion 
solvent evaporation method showed an encapsulation efficiency of 68.2% and 
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drug loading of 8.34% (w/w), which is a lower drug loading but an 
encapsulation efficiency more than 3 times than what was achieved in this 
study (Li et al., 2016) (Table 2-2). However, it is worth noting that the methods 
used to formulate the PLGA NPs and PEG-PLGA NPs in those studies was 
optimised for those specific NPs, while the solvent evaporation method used 
in this current study was optimised for size of PGA-co-PDL NPs. Also, most 
studies dissolve resveratrol into ethanol or acetone and used that mixture as 
the first water phase (w1) or together with the polymer in ethyl acetate (Sanna 
et al., 2015; Li et al., 2016). Whereas, in this study the resveratrol was added 
together with the polymer into the DCM. This could explain the discrepancy of 
results and why the PGA-co-PDL NPs had the highest encapsulation. 
Therefore, if the formulation parameters were optimised for each polymer, the 
EE% might have been better, however, the aim was to do a direct comparison 
at this stage. Hence, the same set of formulation parameters were used. 
Solvents in which the polymer is less soluble in, which will cause the polymer 
to solidify faster, can be used to increase the drug loading/encapsulation 
(Thompson et al., 2007). In order to obtain a stable double emulsion, the 
primary emulsion (w1/o) must be stable, which is dependent on the droplet 
size, amounts of dispersed and continuous phase, and the affinity of the 
emulsifier for both phases (Matos et al., 2014). The emulsifier in this study was 
polyvinyl alcohol), a highly hydrophilic  surfactant (Park et al., 2018). A high 
concentration of hydrophilic surfactants decrease encapsulation due to oil film 
rupture and leaking of the inner water droplets (Matos et al., 2014).  
The drug loading capacity of NPs are important since a higher drug loading 
has several benefits. A higher drug loading means that less excipient (in this 
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case polymer) is used to deliver the same dosage of the active pharmaceutical 
agent (API). It would be desirable to have a high drug loading and there is 
evidence to suggest that drug loading of 9% (w/w) seems more beneficial than 
a higher one (Chu et al., 2013). The drug loading of PGA-co-PDL was 
0.07±0.009 mg/mg or 7±0.9% (w/w). Due to the high drug loading and 
encapsulation efficiency of PGA-co-PDL NPs, they were subsequently 
analysed further.  
2.3.4.2.3. Stability studies  
The PGA-co-PDL NPs (BNP, 5% RNP and 10% RNP) showed good stability 
for size and charge in water stored at both 4 °C and 37 °C over the 28 days. 
However, the stability of the three formulations in media at 37 °C showed a 
definite increase in the size of the NPs, especially the BNP, which went from 
294.6±2 nm on Day 1 to 454.6 ±12 nm on Day 2, and on Day 7 it rose to a 
statistically significant (p< 0.0001) 2093±360 nm. The dramatic increase in the 
size of the NP in media is most likely attributed to the NPs forming complexes 
with the proteins present in the cell culture medium (Schulze et al., 2008; 
Maiorano et al., 2010; Moore et al., 2019). 
2.3.4.2.4. Release studies 
The release study for PGA-co-PDL NPs was done in PBS at 37 °C. Two 
methods were used in order to assess the release of resveratrol from these 
formulations. Both methods had the same release profile. Interestingly, using 
Equation 2-3, it was found that between 44 and 36 % of resveratrol is 
immediately released upon contact with the release media from 5% RNP and 
10% RNP, respectively. This may be attributed to resveratrol located on the 
surface of the NPs (Huang and Brazel, 2001; Kamaly et al., 2016) The 
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percentage of resveratrol released ranged from 92-99% after 30 and 60 
minutes for 5% RNP and 10% RNP, respectively. It would be ideal to have a 
more sustained drug delivery system in order to maintain the local drug 
concentration at a constant level, decreasing side effects, reducing dosing 
frequency and increasing patient compliance (Hsu et al., 2015; Patel and 
Patel, 2015). There are several potential causes of a burst release profile 
including formulation conditions, heterogeneity of matrices, properties of the 
drug, and percolation limited diffusion (Huang and Brazel, 2001; Peppas and 
Narasimhan, 2014). During the formulation process some of the drug may not 
encapsulate inside the matrix of the nanoparticle and instead get trapped on 
the surface of the nanoparticle which is then immediately released upon 
contact with a release medium (Huang and Brazel, 2001; Kamaly et al., 2016). 
During a drying process, such as with freeze-drying or spray drying, the water 
present in the NPs tends to move to the surface of the NPs and evaporates. 
Drugs may move along with water to the surface of the nanoparticles through 
convection which could lead to burst release of the drug (Huang and Brazel, 
2001; Kamaly et al., 2016). This is interesting since the NPs were freeze-dried 
before doing the release study. Perhaps, the release study should have been 
performed without drying, but this would reduce the accuracy of the weighing 
of the NPs. There are many factors that influence drug release rate, including 
drug solubility, molecular weight and size, particle size and shape, polymer 
properties (solubility, etc.), formulation processing technique, excipients, etc. 
(Varma et al., 2004). PGA-co-PDL NPs may have given the best encapsulation 
efficiency, but the other polymers may have given a better release profile. 
PLGA NPs have shown burst release, however, PEGylation has shown to slow 
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down the release profile of PLGA and could perhaps do the same for PGA-co-
PDL- PEG2000 (Hsu et al., 2015).  
 
2.3.4.3. Cell viability studies  
The detection of cell viability is the most generally used parameter to assess 
cytotoxicity (Kroll et al., 2009). Cell viability is a measure of healthy, living cells 
in a given population (Adan, Kiraz and Baran, 2016). Assays based on cell 
viability include those detecting mitochondrial activity, such as 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and Alamar blue, 
or membrane integrity, such as LDH (which assesses necrotic or late apoptotic 
cell death) (Mitjans, Nogueira-Librelotto and Vinardell, 2018). Many of these 
in vitro assays used to test the cytotoxicity of NPs were made for the hazard 
characterisation of chemicals which differ tremendously from NPs (Kroll et al., 
2009; Dhawan and Sharma, 2010). Several features of NPs, such as high 
adsorption capacity, catalytic activity, hydrophobicity, optical and magnetic 
properties, and surface charge, may interfere with the assays  on top of the 
concern that in vitro testing cannot mimic the complexity of in vivo testing in 
animal models or the human body (Kroll et al., 2009; Sukhanova et al., 2018). 
Evidence suggests that there is no correlation between in vitro and in vivo 
pulmonary toxicity of NPs (Sayes, Reed and Warheit, 2007; Warheit, Sayes 
and Reed, 2009; Sayes, 2020). The colorimetric MTT assay is used to detect 
mitochondrial activity in the conversion of the yellow tetrazolium, MTT, to a 
purple water-insoluble formazan (Kroll et al., 2009). This assay has been used 
in cytotoxicity studies of various NPs (Kroll et al., 2009). Carbon and PLGA-
polyethylene oxide (PLGA–PEO) NPs have been shown to alter the light 
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absorption of this assay, skewing the results of the assay (Wörle-Knirsch, 
Pulskamp and Krug, 2006; Belyanskaya et al., 2007; Guadagnini et al., 2015). 
The LDH assay works on the principle that the cytosolic enzyme, LDH, is 
present in many cells and that upon plasma membrane damage, it gets 
released into the cell culture medium. Extracellular LDH then catalyses the 
conversion of lactate to pyruvate via the reduction of NAD+ to NADH (Decker 
and Lohmann-Matthes, 1988; Fotakis and Timbrell, 2006; Han et al., 2011). 
Diaphorase, NADH dehydrogenase, utilises NADH to reduce a tetrazolium salt 
(INT) to a red formazan product which can be measured to determine the 
amount of LDH released into the cell culture medium. Trace metal-containing 
NPs and silver NPs have been shown to interfere with the LDH assay (Suska 
et al., 2005; Han et al., 2011). Differentiating between healthy, necrotic, and 
apoptotic cells can be achieved by the detection of externalised 
phosphatidylserine on the cell surface (Zwicker et al., 2019). 
Phosphatidylserine, usually located on the inside of the plasma membrane of 
a healthy cell, is exposed on the surface of an apoptotic cell (Koopman et al., 
1994; Shlomovitz, Speir and Gerlic, 2019). Annexin V, a Ca2+-dependent 
phospholipid-binding protein, has high affinity for phosphatidylserine and, 
when fluorescently-labelled, can be employed to detect apoptotic cells 
(Fleisher and Oliveira, 2019; Zwicker et al., 2019). However, Annexin V, due 
to a broken plasma membrane, will bind to the phosphatidylserine on the inner 
side of the plasma membrane of necrotic cells, producing a false negative 
result (Kroll et al., 2009; Crowley, Marfell, Scott and Waterhouse, 2016). 
Therefore, co-staining with propidium iodide, which will solely stain necrotic 
cells, is necessary to distinguish between necrotic and apoptotic cells 
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(Crowley, Marfell, Scott, Boughaba, et al., 2016). Gold NPs adsorbed the 
propidium iodide and entered healthy cells, leading to false positives for 
necrosis (Shukla et al., 2005). The neutral red assay is based on the principle 
that viable cells will exclusively accumulate the neutral red dye in lysosomes 
through non-ionic passive diffusion, where it can be quantified via 
fluorescence or absorption measurement (Gomez Perez et al., 2017). Carbon 
NPs induced adsorption of the dye, manipulating the ability of the assay to 
assess cell viability (Casey et al., 2007). There are many studies showing the 
interference of metallic and carbon-based NPs, but not many have looked at 
the interference of polymeric NPs (Warheit, Sayes and Reed, 2009; Ong et 
al., 2014).  
MTT assay and staining with Calcein AM and propidium iodide, and CellTiter-
Glo assay were used to assess the cytotoxicity of the PGA-co-PDL NPs. The 
CellTiter-Glo assay uses luminescence to measure the cell viability by 
quantifying the amount of ATP (Sakamuru, Attene-Ramos and Xia, 2016). 
None of these assays gave consistent results (results not shown). Studies 
recommend using at least two different methods to assess cytotoxicity, in order 
to verify the results (Matuszak et al., 2016). Therefore, two cell viability assays 
were used to assess the efficacy of PGA-co-PDL NPs as a delivery system.  
Alamar Blue (resazurin sodium salt) involves the reduction of resazurin (blue 
and nonfluorescent) by healthy cells to resorufin, which is pink and highly 
fluorescent (Brien et al., 2000). The reduction is said to be due to the 
enzymatic actions of mitochondrial, cytosolic, and microsomal enzymes 
(Vega-Avila and Pugsley, 2011; Rampersad, 2012; Munshi, Twining and Dahl, 
2014). Whereas Alamar Blue determines the degree of cytotoxicity by 
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measuring the number of viable cells that remain after exposure to the 
treatment, the LDH assay evaluates the cytotoxicity by measuring the amount 
of cytoplasmic enzyme (i.e. LDH) released after being exposed to the 
treatment (i.e. measures the amount of cell death).  
For the Alamar Blue assay, the Calu 3 cells were treated with various 
concentrations of BNP, 5% RNP, 10% RNP, and free-resveratrol for 24 hours. 
The IC50 was determined from a concentration-response sigmoid curve of 
experimentally-derived cytotoxicity data plotted in GraphPad Prism. The PGA-
co-PDL BNP was shown to possess good cytocompatibility, with none of the 
tested concentrations reducing the cell viability to less than 85% (Figure 2-
30). Therefore, no IC50 could be calculated for the PGA-co-PDL BNP since 
there was no significant reduction in viability. These results are consistent with 
those previously shown by studies of PGA-co-PDL NPs/microparticles on 
A549 and normal human bronchial epithelial (16HBE14o-) cells (Tawfeek et 
al., 2011; Kunda, 2014). MTT assay results of PGA-co-PDL NPs (1.25 mg/mL) 
on A549 cells showed a 70.84 ± 6.99% cell viability after 24 hours (Kunda, 
2014). Similarly, spray-dried PGA-co-PDL microparticles with no excipients 
were exposed to 16HBE14o- cells and it showed a cell viability of 87.14 ± 
3.40% even at 5 mg/mL after 24 hours (Tawfeek, 2013). These results suggest 
that PGA-co-PDL NPs is a good delivery system that does not have an 
inherent cytotoxic effect. The Alamar blue assay showed that the 5% RNP, 
10% RNP, and free-resveratrol had a concentration-dependent cytotoxic effect 
on the cell viability of the Calu 3 cells (Figures 2-27, 2-28, 2-29). The IC50 after 
24 hours of treatment with the free resveratrol was 0.049 ± 0.014 mg/mL or 
213 ± 63 µM (Figure 2-27). Trotta et al observed that Calu 3 cells were less 
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sensitive to resveratrol. Resveratrol was well-tolerated and non-toxic to Calu 
3 cells at concentrations as high as 160 µM, even after 72 hours, with cell 
viability being maintained above 95% (Trotta et al., 2015). This gives credence 
to the high IC50 for resveratrol obtained in this study. In this study, it was found 
that the IC50 values of the 5% RNP and 10% RNP were 47 ± 30 µM (Figure 
2-28) and 86 ± 38 µM (Figure 2-29), respectively. When compared to the IC50 
of the free-resveratrol, it is evident that the delivery system caused a maximum 
decrease in IC50 of 78% (Table 2-3). This indicates that the PGA-co-PDL NPs 
are more effective in exposing the resveratrol to the cells than the free-
resveratrol. This seems to be true even for the well-established anticancer 
drugs, such as doxorubicin and paclitaxel. One study found that doxorubicin 
NPs and paclitaxel NPs decreased their respective IC50 values by 8 times and 
9 times, respectively, as compared to the free-drug in P-glycoprotein-
overexpressing human ovarian carcinoma cells (Dong et al., 2009). Phenolic 
compounds such as quercetin have also showed decreases in IC50 (higher 
cytotoxicity efficacy) when loaded into NPs. Quercetin loaded into solid lipid 
NPs reduced its 24 hours IC50 in MCF-7 cells by 50%, as compared with free 
quercetin (Niazvand et al., 2019). Similarly, resveratrol-loaded glycyrrhizic 
acid-conjugated human serum albumin NPs decreased the IC50 after 48 hours 
by 35% as compared to free-resveratrol in HepG2 cells (M. Wu et al., 2017). 
Another study found that resveratrol-loaded gelatin NPs decreased the IC50 
after 24 hours by 50% compared with free resveratrol in NCI-H460 non-small 
cell lung cancer cells (Karthikeyan et al., 2013).  
The ANOVA and subsequent Tukey’s comparison revealed that there was no 
statistical difference (p>0.99) between the BNP and the untreated cells 
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(negative control) (Figure 2-30). This means that for these sets of 
experiments, the BNP-treated Calu 3 cells were physiologically similar to the 
negative control cells. As explained earlier, this bodes well for the BNP as a 
delivery system and implies that the cytotoxicity seen in the 5% RNP and 10% 
RNP treated cells were due to the resveratrol loaded into these NPs. The 5% 
RNP and 10% RNP decreased the cell viability of Calu 3 cells in a 
concentration-dependent manner (Figure 2-30). Compared to BNP,the 5% 
RNP and 10% RNP caused significant decreases in cell viability at 1 mg/mL 
(p<0.005) and 0.25-1 mg/mL (p<0.05), respectively. This further suggests that 
the cytotoxicity of the 5% RNP and 10% RNP was due to the resveratrol and 
not the PGA-co-PDL NPs, since the same amount of polymer was present in 
the 1 mg/mL BNP, 1 mg/mL 5% RNP and 1 mg/mL 10% RNP. The reduction 
in cell viability also shows that, despite the burst release of resveratrol during 
the release study, it would seem that the PGA-co-PDL NPs effectively 
delivered the resveratrol to the cells.  
For the LDH assay the cells were treated for both 48 hours and 72 hours. 
Preliminary tests showed that no real difference in cytotoxicity was noticeable 
at 24 hours (data not shown). In order to accommodate the necessary controls 
on the treatment plate for the LDH assay, it was decided that the most efficient 
way was to have a single BNP concentration that corresponded to the highest 
amount of polymer present in the concentrations of the 10% RNP, i.e. 300 µM. 
Both BNP and 10% RNP, at 300 µM, increased LDH release to the same 
extent after 48h (p< 0.05), whereas, after 72 h, while both BNP and 10% RNP 
still increased LDH release, the LDH release by 10% RNP was greater than 
that of BNP (p< 0.005) (Figures 2-31, 2-32). This could indicate that the LDH 
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release could be due to encapsulated resveratrol, since the polymer contents 
of both formulations were equal. Moreover, the free-resveratrol did not cause 
a significant increase in LDH release compared to the control at both 48 and 
72 hours (p>0.05). However, at 72 hours, the 10% RNP at 300 µM caused a 
significant increase in LDH release compared to free-resveratrol at the same 
concentration (p<0.001). This shows the improvement in the efficacy of 
resveratrol using PGA-co-PDL NPs as a delivery system. 
Together, the results showed that resveratrol encapsulated into PGA-co-PDL 
NPs reduced Calu 3 cell viability in a concentration- and time-dependent 
manner. These results are consistent with results obtained by a previous study 
in which resveratrol (0-100 µM) administered to A549 and CH27 human lung 
carcinoma cells was found to cause a concentration-dependent increase in 
LDH leakage (Weng et al., 2009). However, as NPs are not able to be inhaled 
into the lungs, the resveratrol-loaded NPs will need to be spray-dried into 
nanocomposite microparticles (Elsayed and AbouGhaly, 2016; Rezazadeh et 
al., 2018). This is the focus of the next chapter.  
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2.3.5. Conclusion 
In this study, a comparison of four different polymers used for the formulation 
of resveratrol-containing NPs and characterised in terms of size, charge, drug 
loading and encapsulation efficiency was undertaken. PGA-co-PDL NPs were 
chosen as the most effective due to the higher encapsulation efficiency 
obtained. Subsequent cell viability tests (Alamar blue) of PGA-co-PDL NPs 
showed that the blank PGA-co-PDL NPs had no inherent cytotoxic effect on 
the Calu 3 cells. More importantly, it demonstrated that the PGA-co-PDL-
encapsulated resveratrol was more effective than free-resveratrol, reducing 
the IC50 by 78%. Furthermore, the LDH assay confirmed that the cytotoxic 
effects were due to the resveratrol encapsulated inside the NPs and not the 
delivery system itself. Together, these results demonstrated that the 
resveratrol-encapsulated PGA-co-PDL NPs has a concentration- and time-
dependent cytotoxic effect on Calu 3 cells.  
This study showed the potential of resveratrol-encapsulated PGA-co-PDL NPs 
to treat cancer and hence further studies towards the incorporation of the PGA-
co-PDL NPs into micron-sized nanocomposite microparticles via spray drying 
to enable pulmonary delivery of the NPs were subsequently undertaken.
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3 CHAPTER 3: Formulation of Resveratrol Loaded PGA-co-PDL 
Nanoparticles into Aerosolisable Microcarriers 
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3.1. Introduction 
Inhalable chemotherapy, which involves the local administration of 
chemotherapy to the lungs, offer a promising alternative to intravenous 
administration (Abdelaziz et al., 2018). There are many advantages to 
delivering drugs via the lungs for both local and systemic treatment, including 
high bioavailability, since the first pass metabolism is bypassed, rapid onset of 
action due to direct targeting at the disease site  (lung cancer cells), self-
administration (dry powder inhalation devices) and non-invasiveness 
(increased patient compliance) (Sung, Pulliam and Edwards, 2007; Mahmud 
and Discher, 2011; Thorley and Tetley, 2013; Lee et al., 2015).  
In chapter 2, PGA-co-PDL NPs were demonstrated to be an effective delivery 
system for resveratrol. However, the size of the NPs (approximately 200 nm) 
poses a problem for pulmonary delivery (Pilcer and Amighi, 2010). The NPs 
will therefore be incorporated into nanocomposite microparticles (NCMPs) 
using spray drying to obtain the ideal particle size range of 1-5 µm for lung 
deposition (Figure 3-1) (Rezazadeh et al., 2018). Spray drying is an 
established technique for the production of particles which involves the 
transformation of a fluid material into dried particles, by means of a gaseous 
hot drying medium (Cal and Sollohub, 2010). The spray drying process 
involves using excipients which have several functions including, enhancing 
the flowability of drug particles to ease filling of the dry powder inhaler (DPI), 
enhancing dispersion of drug particles during emission, muco-adhesion in 
case of chitosan and decreasing concentration of the drug to facilitate accurate 
delivery of the dose (Peng et al., 2016). 
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Figure 3-1 Illustration of nanocomposite microparticle containing 
resveratrol-loaded nanoparticles 
 
L-leucine is a hydrophobic amino acid which has been well-established as a 
dispersion enhancer (Takeuchi et al., 2018). It translocates to the surface of 
the particles after spray drying and decreases the interaction forces between 
particles (Nieto-Orellana et al., 2018). Chitosan is a natural polycationic linear 
polysaccharide, that has been shown to be mucoadhesive, non-immunogenic 
and non-toxic (Cheung et al., 2015). It forms electrostatic interactions with the 
sialic groups of mucins in the mucus layer (Hejjaji, Smith and Morris, 2018; 
Collado-gonz, Gonz and Goycoolea, 2019). A bioadhesive polymer such as 
chitosan is capable of prolonging the presence of the formulation in the lungs, 
thus increasing the efficacy of a formulation. Clarithromycin-loaded 
microparticles were formulated via spray drying with L-leucine and chitosan 
(Dimer et al., 2015). The spray dried microparticles had a good yield (60.7 ± 
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2.3%) with a drug loading of 36.0 ± 1.4% w/w, a high FPF of 73.3 ± 2.3%, and 
a mass median aerodynamic diameter (MMAD) of 1.8 µm (Dimer et al., 2015). 
Interestingly, the deposition of the spray-dried microparticles was assessed 
using Pharmaceutical Aerosol Deposition Device on Cell Cultures 
(PADDOCC) using Calu-3 cells. The PADDOCC system comprises of three 
components, namely, the air flow control unit, the aerosolisation unit, and the 
deposition unit, which are all connected by silicon tubes (Hein et al., 2011). 
The system was designed to imitate the entire aerosol drug delivery process, 
including aerosol generation, aerosol deposition onto pulmonary epithelial 
cells, and drug transport across this biological barrier, to help investigate new 
aerosol formulations in the early stage development (Hein et al., 2010). Using 
the PADDOCC system, it was shown that 8.7 µg/cm2 of the spray dried 
microparticles deposited on Calu 3 cells were transported to the basolateral 
compartment after 24 hours (Dimer et al., 2015).  
3.2. Aims and Objectives  
The aim of this study was to develop NCMPs for the dry powder delivery of 
resveratrol PGA-co-PDL NPs to the lung.  
The objectives of the study were:  
1. Incorporate BNP, 5% RNP, and 10% RNP into NCMPs via spray drying 
using L-leucine and chitosan as excipients:  
a. Investigate size and charge of NPs recovered from NCMPs.  
b. Analyse the NCMPs for yield, drug loading, encapsulation efficiency, and 
the release of resveratrol from NCMPs.  
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c. Study the in vitro aerosolisation deposition and cell toxicity of the NCMPs. 
3.3. Materials and Methods 
3.3.1. Materials 
Microparticle synthesis: L-leucine and low molecular weight chitosan were 
purchased from Sigma-Aldrich, UK. 
Polymer synthesis and cell culture: Same as in chapter 2.  
3.3.2. Methods 
3.3.2.1. Polymeric nanoparticle synthesis and analysis  
PGA-co- PDL was synthesised and analysed as described previously, in chapter 
2, section 2.3.2.1.1.  
3.3.2.2. Polymeric nanoparticle formulation 
Blank (BNP), 5%- (5% RNP), and 10%-resveratrol loaded PGA-co-PDL NPs 
(10% RNP) were prepared and analysed according to the methods described 
in Chapter 2, sections 2.3.2.3-4.  
3.3.2.3. Nanocomposite microparticle formulation  
3.3.2.3.1. Spray drying  
The NPs were formulated into NCMP using a Büchi B-290 mini spray-dryer 
(Büchi Labortechnik, Flawil, Switzerland). The spray-dryer was equipped with 
a nozzle atomiser with a nozzle orifice featuring a diameter of 0.7 mm. The 
parameters for the spray drying process were optimised previously 
(Almurshedi, 2018) using; a feed rate of 10% (corresponding to 2.5 mL/min), 
an atomising air flow of 400 L/h, aspirator capacity of 100%, and an inlet 
temperature of 100 °C (corresponding outlet temperature of 47-50 °C). The 
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spray-dryer had a high-performance cyclone (Büchi Labortechnik, Flawil, 
Switzerland) attached, to facilitate the removal of the dry NCMPs from the air 
stream.  
The polymeric NPs were incorporated into NCMPs using L-leucine (LEU) and 
low molecular weight chitosan (CHI) as microcarriers at a nanoparticle to 
microcarrier ratio (w/w) of 1:1.5:1 (NPs:LEU:CHI). This ratio was chosen since 
it showed good results in a previous study (Almurshedi, 2018). L-leucine and 
chitosan were dissolved under stirring in distilled water (10 mL) or acetic acid 
(0.1%) aqueous solution (10 mL), respectively. A quantity of PGA-co-PDL NPs 
was dispersed in the solution containing L-leucine with stirring at 25 °C for 1 
min. The chitosan solution was then added to the mixture of L-leucine and 
NPs, which made the feed solution for spray drying. After spray drying, the 
NCMPs were collected and stored inside a desiccator under vacuum until 
needed.  
3.3.2.4. Nanocomposite microparticle analysis  
3.3.2.4.1. Yield 
The yield was defined as the difference between the combined weight of the 
NPs and microcarriers and the weight of the dry powder collected at the end 
of the spray drying process multiplied by 100 % (w/w) (n=3) as illustrated in 
Equation 3-1.  
𝑌𝑖𝑒𝑙𝑑 (%) =   
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑑𝑟𝑦 𝑝𝑜𝑤𝑑𝑒𝑟 𝑐𝑜𝑙𝑙𝑒𝑐𝑡𝑒𝑑 𝑎𝑓𝑡𝑒𝑟 𝑠𝑝𝑟𝑎𝑦 𝑑𝑟𝑦𝑖𝑛𝑔 (𝑚𝑔)
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑁𝑃𝑠 𝑎𝑛𝑑 𝑚𝑖𝑐𝑟𝑜𝑐𝑎𝑟𝑟𝑖𝑒𝑟𝑠 𝑏𝑒𝑓𝑜𝑟𝑒 𝑠𝑝𝑟𝑎𝑦 𝑑𝑟𝑦𝑖𝑛𝑔 (𝑚𝑔) 
✕ 100 Equation 3-1 
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3.3.2.4.2. Particle size and zeta potential  
The spray dried NCMPs (5 mg) were dispersed in deionised water (dH2O; 5 
mL), vortexed for 5 minutes and an aliquot (2 mL) was pipetted into a cuvette; 
the size, PDI, and charge was measured as reported in chapter 2, section 
2.3.2.4.1 on a Malvern Zetasizer Nano at 25 °C (n=3).  
3.3.2.4.3. Morphology 
Scanning electron microscopy (SEM, FEI Quanta™ 200 ESEM, The 
Netherlands) was used to visualise the morphology and size of the spray-dried 
NCMPs. The samples were prepared by layering the powder on a conductive 
carbon tab mounted on aluminium stubs (pin stubs, 13 mm). A sputter coater 
(EmiTech K 550X Gold Sputter Coater, 25 mA for 3 min) was then utilised to 
coat the samples with palladium (10-15 nm). 
3.3.2.4.4. Moisture content  
The moisture content of the spray-dried NCMPs was ascertained by using 
thermo gravimetric analysis (TGA, TA instruments TGA Q50, UK). An open 
platinum TGA pan was loaded with samples (4-15 mg). The pan was 
suspended from a microbalance and heated from 25-650 °C at a rate of 
10 °C/min. The moisture content of the sample was analysed from the mass 
loss recorded from 25-120 °C using the equipped software (TA Universal 
Analysis 2000 software). 
3.3.2.4.5. Drug loading and encapsulation efficiency (EE) 
Each formulation (NCMP-BNP, NCMP-5% RNP, and NCMP-10% RNP) was 
weighed (4-12 mg) and dissolved in 0.1% acetic acid (aqueous; 1 mL). This 
mixture was sonicated for 5 minutes using an ultrasonic bath (Ultrawave, UK) 
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to burst open the NCMPs. Methanol (1 mL) was then added to the sonicated 
mixture and sonication was repeated for 5 minutes using the ultrasonic bath in 
order for the released resveratrol to enter into the methanol, since the 
resveratrol is more soluble in methanol than the 0.1% aqueous acetic acid. 
The resultant solution was filtered through Captiva Econofilter PTFE 13 mm 
0.45 µm (Agilent Technologies, USA) into 2mL crimp vials (Agilent 
Technologies, USA).  
High performance liquid chromatography (HPLC) (1200 series; Agilent 
Technologies, USA) using a YMC-Triart C18 150 x 4.6 mm I.D. S-5 µm, 12 nm 
column (YMC Co. LTD., Japan) was used to determine the amount of 
resveratrol encapsulated in the NCMPs. The samples previously prepared and 
loaded into the crimp vials were placed into the HPLC tray. The samples (20 
µL) were injected into the system running a mobile phase of methanol:water 
(51:49%; v/v) at a flow rate of 0.54 mL/min. The variable wavelength detector 
(VWD; Agilent Technologies, USA) was set at 306 nm. The NCMP-BNP was 
used as a control.  
Previously, resveratrol (0.122 µg/mL-1000 µg/mL) was run on the HLPC using 
the same parameters as above. The results of the area under the curve was 
plotted against the various concentrations to obtain a calibration curve. This 
calibration curve was used to determine the amount of resveratrol 
encapsulated in the NCMPs. 
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3.3.2.4.6. Release study  
NCMP-BNP, NCMP-5% RNP, and NCMP-10% RNP (10 mg) were placed in 
separate sealed Falcon tubes containing PBS (10 mL; pH 7.4). The tubes were 
placed on a Grant-Bio PTR-35 multi-function rotator (Grant Instruments, UK) 
stirring at 30 rpm in a Stuart S160 incubator (Stuart Equipment, UK) at 37 °C. 
At pre-determined intervals, the tubes were removed from stirring and 
centrifuged using a Hermle Z400 centrifuge (Hermle LaborTechnik, Germany) 
at 5000 rpm for 10 minutes. Afterwards, an aliquot (1 mL) of the supernatant 
was removed and replaced with a fresh aliquot of PBS (1 mL). The supernatant 
was analysed via HPLC for resveratrol content using the method described in 
chapter 2, section 2.3.2.4.2. The cumulative resveratrol release (CRR) was 
calculated using Equation 3-2.  
𝐶𝑅𝑅 % =
𝐶𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑣𝑒 𝑟𝑒𝑠𝑣𝑒𝑟𝑎𝑡𝑟𝑜𝑙 𝑟𝑒𝑙𝑒𝑎𝑠𝑒
𝑟𝑒𝑠𝑣𝑒𝑟𝑎𝑡𝑟𝑜𝑙 𝑙𝑜𝑎𝑑𝑒𝑑 
  × 100 %                         Equation 3-2  
 
3.3.2.4.7. In vitro aerosolisation studies  
The mass median aerodynamic diameter (MMAD) of the spray-dried NCMPs 
was determined by using a Next Generation Impactor (NGI; Copley Scientific, 
Nottingham, UK).  
The NGI consists of 8 stages (stage 8 being filter paper) with various cut-off 
diameters. At 60 L/min, the 7 stages have the following diameters: stage 1 
(8.06 µm); stage 2 (4.46 µm); stage 3 (2.82 µm); stage 4 (1.66 µm); stage 5 
(0.94 µm); stage 6 (0.55 µm); and stage 7 (0.34 µm)(Marple et al., 2003).  
The NGI was equipped with a stainless-steel induction port (USP throat 
adaptor) and pre-separator (which was filled with 15 mL dH2O). The removable 
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impactor cups under each stage was coated with 1% tween 80: methanol 
solution to remove particle bounce (Hamishehkar et al., 2018). The impactor 
cups were weighed before and after each run to determine the particle mass 
deposited.  
All three formulations of spray-dried NCMPs were weighed and manually 
loaded into hydroxypropyl methylcellulose capsules (size 3) (3 capsules, each 
corresponding to 10-15 mg spray-dried powder). The loaded capsules were 
placed inside a Cyclohaler® (Teva Pharmaceutical Industries Ltd.) that was 
attached to a mouthpiece adaptor (Copley Scientific, UK) connected to the 
induction port to form an airtight seal.  
Three capsules were loaded and released for each sample and experiments 
were done in triplicate. The overall dose for each sample was about 30 mg. A 
Copley HCP5 vacuum pump (Copley Scientific, UK) and a Copley TPK 2000 
critical flow controller (Copley Scientific, UK) were used to establish a flow rate 
of 60 L/min in order to simulate the flow rate in a healthy adult lung. A Copley 
DFM 2000 flow meter (Copley Scientific, UK) was employed to ensure the 
correct flow rate before each experiment.  
The samples were drawn from the Cyclohaler® through the induction port into 
the NGI for 4 seconds per run.  
The MMAD and the geometric standard deviation (GSD) were determined 
using online software (http://www.mmadcalculator.com). The emitted dose 
(ED), respirable fraction (RF), and fine particle fraction (FPF) were calculated 
using Equations 3-3, 3-4, 3-5 (Stocke et al., 2015): 
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𝐸𝐷 % =
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑚𝑎𝑠𝑠 𝑖𝑛 𝑐𝑎𝑝𝑠𝑢𝑙𝑒𝑠−𝐹𝑖𝑛𝑎𝑙 𝑚𝑎𝑠𝑠 𝑖𝑛 𝑐𝑎𝑝𝑠𝑢𝑙𝑒𝑠
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑚𝑎𝑠𝑠 𝑖𝑛 𝑐𝑎𝑝𝑠𝑢𝑙𝑒𝑠 
  × 100 %       Equation 3-3 
𝑅𝐹 % =
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 𝑜𝑛 𝑠𝑡𝑎𝑔𝑒𝑠 2−7
𝑇𝑜𝑡𝑎𝑙 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒 𝑚𝑎𝑠𝑠 𝑜𝑛 𝑎𝑙𝑙 𝑠𝑡𝑎𝑔𝑒𝑠 
  × 100 %                              Equation 3-4 
𝐹𝑃𝐹 % =
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 𝑜𝑛 𝑠𝑡𝑎𝑔𝑒𝑠 2−7
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑚𝑎𝑠𝑠 𝑖𝑛 𝑐𝑎𝑝𝑠𝑢𝑙𝑒𝑠
  × 100 %                              Equation 3-5 
 
3.3.2.5. Cell culture 
Human lung adenocarcinoma cell line (Calu-3) was grown in Minimum 
Essential Medium Eagle (MEM) media supplemented with 10 % foetal bovine 
serum (FBS), 1 % L-glutamine, 1% penicillin-streptomycin, 1% MEM Non-
essential amino acids and 1% sodium pyruvate in a 75 cm2 tissue culture flask 
incubated in a humidified incubator at 37 °C with 5% CO2. 
3.3.2.5.1. Cell toxicity studies 
The Pierce™ LDH Cytotoxicity Assay Kit (ThermoFisher Scientific, UK) was 
used to determine the in vitro cytotoxicity of the NCMPs. Lactate 
dehydrogenase (LDH) is a soluble cytoplasmic enzyme that is present in 
almost all cells and is released into the extracellular space when the plasma 
membrane is damaged (Burd and Usategui-Gomez, 1973). The LDH 
cytotoxicity assay works by detecting this LDH being released into the cell 
culture medium using a tetrazolium dye. The conversion happens in a two-
step process. Firstly, reduced nicotinamide adenine dinucleotide (NADH) is 
produced by LDH when it catalyses the oxidation of lactate to pyruvate. 
Secondly, the newly formed NADH in the presence of an electron acceptor 
converts the tetrazolium salt into a coloured formazan product that can be 
detected using a spectrophotometer (Korzeniewski and Callewaert, 1983). 
The linearity of the assay allows for calculating the percentage of necrotic cells 
134 
 
in a sample. An established protocol was used to run the assay and analyse 
the data (Chan, Moriwaki and De Rosa, 2013).  
The LDH assay was performed exactly as is described in chapter 2, section 
2.3.2.6.2. However, the cells were treated with NCMPs and free-resveratrol at 
concentrations of 0-5.75 mg/mL for 48 hours.  
3.3.2.6. Statistical analyses  
All statistical analyses were performed using GraphPad Prism 7. One-way 
analysis of variance (ANOVA) followed by Tukey's multiple comparisons test 
was employed to compare the formulations with each other. Statistically 
significant differences were assumed when p<0.05. The level of confidence 
was set as 95%. All values are expressed as their mean ± standard error of 
mean (cell studies) or mean ± standard deviation (all other studies). 
3.3.3. Results  
3.3.3.1. Nanocomposite microparticle analysis  
3.3.3.1.1. Yield  
Using Equation 3-1, it was found that the yield ranged from 31.8-73.2% across 
the three formulations in the following order NCMP-BNP (73.2 ± 29.9%) > 
NCMP-5% RNP (56.5 ± 10.4%) > NCMP-10% RNP (31.8 ± 18.0%). There was 
no statistically significant difference (p> 0.5) between the three NCMPs.  
3.3.3.1.2. Particle size and zeta potential  
The size of the NPs recovered from the spray-dried NCMPs after re-dispersion 
in dH2O was 1322 ± 306 nm and PDI 0.432 ± 0.220 for the NCMP-BNP, 1207 
± 443 nm and PDI 0.241 ± 0.06 for the NCMP-5% RNP, and 1744 ± 925 nm 
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and PDI 0.524 ± 0.424 for the NCMPs-10% RNP (Figure 3-2). All recovered 
NPs were statistically larger compared to the pre-spray-dried formulations.  
The surface zeta potential of the reconstituted nanoparticles recovered all 
changed to positive, likely due to the added chitosan (Figure 3-3). 
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Figure 3-2 Size of PGA-co-PDL nanoparticles vs PGA-co-PDL 
nanoparticles reconstituted from nanocomposite microparticles in 
distilled water, n=3. Unpaired t-test was used to compare each pair 
of means as shown. 
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Figure 3-3 Charge of PGA-co-PDL nanoparticles vs reconstituted 
PGA-co-PDL nanoparticles from nanocomposite microparticles in 
distilled water, n=3. Unpaired t-test was used to compare each pair 
of means as shown. 
 
3.3.3.1.3. Morphology  
The surface morphology of the NCMPs were assessed using SEM. The 
NCMPs had a wrinkly surface with noticeable cavities/indentations in the 
middle of the particles (Figure 3-4). There was a heterogenous size 
distribution ranging from <1 µm to > 8 µm (Figure 3-4). 
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Figure 3-4 SEM images of NCMP-BNPs. Pictures were taken at 
3000× and 5000× magnifications 
 
3.3.3.1.4. Moisture content  
The moisture content of the NCMPs was determined using TGA and the 
thermograms show that the spray-dried NCMPs contained a residual moisture 
content of 4.695 ± 1.769% w/w (NCMP-BNP), 4.441 ± 1.078% w/w (NCMP-
5% RNP), and 4.896 ± 0.762% w/w (NCMP-10% RNP) (n=2) (Figure 3-5).  
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Figure 3-5 Thermogram of (a) NCMP-BNP, (B) NCMP-5% RNP, 
and (c) NCMP-10% RNP 
 
3.3.3.1.5. Drug loading and encapsulation efficiency (EE%) 
The drug loading and encapsulation efficiency (Table 3-1) of the NCMPs were 
calculated using a standard curve (Figure 3-6). The lowest concentration at 
which resveratrol can be detected (LOD) or quantified (LOQ) were calculated 
as 0.061 and 0.18 µg/mL, respectively. 
Theoretical drug loading (TDL) was calculated using the Equation 3-6: 
𝑇𝐷𝐿 =
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑟𝑒𝑠𝑣𝑒𝑟𝑎𝑡𝑟𝑜𝑙 (mg) 𝑖𝑛 𝑁𝑃𝑠 𝑎𝑑𝑑𝑒𝑑 
𝐶𝑜𝑚𝑏𝑖𝑛𝑒𝑑 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑁𝑃𝑠,𝐿𝑒𝑢𝑐𝑖𝑛𝑒,𝑎𝑛𝑑 𝐶ℎ𝑖𝑡𝑜𝑠𝑎𝑛 (𝑚𝑔)
           Equation 3-6 
5% 𝑅𝑁𝑃 (𝑇𝐷𝐿) =
1.56 𝑚𝑔 
140 𝑚𝑔
= 11.14 µg/mg 
10% 𝑅𝑁𝑃 (𝑇𝐷𝐿) =
2.8 𝑚𝑔 
140 𝑚𝑔
= 20 µg/mg 
EE% was calculated using Equation 3-7. 
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𝐸𝐸% =
𝐷𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 𝑐𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 𝑓𝑟𝑜𝑚 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑐𝑢𝑟𝑣𝑒 (µg) 
𝑇𝐷𝐿 (µg)
 𝑥 100 Equation 3-7 
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Figure 3-6 Resveratrol standard curve using HPLC (R2=0.9995) 
n=3 
 
Table 3-1 Drug loading and encapsulation efficiency of NCMP-5% 
RNP and NCMP-10% RNP 
Formulation 
Drug loading 
(µg/mg)* 
encapsulation 
efficiency (%) 
NCMP-5% RNP 2.23 ± 0.01 20.00 ± 0.04 
NCMP-10% RNP 7.97 ± 0.01 39.85 ± 0.05 
* µg/mg – concentration of resveratrol in micrograms per 1 milligram of NCMPs 
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3.3.3.1.6. Release study  
The percentage cumulative resveratrol released in vitro from the NCMPs, 
calculated using Equation 3-2, showed that only 20-25% of resveratrol was 
released over 24 hours (Figure 3-7).The percentage of resveratrol released 
after 15 minutes was 6.4 ± 0.04% and 3.5 ± 0.03%, 1 hour was 17.9 ± 0.20% 
and 13.3 ± 0.07%, 4 hours was 22.7 ± 0.25% and 18.2 ± 0.09%, and after 24 
hours 25.8 ± 0.25% and 21.5 ± 0.1% for NCMP-5% RNP and 10% NCMP-
10% RNP, respectively. 
0 2 4 6 8 1 0 1 2 1 4 1 6 1 8 2 0 2 2 2 4
0
5
1 0
1 5
2 0
2 5
3 0
t i m e  ( h o u r s )
c
u
m
u
l
a
t
i
v
e
 
r
e
l
e
a
s
e
 
(
%
)
N C M P - 5 %  R N P
N C M P - 1 0 %  R N P
 
Figure 3-7 In vitro release profile of NCMPs-5% RNP and NCMPs-
10% RNP in PBS (pH 7.4) at 37 °C 
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3.3.3.1.7. In vitro aerosolisation studies 
The ED of all three NCMPs was above 98%. The RF was 72 ± 3.4%, 74 ± 
4.5%, 70 ± 1.7% for NCMP-BNP, NCMP-5% RNP, and NCMP-10% RNP, 
respectively (Table 3-2). The FPF and its corresponding mass relates to the 
percentage and amount of the formulation that would reach the lower echelons 
of the lungs (Stages 2-7 in Figure 3-8). NCMP-BNP had an FPF and 
corresponding mass of 38.9 ± 7.2% and 7 ± 1.3 mg (per capsule). Meanwhile, 
the NCMP-5% RNP and NCMP-10% RNP had an FPF and mass of 46.7 ± 
5.7% and 6 ± 0.9 mg and 39.8 ± 4.8% and 7 ± 0.84 mg, respectively. The 
MMAD of NCMP-BNP, NCMP-5% RNP, and NCMP-10% RNP were 3.96 ± 
0.69 µm (n=4), 3.11 ± 0.51 µm (n=4), and 3.59 ± 0.43 (n=3), respectively. 
These results all suggest that the majority of the ED of the formulations are to 
be delivered to the lower bronchi-alveolar regions of the lungs.  
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Figure 3-8 Percentage of NCMPs deposited at each stage of the 
NGI n=4 
 
Table 3-2 Emitted Dose, Respirable Fraction, and Fine Particle 
Fraction of NCMP-BNP, NCMP-5% RNP, and NCMP-10% RNP 
NCMPs Emitted Dose 
(%) 
Respirable 
Fraction (%) 
Fine Particle 
Fraction (%) 
NCMP-BNP 98.7 ± 0.8 72.0 ± 3.4 38.9 ± 7.2 
NCMP-5% RNP 98.9 ± 1.3 74.5 ± 4.5 46.7 ± 5.7 
NCMP-10% 
RNP 
98.7 ± 1.9 69.8 ± 1.7 39.8 ± 4.8 
 
143 
 
3.3.3.1.8. Cell viability studies  
3.3.3.1.8.1. LDH assay 
There was no statistically significant difference (p> 0.05) between the three 
NCMPs tested and the control (Figure 3-9). At 2.5 mg/mL, the NCMP-BNP 
induced an LDH release of 56 ± 21 % compared to the maximum LDH release 
by cell lysis. At higher concentrations, 2.8 mg/mL, the NCMP-5% RNP and 
NCMP-10% RNP resulted in lower LDH release, 43 ± 20 % and 34 ± 10 %, 
respectively. This indicates that the NCMP-BNP caused more cell damage 
than the NCMP-5% RNP and NCMP-10% RNP. However, it should be noted 
that this experiment was fraught with problems and the NCMPs may have 
caused interference with the assay that confounded the results. 
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Figure 3-9 The effect of NCMP-5% RNP and NCMP-10% RNP on 
LDH release in Calu 3 cells after 48 hours 
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3.3.4. Discussion 
The aim of this study was to develop NCMPs for the dry powder delivery of 
resveratrol PGA-co-PDL NPs to the lung. PGA-co-PDL NPs with a diameter in 
the region of 250 nm , would be readily uptaken into the cells, but they are 
incapable of depositing directly into the lungs since they would be exhaled 
without settling in the alveoli (Pilcer and Amighi, 2010; Florence, 2012). In 
order to be inhaled and efficiently deposited into the lungs, particles need to 
have an aerodynamic diameter in the range of 1-5 µm (Yildiz-Peköz et al., 
2018).Thus, the PGA-co-PDL NPs optimised in Chapter 2 had to be 
formulated into NCMPs for pulmonary administration by dry powder inhalation. 
NCMPs were formed via spray drying using L-leucine and chitosan as 
excipients. L-leucine, a hydrophobic amino acid, is beneficial as an excipient 
due to its ability to reduce the aggregation of particles produced via spray 
drying (Takeuchi et al., 2018). L-leucine has been shown to increase the FPF 
(Takeuchi et al., 2018). Chitosan is a natural polycationic linear 
polysaccharide, that has been shown to be mucoadhesive, non-immunogenic 
and non-toxic (Cheung et al., 2015). It forms electrostatic interactions with the 
sialic groups of mucins in the mucus layer (Hejjaji, Smith and Morris, 2018; 
Collado-gonz, Gonz and Goycoolea, 2019). Chitosan was shown to modify the 
release profile of drugs in spray-dried formulations (Learoyd et al., 2008) 
Leucine and chitosan in combination was shown to enhance the dispersibility 
and modify the drug release profile of dry powder formulations of hydrophilic 
terbutaline sulfate, and hydrophobic beclomethasone dipropionate (Learoyd 
et al., 2009). In this study, it was anticipated that spray drying the PGA-co-PDL 
NPs with L-leucine (aerosolisation enhancer) and chitosan (drug release 
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modifier) would result in NCMPs that showed good dispersibility, would adhere 
to the mucosal surface of the lungs and upon dispersion the NPs would deliver 
a sustained drug release profile.  
The yield of the spray-dried NCMPs had the following order NCMP-BNP (73.2 
± 29.9 %) > NCMP-5% RNP (56.5 ± 10.4 %) > NCMP-10% RNP (31.8 ± 
18.0 %). There was no statistically significant difference between the three 
NCMPs (p>0.05). This may be due to the difficulty in removal of the powder 
from the sides of the cyclone, due to some of the liquid droplets attaching to 
the inside wall of the drying chamber and cyclone of the spray-dryer and the 
difficulty in removal of chitosan. Vancomycin hydrochloride-encapsulated 
chitosan microspheres were prepared via spray drying with different chitosan: 
drug ratios (Cevher et al., 2006). The low yields were attributed to liquid 
droplets attaching to the inside of the wall of main chamber of the spray-dryer 
(Cevher et al., 2006). Similarly, liquid droplets attaching to the inner chambers 
of the spray dryer was also blamed for the decreased yield for liposomes 
spray-dried into NCMPs with chitosan and L-leucine as excipients 
(Almurshedi, 2018). 
 After deposition into the lung, the NCMPs are thought to disperse, releasing 
the drug-loaded NPs within the alveoli (Tomoda et al., 2008). The size of the 
NPs recovered from the spray-dried NCMPs after re-dispersion in dH2O were 
statistically larger than before spray drying (p<0.05) (Figure 3-2). Some 
studies found that NPs recovered from the NCMPs were 10–20% bigger and 
others found it was 30% bigger than the original NPs (Sham et al., 2004; 
Chaubal and Popescu, 2008). Preparation of 5% and 10% TAS-103 -PLGA 
NPs via single-emulsion solvent evaporation resulted in NPs of 201 nm and 
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211 nm, respectively (Tomoda et al., 2009). The NPs were spray-dried into 
NCMPs using trehalose dihydrate as an excipient (Tomoda et al., 2009). When 
the NCMPs containing 5% and 10% TAS-103 -PLGA NPs were dispersed in 
distilled water, the NCMPs decomposed and yielded NPs of 231 and 241 nm, 
respectively (Tomoda et al., 2009). Gelatin and polybutylcyanoacrylate 
(PBCA) NPs were prepared with a mean particle sizes of 242 ± 17 and 173 ± 
59 nm, respectively (Sham et al., 2004). After spray drying with lactose, the 
particles were dispersed in water and the mean particle sizes of the gelatin 
and PBCA NPs increased to 319 ± 58 and 231 ± 33 nm, respectively (Sham 
et al., 2004). PGA-co-PDL Blank NPs and BSA adsorbed NPs were spray-
dried in NCMPs using L-leucine (Kunda, 2014). The size of the NPs recovered 
from the NCMPs was 210 ± 16 and 223 ± 2 nm compared to 204 ± 3 and 299 
± 32 nm before spray drying for PGA-co-PDL Blank NPs and BSA adsorbed 
NPs, respectively. pH sensitive liposomes (PSL NPs) were prepared with an 
average size range of 42-57 nm (Almurshedi, 2018). After spray drying with L-
leucine (1.5 w/w) and various concentrations of low molecular weight chitosan 
(0.5-2 w/w), the recovered PSL NPs, 62.4-89.4 nm, were larger than the 
original PSL NPs (Almurshedi, 2018). Increased chitosan concentration 
resulted in an increase in recovered PSL NPs size (Almurshedi, 2018). 
Trehalose dihydrate and lactose are readily soluble in water and although L-
leucine is hydrophobic, it can disperse in water, which will explain the recovery 
of NPs from NCMPs using these excipients (Lipiäinen et al., 2018; Sansone 
et al., 2018; Focaroli et al., 2019). On the other hand, chitosan swells (forming 
a gel) when exposed to an aqueous medium, which could explain the 
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increased size of the NPs recovered from the NCMPs spray-dried with 
chitosan (Aranaz et al., 2017).  
The surface zeta potential of the reconstituted NPs recovered were all positive 
where-as the NPs had been negatively charged before spray drying (Figure 
3-3). This positive change is most likely due to the chitosan, a cationic 
polysaccharide, coating the NPs (Ranjan et al., 2011; Muhsin et al., 2016). 
Similar results were found previously when liposomes were spray-dried into 
NCMPs using L-leucine and chitosan. It was found that the reconstituted 
liposomes tended to move towards a more positive zeta potential as the 
concentration of chitosan increased (Almurshedi, 2018).  
The morphological analysis via SEM showed particles that had 
wrinkly/corrugated surfaces with noticeable cavities/indentations in the middle 
of the particles (Figure 3-3). These cavities are caused by L-leucine 
possessing the ability to migrate to the surface of the particle droplet during 
the rapid atomisation phase of spray drying. Being hydrophobic, L-leucine, 
blocks water from adsorbing onto the surface of the particle which produces 
the cavities upon drying (Merchant et al., 2014). This shape is thought to 
reduce the cohesion forces, because of the reduced contact area (Chew and 
Chan, 2001; Irvine, Afrose and Islam, 2018). L-leucine was shown to produce 
this morphology when used as an excipient for spray-dried PGA-co-PDL 
NCMPs (Kunda, Alfagih, Dennison, Somavarapu, et al., 2015). The same 
surface morphology with pitted particles were obtained when liposomes were 
spray-dried with the same ratio of L-leucine and chitosan, 1.5:1 (Almurshedi, 
2018). It was shown that only when the L-leucine:chitosan ratio increased to 
1.5:2, did the particles start to become smoother and the pitting was less 
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pronounced (Almurshedi, 2018). This was further shown when levofloxacin 
spray-dried with L-leucine (20% w/w) resulted in broken particles with deep 
pitting, but the levofloxacin spray dried with octanoyl chitosan (20% w/w) and 
L-leucine (5% w/w) showed a smoother particle with no evidence of the pitting 
(Merchant et al., 2014). The reduction in the pitting of the particles can be 
attributed to the chitosan increasing the viscosity of the fed solution, 
counteracting the ability of the L-leucine to displace the water on the surface 
of the droplet. It was found that microspheres produced using a low viscosity 
grade of chitosan showed a wrinkly surface morphology compared to 
microspheres prepared using a high viscosity grade which had a smooth 
surface (He, Davis and Illum, 1996). Increased feed viscosity, due to increased 
concentrations of chitosan, has also been implicated in increased particle 
sizes, lower encapsulation efficiency, and decreased drug release 
(Jarudilokkul, Tongthammachat and Boonamnuayvittaya, 2011; Cho et al., 
2014). 
The resveratrol content of the NCMP-5% RNP and NCMP-10% RNP was 2.23 
µg and 7.79 µg, respectively (Table 3-1). This is between 20-40 % of the 
amount predicted in Equation 3-6. This encapsulation efficiency is low and 
this could be attributed to the NPs. In chapter 2, it was shown that the PGA-
co-PDL 5% RNP and 10% RNP had burst release profiles, with up to 44 % of 
resveratrol released immediately upon contact with the release medium. This 
was attributed to some resveratrol not encapsulating inside the nanoparticle 
during the formulation process, but instead being trapped on the surface of the 
nanoparticle, which is then immediately released upon contact with a release 
medium (Huang and Brazel, 2001; Kamaly et al., 2016). This process might 
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also occur during the NCMPs formulation process, when the NPs are placed 
inside the distilled water or acetic acid (0.1%) aqueous solution of L-leucine 
and chitosan.  
In chapter 2, it was shown that the encapsulation efficiency of the PGA-co-
PDL 5% RNP and 10% RNP were quite high at 78 and 70 %, respectively. 
Therefore, increasing the encapsulation efficiency of the NPs might not be 
feasible to increase the amount of drug inside of the NCMPs, especially since 
the encapsulation efficiency of the NPs is lowering with increased amount of 
drug added (as shown in chapter 2, Table 2-2). However, since the amount of 
drug inside of the NCMPs are increasing with a higher drug loading in the NPs, 
it could be argued that increasing the ratio of NPs would increase the 
encapsulation efficiency of the NCMPs, up to a certain point (Table 3-1)  
 In chapter 2, the results from the release study for the PGA-co-PDL NPs 
showed no further release after 1 hour. During this study, the respective 
release profiles of the NCMP-5% RNP and NCMP-10% RNP were analysed. 
Both formulations had a very slow cumulative release of resveratrol (CRR) 
(Figure 3-7). The CRR was calculated from Equation 3-2 with 100% 
represented by the initial drug loading (Table 3-1). The percentage of 
resveratrol released after 15 minutes was 6.4 ± 0.04% and 3.5 ± 0.03%, 1 hour 
was 17.9 ± 0.20% and 13.3 ± 0.07%, 4 hours was 22.7 ± 0.25% and 18.2 ± 
0.09%, and after 24 hours 25.8 ± 0.25% and 21.5 ± 0.1% for NCMP-5% RNP 
and NCMP-10% RNP, respectively. The release rate went from 13-18 % in the 
first hours then slowed to 3-4 % further release over the last 20 hours. This 
could be attributed to two things. Firstly, the amount of resveratrol 
encapsulated inside the NCMPs used in the release study could have differed, 
151 
 
largely, from the amount displayed in Table 3-1. This could have been 
ascertained by bursting the particles after 24 hours and analysing it via HLPC 
to check if there was any resveratrol left. Secondly, this could be due to a 
reduction in resveratrol release due the NPs being within a chitosan matrix 
(Liu et al., 2019). Previous studies have shown that the ratio of chitosan is 
inversely proportional to the release rate of a drug from a formulation 
(Almurshedi, 2018). Apart from the increased viscosity, it is suggested that the 
hydrophilic nature of the chitosan present in the microparticle causes it to swell 
when it comes into contact with the water, which produces a gel layer that the 
drug has to diffuse through (Aranaz et al., 2017). This gel diffusion results in 
the sustained release profile. Logically, the greater the concentration of 
chitosan, the greater the thickness of the gel the drug has to diffuse through, 
which ultimately leads to a greater drug retention and slower release profile 
(Thein‐Han et al., 2004). There are three mechanisms for the release of a drug 
through the NCMPs, including release from the surface of polymeric NPs, 
diffusion through the swollen gel like layer, and release of the drug due to 
erosion of the polymer. In the majority of cases, the release of the drug is due 
to a combination of these mechanisms (Soares et al., 2016). Both the NCMP-
5% RNP and NCMP-10% RNP produced curves that fit the Higuchi model best 
(R2=0.95). This may suggest that the resveratrol has to diffuse through the 
NPs and the chitosan gel layer in order to be released. Thus, tweaking the 
chitosan ratio and overall viscosity could be used to control the particle sizes, 
drug encapsulation efficiency, and drug release profile.  
Chitosan has a greater affinity for water and tends to absorb the water into its 
matrix protecting it during the spray drying process and resulting in a higher 
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final moisture content (Merchant et al., 2014). TGA thermograms showed that 
the spray-dried formulations contained a residual moisture content between 
4.6-4.9% (Figure 3-5). These results are comparable to previous studies using 
L-leucine as an excipient, which showed a moisture content between 0.5-5% 
(Nieto-Orellana et al., 2018). Since the spray-dried formulations used in this 
study only contained 29% w/w chitosan compared with 43% w/w L-leucine, its 
water absorption may have been less pronounced.  
The results from the in vitro aerosolisation studies using the NGI, showed all 
three NCMPs had a good ED, RF, and FPF. The ED of all three formulations 
were above 98% and the NCMP-BNP, NCMP-5% RNP, and NCMP-10% RNP 
had an RF of 72 ± 3.4%, 74 ± 4.5%, 70 ± 1.7%, respectively (Table 3-2). The 
high ED can be attributed to the inclusion of L-leucine as a dispersibility 
enhancer (Rabbani and Seville, 2005; Learoyd et al., 2008). The efficiency of 
drug deposition in the lower respiratory tract is characterised by the FPF 
(Yildiz-Peköz et al., 2018). The three NCMPs had an FPF of 38.9 ± 7.2%, 46.7 
± 5.7% and 39.8 ± 4.8%, respectively. These results are higher than the FPF 
range of 10-20% provided by conventional DPIs (Suarez and Hickey, 2000; 
Meenach et al., 2013; Yildiz-Peköz et al., 2018). Previous data have 
suggested that the higher the ratio of chitosan to L-leucine, the lower the FPF 
(Almurshedi, 2018). The MMAD of all three NCMPs were between 3.1-4 µm. 
These results place the three NCMPs within ideal range of 1-5 µm for particles 
to be able to deposit in the deep regions of the lung (El-Sherbiny and Smyth, 
2012; Elsayed and AbouGhaly, 2016; Rezazadeh et al., 2018). It seems that 
the use of L-leucine enhanced the dispersibility of the formulations, but the 
excipients together produced a low FPF, which may suggest aggregation of 
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the particles. Kunda et al, spray-dried bovine serum albumin (BSA) adsorbed 
PGA-co-PDL NPs within L-leucine (1:1.5 w/w), at the same ratio and using the 
same spray-dryer parameters as in this study (Kunda, Alfagih, Dennison, 
Tawfeek, et al., 2015). The spray drying resulted in a yield of 42.35 ± 3.17 % 
and the in vitro release study showed an initial burst release of 30.15 ± 2.33 % 
with 95.15 ± 1.08 % BSA released over 48 hours (Kunda, Alfagih, Dennison, 
Tawfeek, et al., 2015). These results are comparable to some of the results 
from this study, however, the MMAD was 1.21±0.67 µm, which was much 
lower than what was achieved in this current study with both L-leucine and 
chitosan as excipients (Kunda, Alfagih, Dennison, Tawfeek, et al., 2015). 
The LDH assay was performed to assess the cytotoxic effects of the NCMPs 
on Calu 3 cells. Although in chapter 2 the cell viability studies produced some 
promising results, the cell viability results from the NCMPs were inconclusive. 
There seemed to be no discernible pattern with the NCMP-BNP and NCMP-
10% RNP. This could have been due, at least in part, to the wide variabilities 
(indicated by large standard error of the mean values) recorded for some of 
the data sets. There has been increasing concern with regards to 
reproducibility in biomedical research (Prinz, Schlange and Asadullah, 2011; 
Errington et al., 2014; Freedman et al., 2015; Baker and Penny, 2016). It could 
also be that due to the low release rate of resveratrol from the particles, the 
cytotoxic effect obtained with the NPs, as shown in chapter 2, was not fully 
replicable in 48 hours. Therefore, a longer incubation period may need to be 
investigated in the future. As with NPs mentioned in chapter 2, the NCMPs 
could be interfering with the LDH assay in various ways (Han et al., 2011; 
Kong et al., 2011; Oostingh et al., 2011; Sukhanova et al., 2018). Certain 
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microparticles have been found to interfere with the MTT and LDH assays 
(Laaksonen et al., 2007; Korhonen et al., 2016) It is imperative that 
optimisation of the cell culture assay takes place. Some of the steps that need 
to be taken include optimisation of seeding cell density (Che, Wang and Li, 
2009). It is essential to ensure that the cells are still in the growth phase at the 
end of the assay (Wright Muelas et al., 2018). Chitosan, although 
biocompatible, has been shown to be cytotoxic and it would be worthwhile to 
assess the effects of both the chitosan and L-leucine, individually and 
combined, on the Calu 3 cells using the LDH assay (Cheung et al., 2015; 
Patrulea et al., 2015).  
3.3.5. Conclusion 
The aim of this study was to develop NCMPs for the dry powder delivery of 
resveratrol PGA-co-PDL NPs to the lung. The PGA-co-PDL NPs synthesised 
in chapter 2 were able to be incorporated into NCMPs using L-leucine and 
chitosan as excipients. The highest yield of the resveratrol-loaded NCMPs was 
the NCMP-5% RNP at 56.5 ± 10.4 %. The recovered NPs from the NCMPs 
showed an increase in size with a change from negative to positive, due to 
chitosan. The NCMPs improved on the release rate by enabling a slow release 
profile over a 24-hour period.  
In chapter 2, the resveratrol-loaded PGA-co-PDL NPs showed a 
concentration- and time-dependent cytotoxic effect on Calu 3 cells and 
reduced the IC50 of resveratrol by 78%, however, further studies are required 
to assess whether this effect is reproducible within a dry powder required for 
pulmonary delivery.
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4 CHAPTER 4: The functionalisation of PGA-co-PDL using a 
modified glycerol 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
156 
 
4.1. Introduction  
Polymeric nanoparticles (NPs) allow for the encapsulation of drugs inside a 
protective polymeric matrix. NPs have been shown to be a suitable delivery 
system for several drugs against various cancers including colon, liver, lung 
and prostate (Karthikeyan et al., 2013; Jung et al., 2015; J. Wu et al., 2017; 
Nassir et al., 2018). In Chapter 2, the ability of resveratrol loaded PGA-co-PDL 
NPs to cause a concentration- and time-dependent decrease in Calu 3 cell 
viability was demonstrated. The resveratrol loaded PGA-co-PDL NPs showed 
a decrease in the IC50 of the resveratrol by 78%. These studies illustrate the 
potential of polymeric NPs as a resveratrol delivery system, but there was no 
elucidation of the mechanism of uptake of the NPs into cancer cells. The 
mechanism of uptake of NPs by cells is a core determinant of the NPs 
biodistribution and toxicity (Foroozandeh and Aziz, 2018). Polar or charged 
species, such as NPs, cannot passively traverse the cell membrane, but rather 
have to make use of endocytosis.  
Endocytosis is an energy-dependent process used for internalising ions and 
biomolecules by cells (Iversen, Skotland and Sandvig, 2011). There are two 
major categories of endocytosis, namely, phagocytosis and pinocytosis 
(Sahay, Alakhova and Kabanov, 2010). Phagocytosis involves the 
internalisation of debris, bacteria or other solutes larger than 0.5 µm by 
specialised phagocytes, such as dendritic cells, macrophages, and neutrophils 
(Zhao and Stenzel, 2018). Pinocytosis has four subclassifications, namely, 
clathrin-mediated endocytosis, caveolae-mediated endo- cytosis, clathrin- and 
caveolae-independent endocytosis and micropinocytosis (Foroozandeh and 
Aziz, 2018). Micropinocytosis involves the non-specific uptake of fluids and 
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particles together into the cell (Oh and Park, 2014). Clathrin- and caveolae-
mediated endocytosis involves the use of receptors and clathrin- and 
caveolae-independent endocytosis involves cells lacking both clathrin- and 
caveolae (Oh and Park, 2014). The nanoparticle (NP) properties seem to 
determine the type of endocytosis employed. Clathrin-mediated endocytosis 
were shown to be the pathway for internalisation of polymer based NPs 
(Foroozandeh and Aziz, 2018). Clathrin-mediated endocytosis seems to be 
preferred when NPs are < 200 nm, and for particles > 200 nm caveolae-
mediated endocytosis came into effect (Rejman et al., 2004; Prabha et al., 
2016). Apart from size, there are several other factors that impact NP uptake 
by cells, including shape, surface charge, hydrophobicity, and surface 
functionality (Behzadi et al., 2017). Visualisation of the cellular uptake using, 
for example, confocal microscopy requires a fluorescent delivery system or 
drug (Kenesei et al., 2016). However, if the delivery system or drug does not 
possess intrinsic fluorescence, a fluorescent agent has to be added. 
Fluorescent molecules may be encapsulated within the delivery system, but in 
order to accurately assess the uptake of the particle, the fluorescent ligand 
needs to be chemically conjugated to either the parent polymer or the surface 
of the NP (Peng and Chiu, 2015; Kenesei et al., 2016; Chatterjee et al., 2017).  
The main objective of nanomedicines is to enhance the treatment efficacy and 
using targeted NPs goes a long way in realising this objective. Targeted drug 
delivery systems aim to enhance efficacy through the accumulation of the drug 
at the specific site of interest, thereby decreasing toxicity throughout the rest 
of the body (Cheng et al., 2015). There are two types of targeting, passive and 
active. Passive targeting involves exploitation of certain characteristics of 
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tumours. For example, the blood vessels of many solid tumours possess 
characteristics that are unique and not usually observed in healthy tissue, such 
as, extensive angiogenesis leading to increased blood supply, increased 
vascular permeability due to vascular mediators and defective vascular 
architecture, and reduced lymphatic drainage from the interstitial spaces of 
tumour tissues (Maeda, 2001). These characteristics are known as the 
Enhanced Permeability and Retention (EPR) effect. Active targeting involves, 
for example, the incorporation of a ligand onto the surface of NPs that 
specifically binds to a particular target site such as, peritumoural and 
intratumoural blood vessels, the extracellular matrix, tumour cells or 
intracellular targets (Wilhelm et al., 2016). Ligands that can be used to target 
cancer cells include antibodies, aptamers, nucleic acids, peptides, sugars, and 
other small molecules (Bertrand et al., 2014; Bazak et al., 2015).  
The attachment of moieties onto the polymer backbone or NP surface requires 
the presence of functional groups within the polymer. The polymerisation of 
poly(lactic-co-glycolic) acid (PLGA), from lactic and glycolic acid, results in the 
formation of one hydroxyl end group (Martins et al., 2018). Hydrolytic 
degradation of the PLGA in an aqueous environment yields PLGA with one 
hydroxyl and one carboxylic acid end group, which may be functionalised 
(Souza, Dorati and Deluca, 2014; Kapoor et al., 2015). A monoclonal antibody 
(mAb) targeting membrane proteins of MCF-7 cells was covalently attached to 
the free carboxylic end group of the PLGA NPs, using 1-ethyl-3-(3-
dimethylaminopropyl)-carbodiimide (EDC) (Kocbek et al., 2007). EDC 
facilitates conjugations of molecules containing a primary amine and a 
carboxylic group (Kocbek et al., 2007). MCF-10A neoT cells, which like MCF-
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7, originate from human breast epithelial cells, were co-cultured with Caco-2 
human colon adenocarcinoma cells. The mAb-labelled PLGA NPs were 
localised exclusively to the MCF-10A neoT cells, while the uncoated PLGA 
NPs were found in both cell lines (Kocbek et al., 2007). Wang et al, exploited 
the affinity of wheat germ agglutinin (WGA) to recognise and rapidly bind to N-
acetylglucosamine and sialic acid residues expressed on colon cells, leading 
to internalisation (Wang, Ho and Lim, 2010). The free carboxyl end group on 
PLGA NPs were used to covalently conjugate fluorescently-labelled WGA 
(fWNPs) and fluorescently-labelled bovine serum albumin (fBNPs) (Wang, Ho 
and Lim, 2010). The fWNPs and fBNPs were assessed for uptake against two 
human colon cancer cells lines (Caco-2 and HT-29) and one human colon 
fibroblast (CCD-18Co). The fWNPs showed a 12-fold higher uptake in Caco-
2 cells compared to fBNPs (Wang, Ho and Lim, 2010). Moreover, the fWNPs 
showed a selective affinity for the cancer cell lines, Caco-2 and HT-29, over 
the normal cell line, CCD-18Co (Wang, Ho and Lim, 2010). Similar 
functionality can be achieved in polymers containing glycerol, due to the free 
secondary hydroxyl group present on glycerol (You et al., 2010; Zhang and 
Grinstaff, 2014).  
Chemical moieties can be attached to a functionalised polymer backbone or 
end group using click chemistry. Click chemistry refers to a group of chemical 
reactions that meet strict conditions including being, “ modular, wide in scope, 
give very high yields, generate only inoffensive by-products that can be 
removed by nonchromatographic methods, and be stereospecific“ (Kolb, Finn 
and Sharpless, 2001). Click chemistry reactions include, cycloaddition 
reactions, nucleophilic ring-opening reactions, non-aldol type carbonyl 
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chemistry, and carbon-carbon additions (Kolb and Sharpless, 2003). In 
biomedical research, click chemistry has been employed in lead discovery, 
optimisation, as well as tagging of proteins, nucleotides, and whole organisms 
(Kolb and Sharpless, 2003). One of the cycloaddition reactions, metal 
catalysed azide/alkyne ‘click’ reaction (also termed copper-catalysed azide–
alkyne cycloaddition (CuAAC)), has shown wide application in the field of 
polymer science (Binder and Sachsenhofer, 2008; Binder, 2019). The CuAAC 
reaction has a high efficiency, high tolerance of functional groups, and solvent 
insensitivity (Binder and Sachsenhofer, 2007). This reaction was used to label 
intact Cowpea mosaic virus particles with fluorescein (Wang et al., 2003). 
Similarly, click chemistry also offers a quick and simplistic way to modify the 
surfaces of nanocarriers with fluorescent tags or targeting ligands (Voigt et al., 
2019). Surface modification can be implemented pre-, intra-, or post-
preparation (Voigt et al., 2019). A tetrazine fluorophore was clicked onto 
polyethylene glycol (PEG) and hyperbranched polyglycerol (hbPG)-modified 
liposomes via CuAAC reaction to determine the intra- and extracellular fate of 
the liposomes (Voigt et al., 2019). Poly(styrene‐co‐maleic anhydride) (PSMA) 
was used to functionalise semiconducting polymer dots (Pdots) made from a 
highly fluorescent semiconducting polymer poly[(9,9‐dioctylfluorenyl‐2,7‐diyl)‐
co‐(1,4‐benzo‐{2,1’,3}‐thiadiazole)] (PFBT) (Wu et al., 2010). The resulting 
carboxyl‐functionalised Pdots were reacted with amine–azido via the standard 
carboxyl–amine coupling catalysed by EDC (Wu et al., 2010). The azide-
functionalised Pdots were then able to click onto alkyne‐functionalised silica 
nanoparticles via CuAAC to convert the optically inert silica particles into highly 
fluorescent probes (Wu et al., 2010). An alkyne-functionalised homopolymer 
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of D,L-lactide (hexyn-pDLLA) was synthesised via ring opening polymerisation 
and coupled with azide-NIR10 via CuAAC reaction to obtain the fluorescent-
labelled polymer (Rahimian et al., 2015). The fluorescent-labelled polymers 
were formulated into ovalbumin-loaded polymeric NPs using double emulsion-
solvent evaporation method and assessed for cellular uptake in Albino BL/6 
mice using fluorescence spectroscopy (Rahimian et al., 2015).  
In this chapter, glycerol will be modified to possess a pendant alkyne group 
and enzymatically polymerised with divinyl adipate (DVA) and ω-
pentadecalactone (PDL) to produce an alkynal functionalised PGA-co-PDL. 
Subsequently, click chemistry will be used to attach a fluorescent azide to the 
modified PGA-co-PDL.  
4.2. Aims and Objectives  
The aim of this study was to design and synthesise functionalised PGA-co-
PDL to enable the attachment of fluorescent ligands for the fluorescent 
detection of NPs within cells.  
The main objectives were to: 
a. Evaluate the feasibility for using click chemistry for polymer modification.  
b. Synthesise a modified glycerol containing an alkyne group.  
c. Polymerisation of alkyne-glycerol containing PGA-co-PDL. 
d. Attach a fluorescent azide to the polymer backbone alkyne groups.  
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4.3. Materials and Methods 
4.3.1. Materials 
Polymer synthesis: Same as in chapter 2. 
Synthesis of modified glycerol (2-(prop-2-yn-1-yloxy)propane-1,3-diol): 
Benzaldehyde, n-hexane, and p-toluenesulfonic acid monohydrate (PTSA) 
were bought from Acros Organics (Fisher Scientific, UK.). Glycerol, 2-Phenyl-
1,3-dioxan-5-ol, N,N-Diisopropylethylamine (DIPEA), Glacial acetic acid 
(AcOH) and sodium hydride (NaH) were purchased from Sigma-Aldrich. 
Diethyl ether (HPLC grade) and Toluene (HPLC grade) were purchased from 
Fisher Scientific, UK. Propargyl bromide was obtained from Alfa Aesar 
(Thermo Fisher Scientific, UK). All chemicals were used as received unless 
otherwise indicated. 
Instruments: FT-IR spectra were obtained using Agilent Technologies 
MicroLab FTIR software running on an Agilent Technologies Cary 630 FTIR 
Spectrometer-IR spectrometer (Agilent, USA). The spectra were collected 
from 650-4000 cm-1 at a resolution of 4 cm-1. NMR analyses were performed 
using either a Bruker 300 MHz (operating at 300.18 MHz for 1H and 75.48 MHz 
for 13C) or a Bruker 600 MHz (operating at 600.31 MHz for 1H, 150.95 MHz for 
13C) NMR spectrometers. Coupling constants (J) are reported in Hertz (Hz) 
and significant multiplicities are described by singlet (s), doublet (d), triplet (t), 
quartet (q), doublet of doublets (dd), or multiplet (m). Mass spectra were 
acquired on a Water’s LCT Micromass LCT mass spectrometer equipped with 
an electrospray ionisation (ESI) source and time of flight (ToF) detector 
(Water’s, US). Analyses were carried out on sample solutions in methanol (1 
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ppb). GPC analysis was performed as in chapter 2, section 2.3.2.2.1. 
Molecular weights of polymers were ascertained from a standard curve (R2= 
0.9891).  
4.3.2. Methods 
4.3.2.1. Synthesis of glycerol (2-(prop-2-yn-1-yloxy)propane-1,3-diol) 
4.3.2.1.1. Stage 1: synthesis of 2-phenyl-[1,3]-dioxan-5-ol  
A 500 mL round bottom flask was charged with benzaldehyde (9 g, 84.81 
mmol), glycerol (9 g, 97.73 mmol), PTSA (60 mg, 3.15 mmol), and toluene 
(300 mL). This flask was placed onto a heating mantle on a hot plate stirrer at 
125 °C equipped with a Dean-Stark apparatus for the removal of water 
produced during the reaction. This reaction was allowed to run to completion 
(i.e., when no water was collected in the Dean-Stark). (Scheme 4-1A). The 
resulting product (2-phenyl-[1,3]-dioxan-5-ol) was purified using column 
chromatography (n-hexane:diethyl ether 3:7) and then analysed using NMR.  
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Scheme 4-1 Synthesis of (A) 2-phenyl-[1,3]-dioxan-5-ol and (B) 2-
phenyl-5-(prop-2-yn-1-yloxy)-1,3-dioxane 
 
4.3.2.1.2. Stage 2: synthesis of 2-phenyl-5-(prop-2-yn-1-yloxy)-1,3-dioxane 
 A 250 mL round bottom flask was charged with 60% w/w sodium hydride in 
mineral oil (0.18 g, 4.44 mmol) and anhydrous THF (40 mL) and stirred 
vigorously at 0 °C under nitrogen. 2-phenyl-[1,3]dioxan-5-ol (0.40 g, 2.22 
mmol) was added to this mixture and allowed to react for 30 minutes (Scheme 
4-1B). Then an 80% w/w solution of propargyl bromide in toluene (0.42 mL, 
4.44 mmol) was added dropwise and the progress of the reaction was 
monitored by thin layer chromatography (TLC; n-hexane:diethyl ether 1:1). 
After 24 hours, the suspension was then filtered using Buchner filtration with 
one layer of filter paper (Whatman GF/A). The filtrate was then transferred to 
a 100 mL round-bottom flask with DCM (30 mL) and the solution was 
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concentrated via rotary evaporation at 40 °C @ 120 rpm (Laborota 4000, 
Heidolph Instruments attached to a Divac pump). The concentrated product 
was dissolved in n-hexane (3 mL) and the solution was warmed in a water 
bath (70 °C). Diethyl ether was added dropwise until the product was 
completely dissolved. The solution was allowed to cool inside the fume 
cupboard and the crystals formed as the solution underwent cooling. The 
desired product was obtained as a white crystalline solid, which was washed 
with cold n-hexane.  
4.3.2.1.3. Stage 3: synthesis of 2-(prop-2-yn-1-yloxy)propane-1,3-diol 
A 50 mL round bottom flask was charged with 2-phenyl-5-(prop-2-yn-1-yloxy)-
1,3-dioxane (0.46 g, 2.06 mmol), methanol (10 mL) and 1 M aqueous 
hydrochloric acid (10 mL) and stirred vigorously (500 rpm) while being allowed 
to react at room temperature for 2 hours. Then 1 M aqueous sodium hydroxide 
was added dropwise until the reaction mixture resulted neutral to litmus paper. 
(Scheme 4-2). The resulting solution was extracted with n-hexane in a 
separating funnel. The organic layer was concentrated via rotary evaporation 
at 40 °C @ 120 rpm. The solid residue was taken in chloroform and the 
resulting suspension was filtered through cotton wool to remove the excess 
sodium chloride salt. The solvent was evaporated at reduced pressure and the 
resulting solid was used without further purification.  
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Scheme 4-2 Synthesis of 2-(prop-2-yn-1-yloxy)propane-1,3-diol 
 
4.3.2.2. Synthesis of NBD azide  
4-Azido-7-nitro-2,1,3-benzoxadiazole (NBD-azide) was obtained according to 
the method described by Lord et al. (Scheme 4-3) (Lord et al., 2010).  
A 50 mL round bottom flask containing a stirring bar was charged with NBD 
chloride (1.50 g, 7.52 mmol), sodium azide (0.54 g, 8.30 mmol), and ethanol 
(15 mL). The mixture was left stirring at 35° C for 6 hours. After 6 hours, the 
solution was poured into ice water, forming a precipitate. The precipitate was 
167 
 
filtered using Buchner filtration and washed with distilled water. The resulting 
product and starting materials were analysed via NMR and FT-IR.  
 
Scheme 4-3 Synthesis of 4-Azido-7-nitro-2,1,3-benzoxadiazole 
(NBD-azide)  
 
4.3.2.3. Polymer synthesis 
To determine if 2-(prop-2-yn-1-yloxy)propane-1,3-diol could be incorporated 
into the PGA-co-PDL polymer, a series of PGA-co-PDL polymers were 
synthesised at 1.25 mmol scale using various ratios of 2-(prop-2-yn-1-
yloxy)propane-1,3-diol and glycerol (Table 4-1). For convenience, PGA-co-
PDL synthesised with 2-(prop-2-yn-1-yloxy)propane-1,3-diol and glycerol will 
be called alkyne-PGA-co-PDL.  
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Table 4-1 Ratios of glycerol or 2-(prop-2-yn-1-yloxy)propane-1,3-
diol integrated into various polymers 
 ratio 
1.25 mmol Polymer 
2-(prop-2-yn-1-yloxy)propane-
1,3-diol 
Glycerol 
PGA-co-PDL 0 100 
Alkyne-PGA-co-PDL 100 0 
50% alkyne-PGA-co-PDL 50 50 
10% alkyne-PGA-co-PDL  10 90 
 
4.3.2.3.1. PGA-co-PDL  
The 1.25 mmol scale PGA-co-PDL polymer was synthesised as previously 
described (Chapter 2, section 2.3.2.1.) but on a 1.25 mmol scale using PDL 
(1.25 mmol; 0.30 g), DVA (1.25 mmol; 0.247), glycerol (1.25 µmol; 0.115 g) 
THF (15 mL) and lipase acrylic resin enzyme (0.85 mg; Sigma Aldrich, UK) 
was added to the mixture.  
4.3.2.3.2. Alkyne-PGA-co-PDL  
The Alkyne-PGA-co-PDL polymer was synthesised as above but replacing the 
glycerol with 2-(prop-2-yn-1-yloxy)propane-1,3-diol (1.25 µmol; 0.16 g) 
(Scheme 4-4).  
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Scheme 4-4 Synthesis of alkyne-PGA-co-PDL 
 
4.3.2.3.3. 50 % alkyne-PGA-co-PDL 
The 50% alkyne-PGA-co-PDL polymer was synthesised as in 4.3.2.3.1., but 
with both the glycerol (0.625 µmol; 0.058 g) and 2-(prop-2-yn-1-yloxy)propane-
1,3-diol (0.625 µmol; 0.081 g).  
4.3.2.3.4. 10 % alkyne-PGA-co-PDL 
The 10% alkyne-PGA-co-PDL polymer was synthesised as in 4.3.2.3.1., but 
with both the glycerol (1.125 µmol; 0.104 g) and 2-(prop-2-yn-1-yloxy)propane-
1,3-diol (0.125 µmol; 0.016 g).  
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4.3.2.4. Metal catalysed azide-alkyne ‘click’ reaction  
4.3.2.4.1. NBD azide reacted with 10 % alkyne-PGA-co-PDL 
The ‘click’ reaction between sodium azide and 10 % alkyne-PGA-co-PDL was 
carried out according to the procedure described by Shao et al., with some 
modifications (Scheme 4-5) (Shao et al., 2011). 
A 50 mL round bottom flask containing a stirring bar was charged with copper 
iodide (3.80 mg, 0.02 mmol), DIPEA (6.97 mL, 0.04 mmol), and AcOH (2.29 
mL, 0.04 mmol) in DCM (2 mL). Then, the 10% alkyne-PGA-co-PDL (2.56 mg, 
1.00 mmol) and NBD azide (0.22 mg, 1.05 mmol) were added to the mixture 
at room temperature. The resulting mixture was allowed to react for 13 
minutes. Then, the reaction mixture was first washed with 1% aqueous 
hydrochloric acid and then with deionised H2O. The organic phase was dried 
using magnesium sulphate. The resulting product was then dissolved in DCM 
(2 mL) and placed in a Falcon 15 mL conical centrifuge tube (Fisher Scientific, 
UK) together with methanol (12 mL) to help with precipitation of the polymer. 
The solution was centrifuged using a Hermle Z400 centrifuge (Hermle 
LaborTechnik, Germany) at 5000 rpm for 10 minutes. The resulting NPs were 
dispersed in DCM (2 mL) and methanol added to a fresh Falcon 15 mL conical 
centrifuge tube and the centrifugation repeated. The resulting NPs were 
dispersed and centrifuged a third time. The resulting NPs after 3 washes were 
analysed via NMR and FT-IR.  
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Scheme 4-5 CuAAC reaction of NBD azide with 10 % alkyne-PGA-
co-PDL  
 
4.3.2.4.2. NBD azide reacted with 2-phenyl-5-(prop-2-yn-1-yloxy)-1,3-dioxane 
The microwave ‘click’ reaction between NBD azide and 2-phenyl-5-(prop-2-
yn-1-yloxy)-1,3-dioxane was adopted from the literature (Scheme 4-6) (Trujillo 
et al., 2019).  
A 35 mL microwave vessel containing a stirring bar was charged with NBD 
azide (0.043 g, 0.21 mmol), 1:1 t-butyl alcohol/water (2 mL), 2-phenyl-5-(prop-
2-yn-1-yloxy)-1,3-dioxane (0.046 g, 0.21 mmol), 1 M copper sulphate 
pentahydrate (10 µL), and sodium ascorbate (2.5 mg) were added. The vessel 
was capped and heated in the CEM Discover SP microwave instrument (CEM, 
UK). The vessel was heated to 80 °C and held at that temperature for 10 
minutes. The vessel was vented and cooled to about 50 °C. The cap was 
removed from the vessel and it was further cooled by the addition of ice water 
(2 mL). Then, 10% aqueous ammonia (5 mL) was added to the vessel and it 
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was stirred for 5 minutes. The reaction mixture was washed with a solution of 
ethyl acetate (3 × 10 mL). The organic phase was dried using magnesium 
sulphate and the solvent was evaporated under reduced pressure. The 
resulting product was analysed via NMR and FT-IR.  
 
Scheme 4-6 CuAAC reaction of NBD azide with 2-phenyl-5-(prop-
2-yn-1-yloxy)-1,3-dioxane 
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4.3.3. Results  
4.3.3.1. Synthesis of modified glycerol 
4.3.3.1.1. Stage 1: synthesis of 2-phenyl-[1,3]-dioxan-5-ol  
The synthesis of 2-phenyl-[1,3]-dioxan-5-ol (4) resulted in the formation  of a 
fluffy white powder. The mass of 2-phenyl-[1,3]dioxan-5-ol obtained was 3.089 
g (20 % yield). ESI-MS, calculated for C10H12O3 - m/z 180.2, found - m/z 203.1 
(M + Na+). FT-IR v max: 3267.0, 3091.8, 3065.7, 2970.6, 2864.4, 1494.6, 
1451.7, 1384.7, 1077.2 cm-1. 1H NMR (300 MHz, CDCl3) δ 7.53 – 7.47 (m, 2H, 
H-e,i), 7.42 – 7.35 (m, 3H, H-f,g,h), 5.56 (s, 1H, H-b), 4.23 – 4.09 (m, 4H, H-
a,a’), 3.64 (d, 1H, H-c), 3.03 (d, 1H, H-d) (Figure 4-1). 13C NMR (75 MHz, 
CDCl3) δ 137.9, 129.1, 128.3, 125.9, 101.7, 72.3, 64.0.  
 
 
 
 
 
 
 
Figure 4-1 Structure of 2-phenyl-[1,3]-dioxan-5-ol with protons 
labelled for NMR 
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4.3.3.1.2. Stage 2: synthesis of 2-phenyl-5-(prop-2-yn-1-yloxy)-1,3-dioxane 
The synthesis of 2-phenyl-5-(prop-2-yn-1-yloxy)-1,3-dioxane (7) resulted in a 
similar white powder as 2-phenyl-[1,3]-dioxan-5-ol. Yield from the production 
of 2-phenyl-5-(prop-2-yn-1-yloxy)-1,3-dioxane was found to be 0.363 g (75 %). 
ESI-MS, calculated for C10H14O3 - m/z 218.25, found - m/z 241.1 (M + Na+). 
FT-IR v max: 3293.1, 3035.9, 2976.2, 2952.0, 2918.5, 2853.2, 2113.4, 1384.7, 
1343.7, 1321.3, 1282.2 cm-1. 1H NMR (600 MHz, CDCl3) δ 7.50 (dd, 2H, H-
e,i), 7.37 – 7.30 (m, 3H, H-f,g,h), 5.56 (s, 1H, H-b), 4.36 (dd, 4H, a,a’), 4.08 
(dd, 2H, H-j), 3.64 (p, 1H, H-c), 2.43 (t, 1H, H-k) (Figure 4-2). 13C NMR (75 
MHz, CDCl3) δ 138.0, 128.9, 128.2, 126.1, 101.4, 79.4, 74.9 68.8, 68.7, 55.6.  
 
 
 
 
 
 
 
 
 
 
Figure 4-2 Structure of 2-phenyl-5-(prop-2-yn-1-yloxy)-1,3-
dioxane with protons labelled for NMR 
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4.3.3.1.3. Stage 3: synthesis of 2-(prop-2-yn-1-yloxy)propane-1,3-diol 
The synthesis of 2-(prop-2-yn-1-yloxy)propane-1,3-diol (8) produced a viscous 
liquid similar in colour to glycerol. Yield from the production of 2-(prop-2-yn-1-
yloxy)propane-1,3-diol was found to be 0.176 g instead of the theoretical 0.268 
g. The reaction thus gave a yield of 66 %. ESI-MS, calculated for C6H10O3 - 
m/z 130.14, found - m/z 153.08 (M + Na+). FT-IR v max: 3360.1, 3281.9, 
2922.2, 2115.2, 1636.3, 1446.2, 1397.7, 1345.5, 1099.5 cm-1. 1H NMR (300 
MHz, CDCl3) δ 4.24 (d, 2H, H-j), 3.86 (s, 2H, H-l,m), 3.73 – 3.54 (m, 5H, H-
a,a’,c), 2.52 (t, 1H, H-k) (Figure 4-3). 13C NMR (75 MHz, CDCl3) δ 79.9, 79.3, 
74.9, 61.9, 57.3. 
 
 
 
 
 
 
Figure 4-3 Structure of 2-(prop-2-yn-1-yloxy)propane-1,3-diol with 
protons labelled for NMR 
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4.3.3.2. Synthesis of NBD azide  
The synthesis of NBD azide (11) resulted in the formation a yellow powder. 
Yield from the production of NBD azide was 1.36 g instead of the theoretical 
1.54 g. The reaction thus gave a yield of 88 %. FT-IR v max: 2111.5 cm-1 (N3). 
1H NMR (300 MHz, CDCl3) δ 8.51 (d, J = 6.1 Hz, 1H), 7.09 (d, 1H) 13C NMR 
(75 MHz, CDCl3) δ 143.6, 138.1, 132.1, 114.9. 
4.3.3.3. Polymer synthesis  
4.3.3.3.1. PGA-co-PDL 
The PGA-co-PDL synthesis resulted in a white, flaky powder, that was too low 
in yield to quantify, monomer composition calculated (1:1:1). Mw: 2.2 KDa. FT-
IR v max: 3432.9, 2915.3,2847.8, 1729.5, 1463.2, 1463.2, 1365.9, 1160.8, 
1040.0, 719.9 cm-1. 1H NMR (300 MHz, CDCl3) δ 44.25 – 3.98 (m, 4H, H-a,c), 
3.77 – 3.54 (m, 1H, H-i), 2.45 – 2.21 (m,5H, H-d,d',i), 1.77 – 1.52 (m, 7H, H- 
e,e',h), 1.27 (d, 22H, H-g) (Figure 4-4). 
 
Figure 4-4 Structure of 1.25 mmol PGA-co-PDL with protons 
labelled for NMR 
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4.3.3.3.2. alkyne-PGA-co-PDL  
The alkyne-PGA-co-PDL synthesis resulted in a viscous liquid that did not 
solidify upon drying, monomer composition calculated (1:1:1). Mw: 2.5 KDa. 
FT-IR v max: 3267.0, 2915.3,2847.8, 1729.5, 1463.2, 1463.2, 1365.9, 1160.8, 
1040.0, 719.9 cm-1. 1H NMR (300 MHz, CDCl3) δ 4.34 – 3.92 (m, 7H), 2.54 – 
2.26 (m, 7H), 1.77 – 1.54 (m, 8H), 1.32 (s, 26H) (Figure 4-5). 
 
 
Figure 4-5 Structure of 1.25 mmol alkyne-PGA-co-PDL with 
protons labelled for NMR 
 
4.3.3.3.3. 50 % alkyne-PGA-co-PDL  
The 50% alkyne-PGA-co-PDL synthesis resulted in a white crystallised 
powder, but too low to quantify, monomer composition calculated (1:1:1). FT-
IR v max: 3425.4, 3265.2, 2916.6, 2849.6, 2115.3, 1729.5, 1462.9, 1416.4, 
1395.9, 1366.1, 1334.4, 1162.9, 1047.4, 721.2 cm-1. 1H NMR (300 MHz, 
CDCl3) δ 4.39 – 3.95 (m, 8H), 3.88 – 3.56 (m, 2H), 2.43 – 2.24 (m, 8H), 1.74 
– 1.54 (m, 8H), 1.27 (d, J = 5.5 Hz, 22H). 
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4.3.3.3.4. 10 % alkyne-PGA-co-PDL  
The 10% alkyne-PGA-co-PDL synthesis resulted in a white crystallised 
powder, but too low to quantify, monomer composition calculated (1:1:1). FT-
IR v max: 3393.7, 2916.6, 2849.6, 1729.5, 1462.9, 1194.6, 721.3. 1H NMR 
(300 MHz, CDCl3) δ 4.34 – 3.98 (m), 3.80 – 3.55 (m), 2.45 – 2.22 (m), 1.76 – 
1.51 (m), 1.45 – 1.16 (m). 
 
4.3.4. Discussion 
The aim of this study was to functionalise PGA-co-PDL with a fluorescent 
ligand, in order to visual the uptake of the NPs synthesised from the polymer. 
Ligands can either be attached to the polymer surface before NP formation or 
afterwards onto the surface of the nanoparticle (Nicolas et al., 2013) The 
enzyme, Lipase B, that is used for the polymerisation of glycerol is 
regiospecific to primary hydroxyl groups and hence, PGA-co-PDL contains a 
free secondary hydroxyl group, which can be exploited to facilitate functionality 
(You et al., 2010; Jan et al., 2013). 
Thompson et al, conjugated the free carboxyl group of ibuprofen to the free 
hydroxyl group of PGA-co-PDL (Thompson et al., 2008). The microparticles 
synthesised from the ibuprofen-conjugated PGA-co-PDL showed a reduced 
burst release and slower release rate compared to microspheres containing 
unconjugated ibuprofen (Thompson et al., 2009). One drawback was storage 
in a humid environment resulted in the hydrolysis of the ester linkages of the 
conjugated material, leading to an increase in burst release (Thompson et al., 
2009). Click chemistry offers a modular approach allowing for stable binding 
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with various moieties (Hein, Liu and Wang, 2008; Juríček et al., 2009). A 
polymer or nanoparticle presenting an azide or alkyne on the surface will be 
able to undergo copper-catalysed azide–alkyne cycloaddition (CuAAC) 
reaction with various ligands (Binder, 2019; Voigt et al., 2019). Glycerol has 
been shown to possess diverse chemistry allowing for azide functionalisation 
(Zhang and Grinstaff, 2014; Gładysz, Ruszkowski and Milecki, 2018) 
The azide functionalisation of glycerol was achieved in a three-step process 
(Scheme 4-1 and Scheme 4-2). Protection of both primary hydroxyl groups 
was achieved by reaction with benzaldehyde and production of cyclic acetal 
(Vrbková, Dračínský and Holý, 2007). As in previous studies, both the 5 and 
6-membered ring products were generated, but compound 4 was isolated 
using column chromatography (Scheme 4-1) (Wang, Hawley and DeAthos, 
2003; Gładysz, Ruszkowski and Milecki, 2018). The FT-IR spectrum of 
compound 4 showed an O-H trough between 3400-3200 cm-1 due to the 
presence of the terminal alcohol. It also showed a C-H stretches for the bonds 
in the benzene ring (3075-3030 cm-1) and the C-H bonds located in the 
cyclohexane attached to the aromatics (2985-2860 cm-1). There was also 
evidence of C-C stretching in the ring (1400-1500 cm-1). The low yield (20 %) 
was comparable to that reported previously (Gładysz, Ruszkowski and Milecki, 
2018). Due to the low yield obtained, 2-phenyl-[1,3]-dioxan-5-ol was 
purchased and used for all subsequent reactions.  
The following step saw the introduction of the alkyne group in the form of 
propargyl bromide reacted onto the unprotected hydroxyl group, resulting in 
compound 7 with a good yield of 75% (Scheme 4-1). This is slightly lower than 
previous reports of 82% yield (Cattiaux et al., 2018). However, it should be 
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noted that the work up for the 82% yield differed as it was purified via column 
chromatography and not crystallisation as employed in this study. The FT-IR 
spectrum of compound 7 showed the O-H trough between 3400-3200 cm-1 
notably absent. Instead there was the C-H stretch at 3295 cm-1 corresponding 
to the terminal alkyne. There was also another peak corresponding to the -C
≡C- stretch. The rest of the peaks C-H aromatic (3100- 3030 cm-1), C-H alkyl 
bonds (2990-2840 cm-1) and C-C stretching in the ring (1400-1500 cm-1) were 
all similar to the FT-IR spectrum of compound 4. 
The next step was to cleave the benzylidene acetal protective group, to allow 
further functionalisation of the hydroxyl group (Scheme 4-2). The two-step 
process for deprotection involved using hydrochloric acid and methanol to 
obtain the desired compound 9, consistent with literature (Gładysz, 
Ruszkowski and Milecki, 2018). The reaction gave a yield of 66%, which is 
similar to the yield of 67% reported in literature (Cattiaux et al., 2018). The FT-
IR of compound 8 showed the notable return of the O-H trough (3500-3322 
cm-1), but this time it corresponds with the two terminal OH bonds. There was 
also the alkyne-C-H stretch (3289 cm-1) attached to the O-H trough and a 
notable absence of the C-H peaks corresponding to the C-H bonds in the 
aromatic ring. This showed the removal of the aromatic ring. There was also 
the retainment of the C-H stretch (2950-2850 cm-1) corresponding to the C-H 
bonds located on the opened cyclohexane and the -C≡C- stretch (2113 cm-
1). 
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With product 8, it was now possible to attempt the polymerisation reaction to 
produce an alkyne-PGA-co-PDL (scheme 4-4). This is the first time this 
polymerisation reaction has been attempted with a modified version of 
glycerol. Firstly, because product 8 was in such low supply, the scale of the 
polymerisation reaction was reduced. The synthesis of PGA-co-PDL using 
DVA, PDL, and glycerol was done on a 1.25 mmol scale. The FT-IR and proton 
NMR results showed that the 1.25 mmol scale PGA-co-PDL produced was 
comparable to the 125 mmol scale PGA-co-PDL (Figure 4-6).  
 
 
Figure 4-6 FT-IR spectrum of (a) 1.25 mmol PGA-co-PDL and (b) 
125 mmol PGA-co-PDL and 1H-NMR of (c) 1.25 mmol PGA-co-
PDL and (d) 125 mmol PGA-co-PDL 
 
A series of 1.25 mmol scale alkyne-PGA-co-PDL were synthesised using DVA, 
PDL, and 100%, 50%, and 10% of compound 8 (Table 4-1). There was a 
noticeable difference between the FT-IR of the 1.25 mmol PGA-co-PDL 
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(Figure 4-6a) and 1.25 mmol alkyne-PGA-co-PDL (Figure 4-7a) with regards 
to the absence of the OH trough (absence of glycerol) and presence of a weak 
peak at 3267 cm-1 corresponding to the alkyne C-H stretch which suggests 
that the alkyne group is present instead of the glycerol as in the case of the 
normal PGA-co-PDL. There is a gradual re-emergence of the OH trough and 
disappearance of the alkyne C-H stretch as the concentration of glycerol 
increased in respect to compound 8 for the 100%, 50%, and 10% alkyne- 
PGA-co-PDL (Figure 4-7a-c). This is logical since there will be a gradual 
increase in the concentration of glycerol in the polymers.  
 
 
Figure 4-7 FT-IR of (a) alkyne-PGA-co-PDL, (b) 50 % alkyne-PGA-
co-PDL and (c) 10 % alkyne-PGA-co-PDL showing the gradual re-
emergence of the hydroxyl trough and (d) 1H-NMR of 10 % alkyne-
PGA-co-PDL 
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Compound 11, NBD azide, was produced by the reaction of compound 9 and 
10, with a yield of 88% (Scheme 4-4). This yield is slightly lower than the 94% 
reported in literature (Lord et al., 2010). Nitrobenzoxadiazole (NBD) 
fluorophores, such as NDB azide, have become useful as small molecule 
labels used in chemical biology and bioanalytical studies (Key and Cairo, 
2011). NDB azide can be photoactivated allowing the visualisation of particles 
conjugated to it (Tobimatsu et al., 2014). The good photostability and 
photoconversion efficiency of NBD azide facilitates long term fluorescence 
observation that may otherwise lead to photobleaching (Lord et al., 2010; 
Minoshima and Kikuchi, 2017). The FT-IR of NBD azide showed a distinctive 
peak at 2111.5 cm-1 (Figure 4-8a).  
 
Figure 4-8 (a) FT-IR and (b) 1H-NMR of NDB azide 
 
The NBD azide and the 10 % alkyne-PGA-co-PDL were reacted via a CuAAC 
reaction (Scheme 4-5). The reaction consists of a three-step catalytic cycle, 
namely the formation of Cu (I) acetylide, cycloaddition, and protonation of C-
Cu bond (Shao et al., 2011). The FT-IR of the reaction product did not have 
the characteristic peak at 2111.5 cm-1 associated with the NBD azide (Figure 
4-9a). This could be due to the low percentage (10%) of alkyne available to 
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bind with NBD azide, which could lead to a low signal to noise ratio for such a 
small molecule in a big polymer. However, the 1H-NMR did not show peaks at 
7.6 ppm and 8.2 ppm, associated with the binding of NBD azide (Figure 4-
9b). Together this suggests that the NBD azide did not successfully bind to the 
polymer. There is concern regarding conjugation onto high molecular weight 
polymers, due to reduced accessibility to reactive sites stemming from higher 
viscosity and potential folding of larger polymers (Pickens et al., 2018). 
Suggested solutions include, adding denaturing agents such as DMSO, 
diluting reaction mixtures, or raising temperature and increasing reaction times 
(Pickens et al., 2018). 
 
Figure 4-9 (a) FT-IR and (b) 1H-NMR spectra of the CuAAC 
reaction between NBD azide and 10 % alkyne-PGA-co-PDL 
 
It was then decided to attach the NDB azide to compound 7 using a microwave 
method CuAAC reaction (Scheme 4-6) (Trujillo et al., 2019). The NMR of the 
crude product was similar to the NMR of the original compound 7 which 
indicates that the reaction was not successful (Figure 4-10). The low 
concentrations of the reactants are most likely the cause of the reactions not 
working (Presolski, Hong and Finn, 2011). It would be beneficial to scale-up 
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the production of compound 7 in order to have a higher concentration with 
which to run the reaction.  
 
Figure 4-10 1H-NMR of (a) 2-phenyl-5-(prop-2-yn-1-yloxy)-1,3-
dioxane and (b) CuAAC reaction between 2-phenyl-5-(prop-2-yn-
1-yloxy)-1,3-dioxane and NBD azide 
 
4.3.5.  Conclusion 
In summary, the three-step reactions to modify glycerol to contain an alkyne 
moiety was successful. This was the first time 2-(prop-2-yn-1-yloxy)propane-
1,3-diol was used in the polymerisation of PGA-co-PDL. The polymerisation 
showed moderate success at integration of the modified glycerol (2-(prop-2-
yn-1-yloxy)propane-1,3-diol) into the polymer. The study was, therefore, able 
to meet the objectives of modifying glycerol to contain an alkyne group and 
then using it to synthesise a polymer containing the alkyne group. However, 
for the click chemistry to be successful, a higher concentration of reactants 
such as 2-phenyl-5-(prop-2-yn-1-yloxy)-1,3-dioxane is needed. Thus, future 
studies need to scale up the production of these reactants.
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5 CHAPTER 5: General discussion and future work 
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5.1. Overview 
Lung cancer has grown from an obscure disease in the 19th century to the 
deadliest cancer today (Witschi, 2001; Cancer Research UK, 2019). 
Chemotherapy is the current first line therapy for advanced stages of lung 
cancer, but has numerous limitations and side effects (Corrie, 2011; Rubio-
Gonzalez et al., 2018). Several nanocarrier delivery systems have been 
developed to improve drug delivery to cancer cells in order to help overcome 
the limitations of systemic chemotherapy (Arora and Jaglan, 2016; Vittorio et 
al., 2017). Nanocarriers, including polymeric nanoparticles (NPs) and 
microparticles (MPs), are currently being researched or on the market for 
cancer treatment (Luque-Michel et al., 2017; Abdelaziz et al., 2018). Phenolic 
compounds, such as resveratrol, caused apoptosis and decreased tumour 
growth in both in vitro and in vivo models; however, resveratrol suffers from 
bioavailability issues (Yin et al., 2013; Huminiecki and Horbańczuk, 2018; 
Santos et al., 2019). Nanocarriers can be utilised to encapsulate the 
resveratrol and help overcome the poor bioavailability (Davidov-Pardo and 
McClements, 2014; Singh and Pai, 2014). Pulmonary delivery for lung cancer 
permits non-invasive circumvention of first pass metabolism and local 
accumulation of the drug at the tumour site to reduce the potential of systemic 
toxicity (Youngren-Ortiz et al., 2017). The size of the NPs (< 1µm) renders 
them incapable of depositing directly into the lungs since they are exhaled 
without settling. A solution to this is to incorporate the NPs into nanocomposite 
microparticles (NCMPs) using spray drying. The aim of this project was to 
formulate and characterise NCMPs of resveratrol-loaded PGA-co-PDL NPs as 
a treatment for lung cancer by dry powder pulmonary delivery. 
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5.1.1. Formulation of polymeric nanoparticles  
Four different polymers were used to synthesise polymeric NPs. Poly(D,L-
lactide-co-glycolide) (PLGA) and Poly(ethylene glycol) methyl ether-block-
poly(lactide-co-glycolide) (mPEG-PLGA) were purchased from Sigma. Where-
as the poly(glycerol adipate-co-ω-pentadecalactone) (PGA-co-PDL) and 
Poly(ethylene glycol methyl ether)-PGA-co-PDL (PGA-co-PDL-PEG2000) were 
synthesised via ring opening polymerisation and polycondensation according 
to methods described in literature (Namekawa, Uyama and Kobayashi, 2000; 
Thompson et al., 2006).  
Polymeric NPs can be used as a versatile drug delivery system; however, their 
drug loading, in vivo distribution, and cell uptake are largely influenced by their 
size (Hickey et al., 2015; Huang and Zhang, 2018). Polymeric NPs between 
100-200 nm are desirable since these particles are ideal for uptake and 
evasion of the alveolar macrophages and they show rapid penetration through 
the respiratory mucus (Dabbagh et al., 2018; Wei et al., 2018). Variations in 
NP size could negatively influence their biodistribution, leading to loss of 
therapeutic efficacy. Thus, it is important to control the size of the NPs during 
the manufacturing process (Huang and Zhang, 2018; Wei et al., 2018).  
In this study, a modified water-in-oil-in water (w1/o/w2) double emulsion 
evaporation method was used. This method was previously optimised to 
produce PGA-co-PDL NPs of 200 nm (Kunda, Alfagih, Dennison, Tawfeek, et 
al., 2015). Although this method was optimised for PGA-co-PDL NPs, it was 
decided to use this method to formulate the other polymeric NPs as well. This 
was done to allow a more like-for-like comparison of particles. Therefore, it 
was surprising to discover that the PGA-co-PDL NPs were consistently > 205 
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nm, while the NPs of the other three polymers (PGA-co-PDL-PEG2000, PLGA, 
and PEG-PLGA) were all < 205 nm. Several parameters were shown to affect 
polymeric NPs made using the double emulsion solvent evaporation method, 
including molecular weight (MWt) of polymer, organic solvent volume, 
aqueous volume, internal aqueous concentration, sonication time, stirrer 
speed, and external aqueous concentration (Kunda, Alfagih, Dennison, 
Tawfeek, et al., 2015). The MWt of the polymer was ranked as the third most 
important factor controlling particle size, with an increased MWt corresponding 
to an increase in particle size (Kunda, Alfagih, Dennison, Tawfeek, et al., 
2015). In this current study, all the parameters were the same, except for the 
MWt of the polymers. Some studies agree that an increased MWt of the 
polymer results in increases in the size of the corresponding NPs. The size of 
PLGA NPs increased when the MWt of the PLGA polymers were increased 
from 14.5 kDa (90.9 ± 2.8 nm) to 213 kDa (143 ± 1.9 nm) (Mittal et al., 2007). 
However, other studies found opposite results. PLA polymers of 17.5 kDa, 50 
kDa, and 90 kDa corresponded with PLA NPs of 250 ± 13 nm, 227 ± 9 nm, 
and 205 ± 8 nm, respectively (Zambaux et al., 1999). Another study also found 
that low MWt (9.3 kDa) PLA produced bigger NPs than high MWt (150 kDa) 
PLA at 235 ± 58 nm and 111 ± 32 nm, respectively (Palacio, Orozco and 
López, 2011). Contrarily, MPs prepared using the double emulsion solvent 
evaporation method showed a direct relationship between polymer size and 
microparticle size (Bragagni et al., 2013). PLA polymers, 10-18 kDa, 18-28 
kDa, and 209 kDa synthesised microparticles of 32, 40, and 68 µm, 
respectively (Bragagni et al., 2013). These studies suggest that direct 
comparison between particle size and MWt can only be done between the 
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same polymers. Certainly, this is what was noticed in this current study. The 
polymers showed the following order with regard to MWt: mPEG-PLGA > 
PGA-co-PDL-PEG2000 > PGA-co-PDL > PLGA; while the NPs had this order 
of size: PGA-co-PDL > mPEG-PLGA > PLGA > PGA-co-PDL-PEG2000.  
Resveratrol, 5% and 10% (w/w), were encapsulated into NPs prepared from 
the four polymers. PGA-co-PDL has previously been studied for the delivery 
of proteins, vaccines and non-steroidal anti-inflammatory drugs, (Gaskell et 
al., 2008; Tawfeek, 2013; Kunda, Alfagih, Dennison, Tawfeek, et al., 2015; 
Tawfeek et al., 2017), but this was the first attempt at encapsulating resveratrol 
into PGA-co-PDL NPs for lung cancer therapy. The PGA-co-PDL not only 
produced NPs of the largest size, but also the highest encapsulation efficiency 
(EE%). The PGA-co-PDL 5% resveratrol-loaded NPs (5% RNP) and 10% 
resveratrol-loaded NPs (10% RNP) had an EE% of 78 ± 0.24% and 70 ± 
0.89%, respectively. The second highest EE% was PGA-co-PDL-PEG2000 
10% RNP at 40 ± 2.32%. The polydispersity index (PDI) values of the PGA-
co-PDL, PGA-co-PDL PEG2000, and PLGA polymeric NPs were less than 
0.14 with the PEG-PLGA NPs being less than 0.35, all indicating a very narrow 
size distribution (Danaei et al., 2018). The NPs from all the polymers presented 
a high zeta potential (-30 mV), which can contribute to physical stability, thus, 
preventing flocculation and aggregation of the NPs (Neves et al., 2016). 
As mentioned before, the double emulsion evaporation method used in this 
study was optimised with PGA-co-PDL. Thus, it is possible that improved NPs 
could have been obtained with the other polymers using different formulation 
parameters. In this study, the resveratrol was co-dissolved with the polymer in 
DCM (representing first water phase (w1)) where-as most studies dissolved 
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resveratrol into ethanol or acetone and used that mixture as w1 (Sanna et al., 
2015; Li et al., 2016). Dissolving the resveratrol in ethanol as w1, allowed Li et 
al. to produce PEG-PLGA NPs with an EE% of 68.2% compared to the EE% 
for PEG-PLGA NPs of 20 ± 0.48% found in this current study (Li et al., 2016). 
Ideally, one would want to optimised the formulation parameters for each 
polymer, but in this study a direct comparison between polymers wanted to be 
made, hence the use of the same parameters for all polymers. That said, the 
PGA-co-PDL blank NPs (BNP), 5% RNP and 10% RNP were taken forward to 
cytotoxicity studies.  
  
5.1.2. Cytotoxicity studies  
The efficacy of PGA-co-PDL NPs as a drug delivery system for resveratrol 
compared to free-resveratrol was assessed using the Alamar blue and LDH 
assays on Calu 3 cells.  
The Alamar blue assay showed that the PGA-co-PDL BNP possessed good 
cytocompatibility, with none of the tested concentrations (up to 1 mg/mL) 
reducing the cell viability to less than 85% after 24 hours. Comparable results 
were found on A549 cells with PGA-co-PDL BNP, 1.25 mg/mL, showing a cell 
viability of 70% according to the MTT assay (Kunda, 2014). The ANOVA and 
subsequent Tukey’s comparison revealed that there was no statistical 
difference between the cell viability of the BNP-treated and the untreated cells 
(negative control) (p>0.99). Thus, providing the concentration of PGA-co-PDL 
NPs is constant, all cytotoxic effects can be attributed to the encapsulated 
resveratrol. Furthermore, the Alamar blue assay showed that 5% RNP, 10% 
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RNP, and free-resveratrol had a concentration-dependent cytotoxic effect on 
the cell viability of the Calu 3 cells. The IC50 after 24 hours of treatment with 
the free-resveratrol was 213 ± 63 µM. Meanwhile, the IC50 values of the 5% 
RNP and 10% RNP after 24 hours were 47 ± 30 µM and 86 ± 38 µM, 
respectively. These results demonstrate that using PGA-co-PDL NPs as a 
delivery system reduced the IC50 of resveratrol on Calu 3 cells after 24 hours 
by up to 78%. This is a greater effect than reported by Karthikeyan et al, who 
reported that the IC50 of resveratrol in NCI-H460 cells after 24 hours decreased 
by 50% when loaded into gelatin NPs (Karthikeyan et al., 2013), although we 
recognise that the sensitivities of different cell types to the same toxic agent 
could be different. 
The LDH assay was used on the Calu 3 cells to give further credence to the 
results obtained using the Alamar blue assay. The resveratrol-loaded PGA-
co-PDL NPs were again tested against free-resveratrol at 24, 48 and 72 hours. 
Preliminary tests showed that there were no noticeable differences between 
the cytotoxicity profiles at 24 hours. However, the LDH results for 48 hours 
and 72 hours showed a concentration- and time-dependant increase in LDH 
release for the resveratrol-loaded PGA-co-PDL NPs and the free-resveratrol. 
The free-resveratrol did not show a significant difference from the control 
(p>0.05). Meanwhile, at 72 hours, the 300 µM 10% RNP caused a significant 
difference in LDH release compared to the control (p<0.001) and the 300 µM 
BNP (p<0.005). This suggests that the LDH release was due to the resveratrol 
encapsulated into the PGA-co-PDL NPs.  
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5.1.3. Spray drying of resveratrol-loaded nanoparticles into NCMPs 
The PGA-co-PDL NPs were spray-dried, using L-leucine and chitosan as 
excipients, to produce NCMP carriers suitable for pulmonary delivery via DPI. 
The NCMPs were produced with a yield ranging from 32-73%. The large 
variance in yield was attributed to the difficulty in the removal of the powder 
from the sides of the cyclone, due to some of the liquid droplets attaching to 
the inside wall of the drying chamber and cyclone of the spray dryer. This has 
been noted in other studies particularly when using chitosan as an excipient 
(Cevher et al., 2006; Almurshedi, 2018). Morphological studies showed that 
the particles possessed wrinkly/corrugated surfaces with noticeable 
cavities/indentations in the middle of the particles. Studies suggest that this is 
due to the hydrophobic nature of L-leucine preventing water from adsorbing 
onto the surface of the particle which produces the cavities upon drying 
(Merchant et al., 2014). Several other studies have noted these cavities, which 
aid in dispersibility of the particles, when using L-leucine (Kunda, Alfagih, 
Dennison, Somavarapu, et al., 2015). 
Aerosolisation studies using an NGI showed that the NCMPs had a MMAD 
between 3.1-4 µm, which is within the ideal range of 1-5 µm for particles to be 
able to deposit in the lung (El-Sherbiny and Smyth, 2012; Elsayed and 
AbouGhaly, 2016; Rezazadeh et al., 2018). The NCMPs had a high ED >98% 
and RF 70-74%, but a low FPF 39-47%, which showed that L-leucine may 
have enhanced the dispersibility, but together the excipients produced a low 
FPF, which may suggest aggregation of the particles. Almurshedi reported that 
as the chitosan:L-leucine ratio increases, the FPF decreases (Almurshedi, 
2018).  
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Once deposited into the lung, the NCMPs need to swell and/or disperse to 
release the enclosed NPs, in order for the cells to take-up the NPs (Tomoda 
et al., 2008). In this study, the size of the NPs released from the NCMPs, after 
dispersion in distilled water, was larger than before spray drying (p<0.05). 
Spray drying with water dispersant excipients, such as trehalose and lactose, 
tends to allow for recovery of NPs that are 10-30% bigger than before spray 
drying (Sham et al., 2004; Chaubal and Popescu, 2008; Tomoda et al., 2009). 
However, rather than dispersing, chitosan tends to form a gel upon contact 
with an aqueous medium, which could hinder the release of the entrapped NPs 
(Aranaz et al., 2017). This gel formation can also be attributed to the NCMPs 
modifying the release profile of the NPs (Liu et al., 2019). Before spray drying, 
all the resveratrol loaded into the NPs was released within 60 minutes, but 
after spray drying only 18% of the resveratrol was released after 60 minutes. 
After 24 hours, the NCMP showed a resveratrol release of 25%.  
5.1.4. Polymer modification through click chemistry 
Polymeric NPs have been used as a drug delivery system for various drugs 
against several cancers including colon, liver, lung and prostate (Karthikeyan 
et al., 2013; Jung et al., 2015; J. Wu et al., 2017; Nassir et al., 2018). Most 
NPs use the unique characteristics of tumours, known as the EPR effect, to 
passively target the cancer cells (Kobayashi, Watanabe and Choyke, 2013; J. 
Wu et al., 2017). However, attaching ligands, such as antibodies, that can 
specifically bind to a particular target site on a tumour cell, would allow for 
active targeting (Wilhelm et al., 2016). Further attachment of a fluorescent 
ligand would help with visualisation of the entry of the NPs into the cells (Robin 
and O’Reilly, 2015; Jiang et al., 2018). 
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Glycerol was modified to 2-(prop-2-yn-1-yloxy)propane-1,3-diol, which 
possesses an alkyne group, using known methods (Vrbková, Dračínský and 
Holý, 2007; Gładysz, Ruszkowski and Milecki, 2018). The 2-(prop-2-yn-1-
yloxy)propane-1,3-diol was used in various ratios alongside glycerol, PDL and 
DVA in the polymerisation reaction to PGA-co-PDL possessing a pendant 
alkyne group on the polymer backbone. This was the first time a modified 
glycerol possessing an alkyne group was used to polymerise this polymer.  
It was found that as the ratio of 2-(prop-2-yn-1-yloxy)propane-1,3-diol to 
glycerol increased in the polymer, there was a noticeable decrease and 
eventual absence of the OH trough, which is characteristic of the pendant 
hydroxyl group on the glycerol molecule. The trough was replaced by an 
alkyne C-H stretch, which suggested that the 2-(prop-2-yn-1-yloxy)propane-
1,3-diol was incorporated into the polymer. 
A type of click chemistry, CuAAC reaction, was used to react the alkyne group 
on the PGA-co-PDL polymer to the azide group of the NBD azide, which was 
synthesised earlier. NBD azide is a fluorophore that can be photoactivated to 
allow the visualisation of particles conjugated to it (Tobimatsu et al., 2014). 
The CuAAC reaction is normally highly efficient, but the lack of the 
characteristic peak on the FT-IR spectrum associated with NDB azide 
suggested the reaction was unsuccessful (Castro, Rodríguez and Albericio, 
2016). The polymer used for the reaction only contained 10% 2-(prop-2-yn-1-
yloxy)propane-1,3-diol (w/w), which means that there was a low concentration 
of alkyne groups on which the NBD azide could bind. This problem may be 
amplified by the concern that further reduction of binding site accessibility may 
196 
 
occur with folding of larger polymers (Pickens et al., 2018). These two 
problems together could explain the lack of success of the reaction.  
It was decided to attempt the CuAAC reaction on a smaller azide, 2-phenyl-5-
(prop-2-yn-1-yloxy)-1,3-dioxane. This was derived from glycerol with the 
secondary hydroxyl groups protected with benzaldehyde, which contains the 
alkyne group and was reacted with the NBD azide. Neither the NMR nor the 
FT-IR spectra indicated that the reaction was successful. Although, the yield 
of the reactions to produce the 2-(prop-2-yn-1-yloxy)propane-1,3-diol was high 
(>60 %), the scale was very low. This meant that the polymerisation reaction 
had to be reduced and the click reactions had to be done on a small scale 
using low concentrations, which can influence the success of a reaction 
(Presolski, Hong and Finn, 2011). These are all issues that need to be 
addressed in future studies. 
5.2. Future work 
Although progress has been made towards a drug delivery system for 
resveratrol, the work is not completed. Some additional studies can be 
performed to build on the successes achieved in this current work, in order to 
help improve the drug delivery system. 
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5.2.1. Optimisation and validation of cytotoxicity studies 
The cytotoxicity studies performed using the NPs need to be validated, while 
the studies performed using the NCMPs have to be optimised.  
As mentioned throughout this thesis, NPs possess unique characteristics that 
have been found to cause interference with various cytotoxicity assays (Kroll 
et al., 2009; Sukhanova et al., 2018). Although previous studies have shown 
more interference from carbon or metallic based NPs, at least one study has 
mentioned polymeric NPs causing interference (Belyanskaya et al., 2007; 
Casey et al., 2007; Guadagnini et al., 2015). In this study, it was noticed that 
the PGA-co-PDL NPs did not yield consistent results in the cytotoxicity assays 
used. Furthermore, the results from the NCMPs were inconclusive. Some 
considerations needed in the cytotoxicity assessment of NPs are as follows: 
It is recommended that the physicochemical characterisations of the 
NPs/NCMPs are fully assessed prior to commencement of cytotoxicity testing 
(Kong et al., 2011). Furthermore, the components of the NPs/NCMPs should 
be tested, separately, for any interference with the assay components, in the 
presence and absence of cells (Ong et al., 2014). The PGA-co-PDL NPs 
showed a good cytotoxicity profile, but when the NCMPs were tested there 
was no distinctive trend noticed. This could have been caused by the 
components of the NCMPs, i.e. the chitosan and L-leucine, either separately 
or synergistically. Only by testing the various components can this be 
identified. The NCMPs were also tested at a higher concentration than the NPs 
and this could have increased the chance of interference (Ong et al., 2014). 
NPs/NCMPs concentration should be limited in the final sample. Therefore, 
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the choice of cytotoxicity assay is important and it is recommended that at 
least two different assays are used (Matuszak et al., 2016).  
Once the right assays are established where NPs/NCMPs showed no 
interference, it is recommended that the cytotoxicity studies performed in this 
study are repeated, in order to achieve reproducibility and thus reliability of 
data. Furthermore, assessment of the NPs/NCMPs both in human lung cancer 
cell lines and human non-cancerous cell lines would be beneficial.  
5.2.2. Increase scale of click chemistry  
A high concentration might be a problem for cytotoxicity studies, but the low 
concentrations used for the click chemistry reactions caused the reactions to 
be unsuccessful (Presolski, Hong and Finn, 2011).  
This part of the project would benefit from having it performed on a bigger 
scale to offset some of the low yields obtained by some reactions. Reactions 
between a small molecule, like the fluorescent moiety used in this study, and 
a high molecular weight polymer have some difficulties due to the nature of 
polymers (Pickens et al., 2018). It would be wise to optimise the click chemistry 
reaction on the smaller molecules that present the azide and alkyne groups. 
This optimised reaction can then be used to “click” the azide molecule onto the 
polymer presenting with the alkyne moiety. Alternatively, the NBD azide can 
be attached to the modified glycerol prior to the polymerisation reaction.  
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5.3. Conclusion 
In this thesis, resveratrol was encapsulated into PLGA, mPEG-PLGA, PGA-
co-PDL-PEG2000, and PGA-co-PDL NPs. All NPs were under 252 nm with 
good PDI (<0.353) and a high zeta potential (> -30 mV). The PGA-co-PDL NPs 
showed the best EE% at 78 ± 0.24% and 70 ± 0.89% and drug loading of 39 
± 0.12 µg/mg and 70 ± 0.89 µg/mg for 5% RNP and 10% RNP, respectively. 
These two NPs showed a burst release profile, with no resveratrol detected 
after 60 minutes in a release medium. The Alamar blue and LDH assays 
showed that the PGA-co-PDL 5% RNP and 10 % RNP had a dose- and time- 
dependent cytotoxic effect on Calu 3 cells. The resveratrol-loaded PGA-co-
PDL NPs reduced the IC50 of resveratrol after 24 hours by up to 78%. The 
selected NPs was then incorporated into NCMP using L-leucine and chitosan 
using spray drying. The NCMP formulations had a high ED >98 % and RF 70-
74%, but a low FPF 39-47%. The MMAD was in the ideal range of 1-5 µm to 
facilitate lung deposition. Moreover, the NCMP seemed to modify the release 
profile of the NPs, presenting a sustained release of resveratrol over 24 hours. 
Glycerol was successfully modified to contain an alkyne moiety and was used 
to polymerise novel PGA-co-PDL with the alkyne moiety present. Further 
studies need to be done in order to build on these successes.  
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